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Throughout pregnancy, immune cells infiltrate and colonize the placenta to ensure fetal
development and successful birth. Thereby, they regulate tissue remodeling and protect
the unborn from invading pathogens. At the same time, immune cells within the placenta
require tight regulation in order to prevent recognition of the embryo as a ’semi-allograft’.
Extra-embryonic tissue actively modulates immune cell functions by expressing growth
factors and cytokines. Preimplanation factor, a 15 amino acid small peptide, is produced
by trophoblast cells and continuously secreted into maternal circulation. It has been shown
to interfere with immune cell functions in autoimmune disease models, but underlying
molecular mechanisms remain unclear.
This work investigated the function of PIF in acute inflammatory scenarios, reflecting its
role within maternal serum. Analysis of leukocyte recruitment in postcapillary venules of
TNF-α stimulated cremaster muscles in the mouse revealed that (i) leukocyte rolling, (ii)
leukocyte adhesion and (iii) neutrophil extravasation is impaired in the presence of PIF. With
the help of several ex vivo and in vitro assays, reduced leukocyte rolling could be linked to
effects of PIF on the endothelial compartment. Impaired leukocyte adhesion and reduced
extravasation in turn could be attributed to a direct effect of PIF on neutrophils. PIF inhibits
K+ efflux via the voltage gated potassium channel KV1.3 on neutrophils, thereby reducing
sustained calcium influx into the cells. Decreased intracellular Ca2+ concentrations impair
post-arrest modification steps, namely neutrophil spreading and adhesion-strengthening,
resulting in increased susceptibility to physiological shear forces and in reduced adhesion
and extravasation.
Taken together, this work demonstrates that PIF modulates neutrophil function during
immune responses, offering therapeutic potential beyond pregnancy to protect patients from
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1.1. The feto-maternal interface
The placenta is the central structure during pregnancy of eutherian mammals. It defines the
feto-maternal interface and exchange of all gas, nutrition and waste is carried out along this
barrier1. The placenta is composed of maternal decidua and extra-embryonic trophoblast.
During blastocyst invasion, trophoblast cells enter decidualized endometric epithelium and
anchor into the tissue2. Even prior to implantation, endometrial cells transit into decidual
cells, preparing for trophoblast invasion3. Resident and infiltrating immune cells start to
remodel the tissue3. Remodeling occurs in several steps until the definitive placental struc-
ture is established in transition from 1st to 2nd trimester1 (Fig. 1.1). There, trophoblast cells,
forming villous trees are bathed by maternal blood, ensuring maximum mass transfer4. Ex-
travillous trophoblast cells anchor the villi into the decidua5. Consequently, ’semi-allogenic’
embryonic cells are in direct contact with maternal decidual cells and maternal blood.
1.1.1. Successful pregnancy: Immune cells cooperating at the feto-maternal
interface
Throughout pregnancy, maternal immune cells colonize the placenta and are a prerequisite
for successful gestation6. Around 40% of the decidua is composed of maternal leukocytes1.
As outlined below, uterine immune cells are often characterized by a unique phenotype,
differing from their counterparts present in other tissues7. In the placenta, they partici-
pate in tissue remodeling and in protection of the growing embryo/fetus from invading
pathogens. Imbalance in the composition of intrauterine immune cells can cause severe com-
plications during pregnancy, such as poor endometrial vascularization, impaired blastocyst
implantation, or fetal loss8. For a long time, pregnancy has been seen as a state of constant
local immune suppression9. With the findings of varying immune cell compositions in the
placenta throughout gestation, the picture emerged that pro- and anti-inflammatory periods
alternate during pregnancy6. Nowadays, it is clear that the ability of maternal immune cells
to adapt to different developmental stages is a prerequisite for successful pregnancy9.
1.1.2. Pro- and anti-inflammatory states during pregnancy
The supportive role of immune cells for successful pregnancy starts even prior to fertilization.
Endometrial immune cells permanently colonize the uterus, regulating normal menstrual
cycle10. Fertilization induces leukocytes to infiltrate the endometrium at time of conception
around day 23-25 of menstrual cycle, thereby taking part in pre-decidualization1,7. Early






















Figure 1.1.: Feto-maternal interface, 2nd and 3rd trimester. Extra-embryonic trophoblast anchors into the
decidua and forms chorionic villi which get bathed with maternal blood to ensure gas, nutrient and waste
exchange. Extravillous trophoblast cells link villi to the decidua. Maternal immune cells colonize the decidua and
fulfill important regulatory functions without initiating immune responses against ’semi-allogenic’ trophoblast
cells. DC: dendritic cell, NK: natural killer cell, Treg: regulatory T cell. (modified from1,4).
and accompanying placentation require a pro-inflammatory milieu6. Endometrial stromal
cells and invading immune cells produce and secrete a variety of pro-inflammatory media-
tors, including interleukin-6 (IL-), IL-8 (CXC-chemokine ligand 8, CXCL8), CXCL1 (mouse),
or tumor necrosis factor-α (TNF-α), important for upregulation of adhesion molecules,
removal of preexisting mucin layers and further attraction of leukocytes6,11. Invading im-
mune cells additionally secrete pro-angiogenic factors like vascular endothelial growth factor
(VEGF) or placental growth factor (PGF)7, enabling tissue remodeling and vascularization of
the decidua. In animal models, deletion of different immune cell populations like dendritic
cells12 or macrophages13 resulted in infertility, ineffective implantation and early abortion,
demonstrating the critical role of immune cells in early pregnancy. Importance of a general
pro-inflammatory milieu has been highlighted by observations that local injury caused
e.g. by endometrial biopsies increases receptivity and doubles the incidence of successful
pregnancy14.
Implantation and placentation is followed by a period of fetal growth and development.
This stage is characterized by an anti-inflammatory environment, lasting from week 13
to week 27 in humans6. During this period, both, immune and trophoblast cells produce
primarily anti-inflammatory mediators like IL-10, IL-15 or tissue growth factor-β (TGF-β)6,1,
reducing cytotoxicity of immune cells and creating immune tolerance. Higher levels of
pro-inflammatory mediators in this period and ensuing recruitment of leukocytes may lead
to miscarriage and preterm birth15.
Parturition and its initiation is again accompanied by pro-inflammatory processes, medi-
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ated in particular by NF-κB-signaling16. In preparation of delivery, immune cells infiltrate
the cervix, decidua and myometrium17, a prerequisite for uterus contractions, subsequent
delivery and separation of the placenta6. After labor, leukocytes play an important role in
postpartum tissue remission and repair17,18.
1.1.3. Immune cell populations within the feto-maternal interface
A lot of different immune cell populations participate in initiation, maintenance and termi-
nation of pregnancy with different ratios and functions, depending on the gestational age19,
among them natural killer (NK) cells, macrophages, dendritic cells (DCs), regulatory T (Treg)
cells, neutrophils, mast cells, and B lymphocytes1,6,7.
NK cells:
Approximately 70% of decidual leukocytes in the 1st trimester are NK cells1. In comparison
to peripheral NK cell populations, uterine NK cells have a distinct phenotype20. They exhibit
lower cytotoxicity and produce a vast variety of growth factors, angiogenic factors, pro-
and anti-inflammatory cytokines21, qualifying them as key regulators of uterine vascular
remodeling22. The specific phenotype of uterine NK cells is in parts mediated by IL-15,
which is secreted by intrauterine macrophages and trophoblast cells23. The importance of
NK cells in normal decidua formation has been shown in mice, where depletion of uterine
NK cells resulted in fetal loss due to incomplete vascularization24. In line, endometrial
biopsies from women with unexplained infertility exhibited reduced numbers of NK cells
compared to biopsies from fertile women25.
Macrophages:
Displaying pro- and anti-inflammatory properties during different stages of pregnancy,
macrophages play a pivotal role. With 20-25%, they constitute the second largest leukocyte
population in 1st trimester deciduas1. During that period, they exhibit predominantly a
M2-like phenotype26, secreting anti-inflammatory mediators like IL-10 and TGF-β7. In early
pregnancy, they further contribute to tissue remodeling and angiogenesis via release of VEGF
or matrix metalloproteinase 9 (MMP9)27,28,29. Additionally, decidual macrophages are impli-
cated to have an important scavenger function by taking up apoptotic trophoblasts, thereby
preventing activation of pro-inflammatory signaling pathways30. Expression of surface
receptors like hemoglobin scavenger receptor (CD163) or mannose receptor (CD206) further
suggests that they also face a role in protecting the fetus against infections by eliminating
invading pathogens31. Deletion of macrophages in mice resulted in implantation failure,
underlining its important role especially in early pregnancy13. Peri-parturition, infiltrating
macrophages into the uterus and cervix exhibit a more pro-inflammatory phenotype17 by
participating in the degradation of the extracellular matrix through secretion of MMPs and





Treg cells play a central role in maintaining an anti-inflammatory environment by suppress-
ing immune responses against paternal antigens34,35. Their important role during pregnancy
has been demonstrated in animal models, where depletion of Foxp3+ Treg cells resulted
in infertility, ineffective implantation and early abortion36. In line, endometrial tissue of
infertile women exhibit reduced amounts of Foxp3 mRNA, indicating impaired T cell differ-
entiation into Treg cells37. Interestingly, these cells persist beyond parturition, decreasing the
resorption rate in a second pregnancy with the same paternal background38.
Dendritic cells:
Like most other leukocytes, uterine dendritic cells (DCs) exhibit a distinctive phenotype
compared to circulating or tissue resident DCs from other organs7. Similiar to NK cells and
macrophages, DCs play a crucial role in early pregnancy, by promoting implantation and
decidua formation, as their depletion causes impaired implantation, embryo resorption and
perturbed angiogenesis12. Supportive functions of DCs for successful pregnancy start even
prior to fertilization. DCs in the vaginal lumen encounter parental antigens from male sperm
directly after copulation39,40. These cells do not migrate into lymph nodes, but are locally
involved in the communication between Treg cells and trophoblast cells41 and are able to
directly activate Treg cells42. Hence, they seem to play an important role in the generation of
immune tolerance towards paternal antigens. In addition, they secrete IL-10 and soluble
human leukocyte antigen-G (HLA-G), further promoting tolerance43.
Neutrophils:
Neutrophils, primarily associated with pro-inflammatory functions, high cytotoxicity and
accompanied tissue damage44 need to be tightly regulated during pregnancy. Therefore,
presence of neutrophils in close proximity to the fetus has been classically correlated with
severe problems like pre-eclampsia or fetal loss18,45. Indeed, high numbers of neutrophils
are present in pre-eclamptic placentae46,47 and neutrophils have been shown to contribute to
fertility problems in women suffering from anti-phospholopid syndrome (APS), an autoim-
mune diseases with a high coincidence of pregnancy related complications48. Surprisingly,
Amsalem and colleagues recently described a 2nd trimester uterine neutrophil population
which is characterized by pro-angiogenic and reduced cytotoxic properties, similar to the
phenotype of decidual macrophages or NK cells49, suggesting that neutrophils infiltrate the
placenta as well and contribute to successful pregnancy. Similar to macrophages, neutrophils
play an important role during labor17. They infiltrate the myometrium, secreting MMPs and
pro-inflammatory cytokines50 and are involved in post-partum tissue repair33. In contrast to
macrophages, neutrophils do not participate in ripening of the cervix17.
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Taken together, maternal leukocytes surrounding the fetus during pregnancy fulfill im-
portant functions in placentation and immune surveillance. Alterations in their quantity
and quality can cause severe perturbations, leading to impaired embryonic development
and eventually fetal death. Therefore, these cells need to be tightly regulated in order to
prevent recognizing the unborn as a ’semi-allogenic transplant’ and to not initiate immune
responses against fetal tissue. Immune cells generally seem to shift towards a regulatory
and less cytotoxic phenotype within the placenta, arguing for tissue-induced tolerance.
1.1.4. Immune cell regulation by trophoblast cells
Trophoblast cells actively shape maternal immune cell functions by expressing a variety of
growth factors and cytokines6,51. Constitutive secretion of CXCL12 (stromal cell-derived
factor-1, SDF-1), CXCL8 and CCL2 (monocyte chemotactic protein-1, MCP-1)6,52 for example
attracts lymphocytes, neutrophils and monocytes. Trophoblast derived IL-15 and TGF-β shift
decidual NK cells into their specific pro-angiogenic and low cytotoxic phenotype21. TGF-β is
further important for the development of of naive CD4+ T into Foxp3+ Treg cells52. Recruited
CD14+ monocytes to the feto-maternal interface differentiate into M2-like macrophages,
induced by macrophage colony-stimulating factor (M-CSF) and IL-1051,53 that is secreted by
trophoblast cells.
Attraction and parallel modulation of maternal immune cells at the feto-maternal interface
needs to be finely tuned to maintain the protective properties of immune cells. At the same
time, they need to be restricted from recognizing extra-embryonic and embryonic tissue as
a ’semi-allograft’ and from initializing immune responses against the unborn. Besides the
mostly tolerogenic phenotype of many of the decidual leukocytes, trophoblast cells express
the atypical chemokine receptor 2 (ACKR2) and internalize and scavenge pro-inflammatory
chemokines, thereby reducing chemokine gradients towards fetal tissue54,55. In addition,
trophoblast cells do not express the classical HLA-A and -B, but HLA-C and non-classical
HLA-E, -F and -G56,57. Decidual NK cells bind to HLA-G via the receptor KIR2DL458
resulting in the suppression of cytotoxic properties of NK cells59. Also other immune cells
like macrophages60, T cells61 and B cells62 bind to HLA-G via the receptors ILT2, ILT463,
resulting in modulation of their functions.
1.1.5. Preimplantation factor (PIF) modulates maternal immune cell functions
during pregnancy
Another factor which is expressed by trophoblast cells of many mammalian species and
which is thought to contribute to feto-maternal crosstalk, is Preimplantation factor (PIF), a
15 amino acid small peptide64,65,66,67. PIF is already secreted at very early gestational stages,
even prior to implantation68 and can be detected in the maternal circulation throughout
pregnancy (Tab. 1.169). Sufficient PIF serum levels are required for embryoic development68
and positively correlate with successful birth66. PIF changes the expression pattern of
endometrial stromal cells and 1st trimester decidua cells towards a pro-receptive milieu70,
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thereby promoting trophoblast invasion67,71,72. In vitro, PIF enhances the expression of
protolerogenic HLA molecules in trophoblast cells73. Until now, the gene encoding for PIF
has not been discovered and its exact origin is still controversial.






PIF was shown to interact with immune cells64,65,74 and therefore suggested to mod-
ulate maternal immune cell function during pregnancy64,75. In a murine model of LPS
induced fetal loss, PIF administration increased fetal survival and changed placental and
serum cytokine profiles76. Interestingly, trophoblast PIF expression increased upon LPS
stimulation. Further, PIF reduces the expression of the endometrial inflammatory marker
prostaglandin F2α 77.
PIF’s properties to modulate immune cell function have been also assessed outside the
context of pregnancy, in animal models for autoimmune diseases. In a model for type I
diabetes mellitus (TIDM), continuous PIF administration lowered the number of invading
immune cells into the mouse pancreas, thereby preserving insulin production and overall
architecture of the islets of Langerhans78. Similar, in a model for experimental autoimmune
encephalomyelitis (EAE), PIF treatment lowered immune cell infiltration into the central
nervous system and attenuated the progression of the disease79. Mueller and colleagues
demonstrated in a newborn rat hypoxic-ischemic brain injury model that PIF administration
has neuro-protective properties by reducing let7 mRNA expression in a toll-like receptor 4
(TLR4) dependent manner80. In a follow-up study they were able to decipher that PIF, via
TLR4, PI3K/Akt and let7 signaling, upregulates anti-inflammatory IL-10 expression81. Fur-
ther, PIF reduced graft-versus host disease after bone marrow transplantation in mice82 and
had positive effects in non-human primates following ovarian tissue transplantation83. In a
mouse model of atherosclerosis, PIF administration reduced sclerotic lesions and lowered
the number of infiltrated immune cells84.
Although, effects of PIF on immune cell function have been proven in several disease models,
molecular mechanisms how PIF interferes with immune cells are not clear. Especially its role
in the maternal circulation is completely unknown. Therefore, immune modulatory proper-
ties of PIF in acute, primarily neutrophil driven, inflammatory scenarios outside the context
of pregnancy were investigated in this study to better understand PIF’s serum function and
to reveal underlying molecular mechanisms of PIF dependent immune modulation.
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1.2. Neutrophil recruitment cascade
Neutrophils are the most abundant white blood cells in the circulation of humans85 and
the first cells to arrive at sites of inflammation44. They belong to the innate arm of the im-
mune system and exert important functions during immune responses by fighting invading
pathogens and recruiting other immune cells86.
Recruitment of neutrophils from postcapillary venules to sites of inflammation follows a
distinct and tightly regulated multi-step cascade of receptor–ligand interactions and subse-
quent signaling events87, including initial tethering and rolling, adhesion and intraluminal













Figure 1.2.: Neutrophil recruitment cascade. To sites of inflammation, neutrophils follow a well defined cascade
of events including tethering, rolling, adhesion, intraluminal crawling, transmigration and interstitial migration.
1.2.1. Tethering and rolling
The initial steps of neutrophil recruitment, tethering and subsequent rolling are mediated by
interaction of selectins, expressed on inflamed endothelial cells and neutrophils with their
respective ligands89,90. Selectins are a family of three type I transmembrane glycoproteins
which bind to fucosylated and sialylated glycoprotein ligands via their calcium-dependent
C-type lectin domain91,92. P-selectin (CD62P) is expressed by megakaryocytes/platelets and
endothelial cells93, where it is pre-stored in α-granules or Weibel-Palade bodies, respec-
tively91. P-selectin is translocated to the cell surface within minutes upon stimulation by
mediators such as thrombin or histamine92. P-selectin interacts with its predominant ligand
P-Selectin Glycoprotein Ligand-1 (PSGL-1, CD162) and CD24 on leukocytes94. Activation
with TNF-α, IL-1β or lipopolysaccharide (LPS) further induces transcriptional upregulation
of P-selectin in mice but not in humans95,96. E-selectin (CD62E) is not pre-stored in vesicles
and needs to be de novo synthesized by endothelial cells upon stimulation90. Bone marrow
and skin endothelial cells constitutively express E-selectin92. On the surface, it interacts with
PSGL-1 and additionally with CD44 and E-selectin ligand-1 (ESL-1)97. L-selectin (CD62L) is
constitutively expressed on leukocytes where it plays a crucial role in lymphocyte homing98.
During recruitment, adherent leukocytes are able to capture free floating leukocytes via
L-selectin–PSGL-1 interaction, a process called secondary tethering99,100. In addition, human
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but not murine L-selectin is able to bind to E-selectin101,102, thereby contributing to leukocyte
rolling.
Selectin bonds with their ligands are characterized as catch bonds, interactions which
require certain tensile forces103,104 and which are enhanced by increasing mechanical ten-
sion on the bonds105. High on- and off-rates of selectin–selectin ligand bonds result in
leukocyte rolling106 along inflamed endothelium and determine characteristic E- and P-
selectin-dependent rolling velocities107,108,109. To roll even at high shear forces, neutrophils
form tethers and slings, subcellular elongations of the cell membrane110.
1.2.2. Slow rolling, arrest and adhesion
Integrins expressed on neutrophils contribute to rolling, arrest and adhesion to inflamed
endothelium. Integrins are heterodimeric transmembrane proteins and consist of an α-
and a β-subunit111 with 18 different α- and 8 β-subunits known to be genetically encoded
in mice and humans87. Neutrophil rolling, adhesion and subsequent crawling is mainly
mediated by members of β2-integrins, namely lymphocyte function antigen-1 (LFA-1, αLβ2,
CD11a/CD18) and macrophage-1 antigen (Mac-1, αMβ2, CD11b/CD18)112. Intracellular
adhesion molecule-1 (ICAM-1) which is constitutively expressed on endothelial cells is
the major ligand for β2-integrins during neutrophil recruitment88, but also other adhesion
molecules like ICAM-2113 or receptor for advanced glycation end products (RAGE)114 are
important β2-integrin ligands in the context of neutrophil recruitment. Upon activation,
integrins change their conformation from a bent, low affinity (low affinity αI domain) to
an extended, intermediate (low/intermediate affinity αI domain) or extended fully acti-
vated conformation (high affinity αI domain, Fig. 1.3-A), thereby increasing the affinity
to their binding partners115. Fan and colleagues116 described a fourth, anti-inflammatory
high-affinity, bent conformation. This state allows integrins to bind to ICAM-1 expressed
on neutrophils, thereby preventing intercellular integrin interactions (Fig. 1.3-B). Recently,
L-plastin (LCP-1) which is expressed in leukocytes, was shown to bind to bent Mac-1, thereby
attenuating leukocyte adhesion117. Rolling along inflamed endothelium allows neutrophils
to recognize pro-inflammatory chemokines and other chemoattractants immobilized on the
luminal surface44. Recognition of chemokines by G-protein coupled receptors (GPCRs) leads
to changes in the conformation of β2-integrins (chemokine induced inside-out signaling)
and concomitant deceleration of rolling neutrophils up to full arrest88. Additional to GPCR-
mediated β2-integrin activation, E-selectin–PSGL-1 engagement activates β2-integrins either
directly via intracellular downstream signaling118,119, or by the release of S100A8/A9 and
autocrine activation via TLR4 downstream signaling120. In humans, E-selectin–L-selectin
interactions are able to induce release of S100A8/A9 as well102.
Talin-1 and kindlin-3 are critical intracellular co-activators of β2-integrins during inside-out
signaling111,121 with distinct roles in integrin activation115,122. Both molecules bind directly
to the intracellular tail of the β2-subunit, thereby shifting integrins into activated states112,123.
Whereas talin-1 is required for both, intermediate and fully activated LFA-1, kindlin-3 is
indispensable only for high-affinity conformation124.
10













Low affinity αI domain
High affinity αI domain
Neutrophil
Figure 1.3.: Different conformations of β2-integrins. (A) Integrins change their conformational state upon
activation, thereby influencing the binding affinity to ligands such as ICAM-1. (B) In the high affinity-bent
conformation, β2-integrins bind to ICAM-1 expressed on neutrophils (modified from111).
1.2.3. Post-arrest modifications, intraluminal crawling and transmigration
To withstand shear forces, neutrophils need to undergo post-arrest modifications, including
adhesion strengthening and spreading, mediated by signaling events downstream of acti-
vated and ligand bound β2-integrins (integrin outside-in signaling)125,126. LFA-1–ICAM-1
engagement activates Src family kinases (SFKs), which among others phosphorylate and acti-
vate Vav-family molecules and phospholipase C γ (PLCγ) via spleen tyrosine kinase (Syk)127.
Downstream signaling via Vav leads to activation of the Rho GTPase family members Cdc42,
Rac and RhoA128, key molecules for cytoskeletal rearrangement. Firm adhesion requires
linkage of the actin cytoskeleton to adhesion spots, consisting of clustered β2-integrins
bound to their endothelial ligands. Talin-1, composed of a head and a rod domain, has
multiple binding sites for the F actin-binding protein vinculin121 and is able to directly bind
to F actin129, therefore linking the actin cytoskeleton to the adhesion complex130. Besides
talin-1 and kindlin-3, a huge variety of molecules gets recruited to focal adhesion sites
during inside-out and outside-in integrin activation131,132,133, promoting integrin clustering,
cytoskeletal rearrangement and firm adhesion.
Before neutrophils exit the blood vessel into the interstitial tissue, they crawl along the vessel
wall to find appropriate spots for transmigration134. Multiple chemoattractans, immobilized
on the endothelial surface, guide their way towards transmigration loci135,136. In addition, ad-
herent platelets at the inflamed vessel wall contribute in directing neutrophil extravasation137.
Whereas LFA-1 is the major β2 integrin during neutrophil adhesion, intraluminal crawling
is predominantly dependent on interactions of activated Mac-1 with endothelial expressed
ICAM-1, ICAM-2 and vascular cell adhesion molecule-1 (VCAM-1, CD106)113,134. At the exit
site, neutrophils first have to pass the endothelial layer, before overcoming the underlying
basement membrane (BM) and the discontinuous layer of pericytes134. Transendothelial
migration (TEM) of neutrophils usually occurs via the paracellular route and to a minor
extent directly through endothelial cell bodies, via the transcellular route138. TEM requires
many ligand–receptor interactions, inducing downstream signaling in both, neutrophils and
endothelial cells139. Engagement of LFA-1 and very late antigen-4 (VLA-4, CD49c/CD29,
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α4β1 integrin) on neutrophils with endothelial expressed ICAM-1 and VCAM-1, respectively
lead to clustering of ICAM-1 and VCAM-1 at EC junctions and to intracellular signaling
in endothelial cells140,141. As a consequence, intracellular VE-cadherin tails get dephospho-
rylated142, resulting in the retraction of VE-cadherin adherens junctions143. Tight junction
molecules from the junctional adhesion molecule (JAM) family, JAM-A144, JAM-B, JAM-
C145, endothelial cell-selective adhesion molecule (ESAM)146, as well as platelet endothelial
cell adhesion molecule-1 (PECAM-1, CD31)147 and CD99148 are all located in and around
endothelial junctions and help guiding neutrophils through the endothelial layer134.
The underlying BM is a highly crosslinked network, mainly composed of laminins and
type IV collagen and incorporated pericytes149. To overcome this barrier, neutrophils use
’low expression regions’, characterized by a less dense meshwork of matrix proteins138.
Neutrophil–endothelial cell engagement induces MST-1 dependent release of vesicle-stored
VLA-3 (α3β1) and VLA-6 (α6β1) and neutrophil elastase (NE)150, a pre-requisite for BM
penetration151. Following BM penetration the cells crawl along pericytes in a ICAM-1–β2
integrin dependent manner152. Within the interstitium, neutrophils migrate to the site of
insult, in a largely β2 integrin independent manner153, involving MMPs154.
1.3. Calcium signaling in neutrophils
Calcium is an evolutionary highly conserved signaling molecule155 which regulates a huge
spectrum of biological processes ranging from signal transduction in neurons to muscle
contractions. Also functions of immune cells156, including neutrophils157 depend on Ca2+
signaling. Thereby, changes in intracellular Ca2+ concentrations ([Ca2+]i) are a hallmark in
neutrophil activation and many functions during neutrophil recruitment depend on Ca2+
signaling158.
1.3.1. Store-operated Ca2+ entry (SOCE)
The predominant mechanism to increase [Ca2+]i in neutrophils is store-operated calcium
entry (SOCE) via Ca2+ release-activated Ca2+ (CRAC) channels159 (Fig. 1.4). Under baseline
conditions, extracellular Ca2+ concentrations are 10 000-fold higher compared to cytosolic
levels160, creating a high electrochemical driving force for Ca2+ to enter the cell. In neu-
trophils, SOCE can be initiated via engagement of numerous receptors with their ligands,
namely by GPCRs161, Fcγ receptors (FcγR)162, activated β2-integrins163,164 and PSGL-1/L-
selectin–E-selectin interaction119,165,166. Fcγ receptors, β2-integrins, PSGL-1, and L-selectin
activate members of the PLC-γ subfamily, PLCγ1 and PLCγ2 via Syk119,167. Activation of
GPCRs dissociates G protein subunits α from βγ, resulting in activation of PLCβ2 and
PLCβ3167. PLCs convert membrane-bound phosphatidylinositol 4,5 bisphosphate (PIP2) into
diacylglycerol (DAG) and inositol-1,4,5 triphosphate (IP3)155. IP3 opens IP3 receptors (IP3R)
in the membrane of the endoplasmic reticulum (ER), triggering the release of Ca2+ out
of the ER into the cytoplasm156. Stromal interaction molecule 1 (STIM1) senses the Ca2+
concentration in the ER168 and translocates to ER regions of close proximity to the plasma
membrane (PM) upon ER Ca2+ store depletion, where it binds to Orai1169, the predominant
CRAC channel in neutrophils166. STIM1–Orai1 engagement in turn opens the Orai1 channel,
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resulting in influx of extracellular Ca2+ into the cell158.
An alternative mechanism of Ca2+ influx besides SOCE is receptor operated calcium entry
(ROCE)170. Transient receptor potential canonical (TRPC) channel 6 and TRPC3, two non-
selective Ca2+ and Na+ channels which are also expressed on neutrophils171 are activated
directly by DAG172, the complementary cleavage product of PIP2 conversion.
Many innate immune defense processes in neutrophils depend on an increase in [Ca2+]i,
among them β2-integrin activation165, cytoskeletal rearrangement173, migration174, degranu-
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Figure 1.4.: Store operated calcium entry (SOCE) in neutrophils. Various receptor–ligand interactions induce
calcium signaling in neutrophils. While Fcγ receptors, LFA-1, L-selectin and PSGL-1 signal via Syk and PLCγ,
activation of GPCRs results in the dissociation of G protein subuntis α from βγ and activation of PLCβ.
Both PLCs convert PIP2 into DAG and IP3, resulting in IP3R activation and subsequent Ca2+ flux out of the
endoplasmic reticulum (ER). Ca2+ store depletion induces translocation of the Ca2+ sensor STIM1 and subsequent
activation of Orai1, leading to influx of extracellular Ca2+ (modified from 158).
1.3.2. Ca2+ signaling during neutrophil rolling and arrest
Ca2+ flux is a key-regulator of adhesion strengthening, neutrophil polarization and of transi-
tion from a rolling and adherent to a migratory phenotype159. Shear stress acting on rolling
and adherent neutrophils plays an important role in synchronizing and enhancing Ca2+
signaling during recruitment of neutrophils176. Neutrophil rolling on E-selectin induces
release of Ca2+ stored in the ER via engagement with PSGL-1 and L-selectin (human) and
downstream activation of the PLCγ/PIP2/IP3R axis119,165 (Fig. 1.5-A). This increase in [Ca2+]i
is amplified by mechanical shear forces, acting on selectin–selectin ligand bonds and results
in a shift from low affinity to intermediate affinity LFA-1165,176. Interaction of intermediate
affinity LFA-1 with ICAM-1 decelerates rolling neutrophils. Chemokine recognition by
GPCRs and subsequent downstream signaling further increase [Ca2+]i 165,177 (Fig. 1.5-B). In
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addition, DAG activates β2-integrins via protein kinase C (PKC)178. Outside-in signaling
mediated by LFA-1 and ICAM-1 contributes to the increase of [Ca2+]i, again in a shear force
dependent manner158,176.
All these inside-out and outside-in signaling events, amplified by mechano-transduction
lead to ER Ca2+-store depletion and CRAC channel dependent Ca2+ influx. Tensile forces,
acting on LFA-1 bonds enhance binding of kindlin-3 to β2-integrin tails and concomitant
recruitment of Orai1 to adhesion spots179,180. Clustering of LFA-1, kindlin-3 and Orai1 locally
increases [Ca2+]i, facilitating the recruitment of talin-1, thereby linking the cytoskeleton to
the focal adhesion spots and mediating adhesion strengthening and neutrophil polarization
(Fig. 1.5-C).
1.3.3. Additional ion channels in Ca2+ signaling – The voltage gated potassium
channel KV1.3
Although Orai1 is the predominant Ca2+ channel mediating Ca2+ influx into activated neu-
trophils, numerous additional ion channels have been shown to be involved in the regulation
of [Ca2+]i in immune cells156,158, among them the voltage gated potassium channel KV1.3181.
KV1.3 channels are tetramers, consisting of 6 transmembrane helices which are expressed in
immune cells, vascular smooth muscle cells and cells of the nervous system182. The role of
KV1.3 in immune cells has mainly been addressed in T lymphocytes183, where it regulates
Ca2+ influx via K+ efflux156. Activation of T lymphocytes by T cell receptors (TCR) or GPCRs
activates PLCγ or PLCβ, respectively, which convert PIP2 into DAG and IP3 184 (Fig. 1.6).
IP3–IP3R interaction initiates the release of ER stored Ca2+ and STIM1 mediated activation
of CRAC channels. Both, ER Ca2+ store depletion and influx of extracellular Ca2+ depolarize
the PM and open the voltage sensitive K+ channel KV1.3183. K+ efflux hyperpolarizes the
PM and maintains a high electrical gradient for cations to enter the cell, thereby sustaining
Ca2+ influx through CRAC channels181.
KV1.3 is also expressed on B lymphocytes185, NK cells186, macrophages187, megakary-
ocytes/platelets188, and DCs189. There is one controversial report about KV1.3 in neu-
trophils190, however, data about its function in this cell type do so far not exist.
1.4. Aim of the thesis
Throughout pregnancy, immune cells colonize the placenta and fulfill important functions,
necessary for successful embryonic development. Different mechanisms have evolved that
ensure immune cell functions in close proximity to the fetus without initialization of immune
responses against the unborn. Nevertheless, immune cell regulation during pregnancy is
still incomplete understood.
Preimplantation factor (PIF) is a small peptide secreted by trophoblast cells and detectable
in maternal circulation during pregnancy. PIF has been shown to modulate immune cell
function in animal models of autoimmune diseases, but the underlying mechanisms how PIF
interferes with immune cells are not known. Therefore, this study aimed to investigate how
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Figure 1.5.: Ca2+ signaling synchronizes neutrophil adhesion under flow. (A) E-selectin dependent neutrophil
rolling induces release of ER stored Ca2+ by downstream signaling of E-selectin ligands PSGL-1 and L-selectin
(humans), amplified by shear forces acting on selectin–selectin ligand bonds. Increase in [Ca2+]i shifts bent,
low affinity LFA-1 integrins to the intermediate state, allowing interaction with endothelial expressed ICAM-1,
followed by deceleration of rolling neutrophils. (B) Activation of GPCRs support ER Ca2+ store depletion and
CRAC channel mediated influx of extracellular Ca2+. Increase in [Ca2+]i together with DAG signaling fully
activate LFA-1 integrins, leading to full arrest of the cells. Tensile forces acting on LFA-1–ICAM-1 bonds recruit
kindlin-3, which in turn recruits Orai1, resulting in formation of a complex that ensures high Ca2+ concentrations
directly at adhesion spots. (C) Talin-1 gets recruited in a Ca2+ dependent manner, linking the adhesion sites to
the cytoskeleton, thereby enabling neutrophil spreading and polarization (modified from158).
PIF interferes with innate immune cells during acute inflammatory processes outside the






























Figure 1.6.: KV1.3 signaling in immune cells. Activation of T-lymphocytes via T-cell receptors or GPCRs results
in the release of ER stored-Ca2+ and subsequent Ca2+ influx via CRAC channels. Increase of [Ca2+]i depolarizes
the cell membrane and opens the voltage gated potassium channel KV1.3. K+ efflux leads to a hyperpolarization
and allows further Ca2+ influx, thereby maintaining high [Ca2+]i.
work wanted to elucidate underlying molecular mechanism, helping to better understand its
biological function in maternal serum and in the placenta and highlighting its potential as
an anti-inflammatory drug in diverse inflammatory disorders.
Therefore, the aims of this work include:
• to investigate which steps of the neutrophil recruitment cascade are affected by PIF
• to uncover which cellular compartment (neutrophils and/or endothelium) is the target
of PIF
• to identify the cellular interaction partner of PIF on neutrophils




C57BL/6 wildtype (WT) mice were purchased from Charles River Laboratories (Sulzfeld,
Germany) and Janvier Labs (Saint Berthevin, France), Kcna3tm1Lys (KV1.3-/-) mice191 were
obtained from Jackson Laboratories. All mice were maintained at the Walter Brendel Center
for Experimental Medicine, LMU, Munich, or at the Biomedical Center, LMU, Planegg-
Martinsried. KV1.3-/- mice were back-crossed inhouse into C57BL/6 background. 8-25 weeks
old female and male mice were used for experiments. The conducted experiments were
approved by the government of Oberbayern, Germany, AZ 55.2-1-54-2531-122/12, -229/15
and ROB-55.2-2532.Vet_02-18-22.
2.2. Human blood samples
Human blood samples were taken from healthy male and female volunteers. Blood sampling
was approved by the ethical committee from the Ludwig-Maximilians-Universität München,
Munich, Germany (Az.611-15).
2.3. Recombinant proteins




scrambledPIF (scrPIF) BioIncept LLC.











2.4. Chemicals, reagents, important items
Table 2.2.: Used chemicals, reagents and important items. m: murine, h: human
Name Supplier Name Supplier
Ketamine Pharmacia GmbH Glass capillaries (0.04x0.4) CM Scientific
Xylazine Bayer Glass capillaries (0.2x2.0) CM Scientific
Catheter tube Smith medical Lysing solution BD
DMSO Sigma-Aldrich EDTA Merck
Transwells Corning Object slides (removable) Ibidi
Paraformaldehdye Applichem Poly-L-lysine Sigma-Aldrich
Giemsa Merck DAPI Invitrogen
Eukitt Sigma-Aldrich ProLong Antifade Thermo Fisher
EGTA Carl Roth Triton X-100 Applichem
Percoll Sigma-Aldrich Sodium deoxycholate Sigma-Aldrich
BSA Capricorn Scientific Tris-HCL Merck
Hepes Sigma-Aldrich Protease inhibitors Sigma-Aldrich
PMN enrichment kit (m&h) Stemcell Phosphatase inhibitors Roche
Polymorphprep Axi-Shield PoC PVDF membrane Immobilon
RPMI 1640 Sigma-Aldrich Blocking solution LI-COR
Penicillin Invitrogen Patch piptetts Science Products
Streptomycine Invitrogen PAP-1 Sigma-Aldrich
FCS Invitrogen TRAM-34 abcam
Casein Sigma-Aldrich Flow-Count Flurospheres Beckman Coulter
2.5. Software
Table 2.3.: Used software.
Name Distributor
VirtualDub (1.9.11) GNU General Public License
ImageJ192 National Institute of Health
MtrackJ193 (ImageJ plugin) Eric Meijering
Kaluza (1.5) Beckman Coulter
FlowJo (10.4) Treestar
Leica Application Suites Leica
IgorPro6 WaveMetrics
Patchmaster HEKA Elektronik
GraphPad Prism 7 Graphpad software




Table 2.4.: Used antibodies. FITC: fluorescein isothiocyanate, APC: allophycocyanin, BV: brilliant violet, PE:
phycoerythrin, PB: pacific blue.
Antigen Dye Reactivity Clone Supplier
E-selectin (CD62E) - rat α-mouse 9A9 Invivo
P-selectin (CD62P) - rat α-mouse RB40.34 Invivo
β2 (CD18) FITC rat α-mouse C71/16 Pharmingen
LFA-1 (CD11a) APC rat α-mouse M17/4 eBioscience
Mac-1 (CD11b) BV510 rat α-mouse M1/70 BioLegend
PSGL-1 (CD162) PE rat α-mouse 2PH1 Pharmingen
CD44 BV570 rat α-mouse IM7 Biolegend
L-selectin (CD62L) FITC rat α-mouse MEL-14 BioLegend
CXCR2 (CD182) APC rat α-mouse 242216 R&D Systems
Ly6G PB rat α-mouse 1A8 BioLegend
Fc block CD16/CD32 - rat α-mouse 93 BioLegend
Fc γ biotin goat α-human polyclonal eBioscience
Steptavidin PerCP-Cy5.5 - - eBioscience
β2 (CD18) - mouse α-human KIM127 Invivo
β2 (CD18) - mouse α-human mAb24 Hycult biotech
LFA-1 (CD11a) - mouse α-human HI111 BioLegend
Mac-1 (CD11b) - mouse α-human ICRF44 BioLegend
CD15 FITC mouse α-human HI98 BioLegend
CD66b PB mouse α-human G10F5 BioLegend
KV1.3 - rabbit α- polyclonal Alomone labs
GAPDH - mouse α- 6C5 Calbiochem
Secondary PE goat α-mouse - Pharmingen
Secondary Alexa488 donkey α-rabbit - Invitrogen
Secondary IRDye800CW goat α-rabbit - LI-COR
Secondary IRDye680RD goat α-mouse - LI-COR
IgG2a-isotype FITC rat α-mouse - eBioscience
IgG2a-isotype APC rat α-mouse RTK2758 BioLegend
IgG2b-isotype BV570 rat α-mouse RTK5430 BioLegend
IgG1b-isotype PE rat α-mouse - life technologies




3.1. Intravital microscopy of the mouse cremaster muscle
Intravital microscopy (IVM) of the mouse cremaster muscle was performed as previously
described150. Briefly, male mice were anesthetized by an intraperitoneal (i.p.) injection of
ketamine/xylazine (125 mg/kg body weight ketamine and 12.5 mg/kg body weight xylaxine
in a volume of 0.1 ml/8 g body weight). The trachea was canulated to ensure sufficient
breathing during image acquisition. The right carotid artery was canulated using a plastic
tube (outer and inner tube diameter: OD: 0.61 mm, ID: 0.28 mm) as well for later blood
sampling (using a ProCyte Dx; IDEXX Laboratories) or antibody administration. The cre-
master muscle was dissected, mounted and constantly superfused with a thermo-controlled
bicarbonate buffer194,195 throughout the entire experiment. IVM was carried out on an Olym-
pusBX51 WI microscope, equipped with a 40x objective (Olympus, 0.8NA, water immersion
objective) and a CCD camera (KAPPA CF 8 HS). Postcapillary venules were recorded using
VirtualDub and blood flow velocity of each venule was determined with the help of a
dual photodiode (Circusoft Instrumentation). Movie sequences were analyzed off-line with
ImageJ software192,193. Different approaches were used to study leukocyte recruitment in
vivo in the mouse cremaster muscle, reflecting different inflammatory scenarios.
3.1.1. TNF-α induced acute inflammation
Injection of TNF-α leads to strong inflammation, accompanied by transcriptional upregula-
tion of many important adhesion molecules, among them E-selectin and ICAM-195. 1 h prior
to induction of inflammation by intrascrotal injection (i.s.) of TNF-α (500 ng), WT or KV1.3-/-
mice were i.s. injected with either 1 µg PIF, a scrambled version of the peptide (scrPIF), a PIF
homolog (H-PIF), 30 µg PAP-1196, a combination of PIF and PAP-1, carrier substance (Ctrl,
0.25% DMSO/PBS), or left untreated, respectively. 2 h after TNF-α stimulation, IVM was
carried out. To study the different contributions of P- and E-selectin during leukocyte rolling
in TNF-α inflamed cremaster muscles, selectin-blocking antibodies were applied via the
carotid artery catheter during the experiments (α-E-selectin: clone: 9A9, 30 µg; α-P-selectin:
clone: RB40.34, 30 µg).
3.1.2. Perivascular neutrophils in TNF-α induced acute inflammation
After IVM, cremaster muscles were removed and fixed with 4% paraformaldehyde (PFA),
stained with Giemsa and mounted (Eukitt) to investigate leukocyte extravasation. Analysis
was conducted at the core facility Bioimaging of the Biomedical Center with a Leica DM2500
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microscope, equipped with a 100x objective (Leica, 1.4NA, oil immersion) and a Leica
DMC2900 CMOS camera.
3.1.3. Trauma induced acute inflammation
Surgical preparation of the cremaster muscle alone results in a rapid release of P-selectin
out of Weibel-Palade bodies and subsequent P-selectin dependent leukocyte rolling along
postcapillary venules91. To study the effects of PIF in this mild, trauma induced acute
inflammatory setting, WT mice received either 1 µg PIF or scrPIF i.s. 2 h prior to IVM.
During the experiment, P-selectin-blocking antibodies (30 µg) were applied via the carotid
artery catheter to fully abrogate leukocyte rolling.
3.1.4. CXCL1 induced leukocyte adhesion
To analyze CXCL1 induced LFA-1 activation in vivo, either 1 µg PIF or scrPIF was applied to
WT mice i.s. 2 h prior to IVM. Leukocyte adhesion was quantified before and after the ad-
ministration of 600 ng CXCL1 via the carotid artery catheter in the same postcapillary venule.
3.2. Neutrophil isolation
3.2.1. Isolation of murine neutrophils
Femurs and tibiae of male and female mice were flushed with PBS through a cell strainer
(grid size: 40 µm). Two different approaches were used to isolate neutrophils. For Percoll
density gradient centrifugation, two percoll solutions with different densities (1.11 and
1.08 g/ml) were layered and the flushed bone marrow derived cells were added on top.
After centrifugation at 1000 g for 30 min at room temperature (RT) without brakes, the
neutrophil-containing cell layer was carefully taken and resuspendend in Hanks Balanced
Salt Solution (HBSS, containing 0.1% Glucose, 1 mM CaCl2 and MgCl2, 0.25% BSA and
10 mM Hepes, pH 7.4). As a second approach, neutrophils were isolated using EasySep
neutrophil negative isolation kit according to the manufacturers protocol.
3.2.2. Isolation of human neutrophils
Blood was withdrawn from human healthy volunteer donors to isolate human neutrophils.
Therefore, two different approaches were used. For density centrifugation, whole blood was
added on a layer of Polymorphprep, centrifuged at 500 g for 30 min at RT without brakes
and the neutrophil- containing cell layer was taken and resuspended in HBSS. Again, an
EasySep neutrophil negative selection kit was used as an additional approach according to
the manufacturers protocol.
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3.3. Cultivation of Jurkat cells
Immortalized human T lymphocyte Jurkat cells were cultured in RPMI 1640 growth medium,
supplemented with 10% FCS, penicillin and streptomycin (both 100 U/ml) at 37 ◦C in 5%
CO2. Cells were a kind gift from Dr. Susanna Zierler (Walther-Straub-Insitute, LMU, Mu-
nich).
3.4. Flow chamber assays
To study the different steps of leukocyte recruitment in a more simplified scenario, small
rectangular borosilicate glass capillaries were coated with different combinations of ad-
hesion molecules to mimic the inflamed endothelium as previously described120. Ad-
hesion molecules were coated for 3 h at room temperature (RT) and blocked with 5%
Casein/PBS over night (ON). Experiments were carried out on an OlympusBX51 WI micro-
scope, equipped with a 20x objective (Olympus, 0.95NA, water immersion objective) and a
CCD camera (KAPPA CF 8 HS). Leukocyte rolling, leukocyte adhesion and leukocyte rolling
velocities were analyzed on the basis of the recorded movie sequences using ImageJ.
3.4.1. Selectin-dependent leukocyte rolling in vitro
Selectin-dependent leukocyte rolling was studied using E-selectin or P-selectin (both 20 µg/ml)
coated flow chambers (0.04 x 0.4 mm). Whole blood of male and female WT mice was col-
lected via the carotid artery catheter into heparinized tubes and incubated with 300 nM PIF,
scrPIF or vehicle control (Ctrl) for 10 min at RT. Flow chambers were perfused with the
pre-treated whole blood at a constant shear stress level of 2 dyne/cm2 using a high precision
syringe pump (Harvard Apparatus).
3.4.2. Leukocyte slow rolling and adhesion in vitro
To study leukocyte slow rolling velocities and adhesion in vitro, glass capillaries (0.04 x 0.4 mm)
were coated with E-selectin (20 µg/ml), ICAM-1 (15 µg/ml) and CXCL1 (15 µg/ml). Whole
blood from WT mice was again withdrawn via the carotid artery catheter into heparinized
tubes, incubated with 300 nM PIF or vehicle control (Ctrl) and perfused through the flow
chambers at a constant shear stress level of 2 dyne/cm2 again using a high precision syringe
pump.
3.4.3. Leukocyte slow rolling and adhesion ex vivo
Leukocyte adhesion and slow rolling was further investigated using ex vivo flow chambers.
Therefore, capillaries (0.04 x 0.4 mm) were coated either with E-selectin, ICAM-1 and CXCL1,
or with E-selectin and ICAM-1. Male WT mice pre-treated with an i.s. injection of either 1 µg
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PIF or scrPIF were directly connected via the carotid artery catheter to the flow chamber.
3.4.4. Human neutrophil rolling and slow rolling in vitro
To study rolling and slow rolling in human neutrophils, glass capillaries (0.2 x 2.0 mm) were
coated with E-selectin (5 µg/ml) alone or with a combination of E-selectin (5 µg/ml) and
ICAM-1 (4 µg/ml). Human neutrophils were isolated using density centrifugation and
incubated with either 100 nM PIF or scrPIF for 10 min at RT in HBSS and perfused through
the microflow devices (106/ml) at a constant shear stress level of 2 dyne/cm2 using a high
precision syringe pump. Movie sequences were recorded with a Zeiss Axioskop2 (provided
with a 20x water objective, 0.5NA and a Hitachi KP-M1AP camera) and analyzed using
ImageJ.
3.4.5. Neutrophil spreading in vitro
Spreading of human neutrophils was investigated in glass capillaries (0.2 x 2.0 mm) coated
with E-selectin (5 µg/ml), ICAM-1 (4 µg/ml) and CXCL8 (10 µg/ml). Human neutrophils
were isolated using density centrifugation and pre-treated with either 300 nM PIF, 10 nM
PAP-1 or vehicle control (Ctrl) for 10 min at RT in HBSS. Cells (106/ml) were then introduced
into the chambers with a constant shear stress level of 1 dyne/cm2 and changes in cell shape
were recorded with a Zeiss Axioskop2 (provided with a 20x water objective, 0.5NA and a
Hitachi KP-M1AP camera). Cell perimeter, circularity (defined as 4π [Area]
[Perimeter]2 ) and solidity
(defined as [Area]
[Convex Area] ) were quantified using ImageJ.
3.5. Fluorescence activated cell sorting (FACS)
3.5.1. Surfacemarkers
Expression levels of surface molecules which are important for neutrophil rolling and
adhesion were analyzed by flow cytometry150. To do this, WT mice received an i.s. in-
jection of 1 µg PIF or vehicle 2 h prior to exsanguination by retro-orbital puncture. In
another set of experiments WT and KV1.3-/- mice were exsanguinated without prior injection.
Whole blood was stained with antibodies against CD18 (β2, clone C71/16), CD11a (LFA-1,
clone M17/4), CD11b (Mac-1, clone M1/70), PSGL-1 (CD162, clone 2PH1), CD44 (clone
IM7), L-selectin (CD62L, clone MEL-14), and CXCR2 (CD182, clone 242216; all 5 µg/µl) for
15 min at RT. α-Ly6G was used to define the neutrophil population (5 µg/µl, clone 1A8).
Erythrocytes were lysed and cells were fixed using FACS lysing solution. Samples were
analyzed with a Beckman Coulter Gallios flow cytometer and Kaluza Flow analysis Software.
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3.5.2. Selectin binding
P- and E-selectin binding to neutrophils was performed as previously described197. Briefly,
WT mice received an i.s. injection of 1 µg PIF or scrPIF 2 h prior to exsanguination by retro-
orbital puncture. Whole blood was incubated with a Fc-blocking antibody (α-CD16/CD32)
for 15 min at 4 ◦C and rm selectin chimeras (recombinant peptide with a human IgG1 part,
3.6 µg/sample) were pre-complexed for 10min at RT with α-human Fc gamma-biotin. Cells
were then incubated with pre-complexed selectins for 50 min at 4 ◦C, fixed with FACS lysing
solution and further stained with fluorescent labeled streptavidin. As control, incubation
was carried out in the presence of EDTA (10 mM) to chelate Ca2+ which is required for
selectin-selectin ligand interaction. α-Ly6G was used to define the neutrophil population.
Samples were analyzed with a Beckman Coulter Gallios flow cytometer and Kaluza Flow
analysis Software.
3.5.3. Soluble ICAM-1 binding
Binding of soluble ICAM-1 to activated neutrophils was carried out as described recently124.
Bone marrow derived neutrophils from WT mice were isolated using Percoll densitiy gradi-
ent centrifugation and resuspended in HBSS buffer and incubated with 300 nM PIF or scrPIF
for 10 min at RT. ICAM-1 (40 µg/ml, with a human IgG1 part) was pre-complexed for 10 min
at RT with α-human Fc gamma-biotin and fluorescent labeled streptavidin and added to
the cells (1.5x106/sample) for 3 min at 37 ◦C together with CXCL1 (10 nM). Stimulation was
stopped by adding ice-cold FACS lysing solution to the cells. α-Ly6G was used to define
the neutrophil population. Samples were analyzed with a Beckman Coulter Gallios flow
cytometer and Kaluza Flow analysis Software.
3.5.4. LFA-1 activation
LFA-1 activation assay was performed as previously described120. Human neutrophils
were isolated using Polymorhprep and incubated with 100 nM PIF or scrPIF for 10 min
at RT. Cells (5x105/sample) were activated with CXCL8 (10 nM) in the presence of either
KIM127- or mAb24-antibody for 5 min at 37 ◦C, both detecting intermediate and high affinity
(KIM127, 10 µg/µl) or high affinity LFA-1 only (mAb24, 10 µg/µl)112 (Fig. 3.1). Stimulation
was stopped by adding ice-cold FACS lysing solution to the cells. α-CD15 (clone W6D3,
5 µg/µl) and α-CD66b (clone G10M5, 5 µg/µl) was used to define human neutrophil popu-
lation. Samples were analyzed with a Beckman Coulter Gallios flow cytometer and Kaluza
Flow analysis Software.
3.5.5. KV1.3 expression
Human and murine neutrophils were isolated using density centrifugation (Polymoprhprep
and Percoll respectively) and stained for 30 min with an α-KV1.3 antibody (polyclonal,













Figure 3.1.: Detection of different LFA-1 affinity states. KIM127 and mAB24 bind to distinct epitopes on the
β2 integrin subunit, serving as markers for integrin activation (α: α-subunit, β: β-subunit)112.
at RT. Jurkat cells were used as control. Samples were analyzed with a Beckman Coulter
Gallios flow cytometer and Kaluza Flow analysis Software. Neutrophils were assigned to
Ly6G-positive and CD15-, CD66b-double-positive populations, respectively.
3.6. Confocal microscopy
Murine and human neutrophils were isolated using density gradient centrifugation and
allowed to attach on poly-L-lysine (0.1%) coated object slides for 15 min. After fixation with
2% PFA for 10 min and blocking with 2% BSA for 1 h at RT, cells were stained ON at 4 ◦C
using α-KV1.3 antibody (polyclonal, rabbit, 5 µg/µl). Alexa488 coupled donkey α-rabbit
(5 µg/µl) was added for 1 h at RT before cell nuclei were stained with DAPI for 5 min at RT.
Samples were embedded in ProLong Diamond antifade mounting medium and imaged at
the Core facility Bioimaging of the Biomedical Center with a Leica SP8X WLL microscope,
equipped with a HC PL APO 40x/1.30NA oil immersion objective. Images were processed
(including removal of outliers and background subtraction in the 488 channel) using ImageJ.
3.7. Western blot
Murine and human neutrophils were isolated using the respective neutrophil enrichment
kit, lysed (106 cells/100 µl), homogenized with modified RIPA lysis buffer (150 mM NaCl,
1% Triton X-100, 0.5% Sodium deoxycholate, 50 mM Tris-HCl pH 7.3, 2 mM EDTA, supple-
mented with protease and phosphatase inhibitors and 1xLaemmli sample buffer) and boiled
for 5 min at 95 ◦C. Jurkat cells were used as positive control. Proteins were resolved by
12% SDS-PAGE and electrophoretically transferred onto PVDF membranes. After blocking,
membranes were incubated with rabbit α-KV1.3 (3 µg/µl) and mouse α-GAPDH (clone
6C5, 1.5 µg/µl) at 4 ◦C ON. Secondary antibodies (goat α-rabbit-IRDye 800CW and goat
α-mouse-IRDye 680RD were added for 1 h at RT. An Odyssey CLx (LI-COR Bioscience) was
used for detection.
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3.8. Patch clamp of isolated human neutrophils
Human neutrophils were isolated using neutrophil negative selection kit and resuspended in
HBSS. For patch clamp experiments in whole-cell configuration, neutrophils were seeded on
poly-D-lysine coated cover slips in standard extracellular solution (containing 140 mM NaCl,
2.8 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, 11 mM glucose, pH 7.2, 300 mOsm).
Borosilicate glass patch pipettes with a resistance of 2–3.5 MΩ were filled with intracellular
solution (containing: 134 mM KF, 2 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, 10 mM EGTA,
pH 7.2, 300 mOsm). Solutions were adjusted to 300 mOsm using a Vapro 5520 osmometer
(Wescor Inc). Cells were clamped at holding potentials of −80 mV intermitted by repeated
200 ms voltage steps from −80 mV to +40 mV using a 10 mV interval applied every 30 s. Cur-
rent maxima at +40 mV were used for the calculation of KV1.3 current amplitudes. Currents
were normalized to cell size as current densities in pA/pF. Capacitance was measured using
the automated capacitance cancellation function of the EPC-10 (HEKA, Harvard Bioscience).
300 nM PIF, 10 nM PAP-1, 1 µM TRAM-34 or carrier substance (Ctrl) were either added to the
bath solution at least 15 min prior to electrophysiological recordings or directly applied via
an application pipette using constant pressure. Experiments were analyzed using IgorPro6
software.
3.9. Transwell assay
Bone marrow derived murine neutrophils were isolated using EasySep neutrophil enrich-
ment kit and resuspended in HBSS. Cells were incubated with 300 nM PIF or scrPIF or
carrier substance for 10 min at RT. 3x105 cells in 100 µl HBSS were added into the upper
compartment and transmigration through the transwells (pore size 5 µm) was induced by
adding CXCL1 (in HBSS, 1 ng/ml or 10 ng/ml) into the lower compartment. Cells were
allowed to migrate for 45 min at 37 ◦C. Cells in the lower compartment were collected
and quantified with a Beckman Coulter Gallios flow cytometer and Kaluza Flow analysis
Software. α-Ly6G was again used to define the neutrophil population and Flow-Count
Fluorospheres were used to count the cells.
3.10. Electric Cell-Substrate Impedance Sensing (ECIS)
Endothelial electric resistance was measured using a electrical impedance system (ECIS
1600R; Applied BioPhysics). Human umbilical vein endothelial cells (HUVECs) from passage
1 or 2 were grown to confluence on coated (Ibidi-treat) gold microelectrodes. Cells were
stimulated with 10 ng/µl TNF-α in the presence of either 300 nM PIF or carrier substance





All data were analyzed and edited using GraphPad Prism 7 software and are depicted as
either mean±SEM, cumulative frequencies, mean or representative images/traces. Statistical
tests were carried out according to the number of groups being compared. For pairwise
comparison, unpaired or paired student’s t-test was used. For more than two groups, a 1-way
or 2-way analysis of variance (ANOVA) with either Dunnett’s (to compare experimental
groups against control) or Turkey’s (to compare all groups with each other) post-hoc test was
carried out. P-values <0.05 were considered statistically significant and marked as follows:
*: <0.05; **: <0.01; ***: <0.001.
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This project has emanated from my master’s thesis (title: ’Analysis of potential immune-
modulatory effects of PreImplantation factor (PIF) on leukocyte recruitment’ at the faculty of
Biology, LMU Munich, 2013). Results in Fig. 4.1-A, Fig. 4.2-A, Fig. 4.14-B, Fig. 4.18, and in
Fig. 4.20-B are based on experiments carried out during this period.
Major part of the present work has been assembled to a manuscript (see part IV) which will
be submitted soon to Science Immunology for peer review.
4.1. PIF disrupts neutrophil adhesion by reducing KV1.3-regulated
SOCE
4.1.1. PIF impairs leukocyte adhesion in vivo, ex vivo and in vitro
To investigate the influence of PIF on leukocyte adhesion in an acute inflammatory, predom-
inantly neutrophil driven198 setting, WT mice were i.s. injected with 1 µg PIF 1 h prior to
stimulation with TNF-α. 2 h after injection of TNF-α, IVM of the mouse cremaster muscle
was performed. As controls, either the carrier substance (Ctrl) or 1 µg of a scrambled version
of the peptide (scrPIF) was applied. In addition, another experimental group received 1 µg
of PIF obtained from a different manufacturer (homologous-PIF; H-PIF). Both, administra-
tion of PIF and H-PIF resulted in significantly reduced numbers of adherent leukocytes to
inflamed postcapillary venules (Fig. 4.1-A). Importantly, administration of PIF or H-PIF did
not alter systemic white blood cell counts (WBC) compared to controls (Tab. 4.1).
To discriminate between the contribution of the endothelial and the hematopoietic compart-
ment to the observed phenotype in vivo, in vitro flow chamber assays were carried out. To
do this, small glass capillaries were coated with E-selectin, ICAM-1 and CXCL1 to mimic
inflamed endothelium. Whole blood from WT mice was incubated with 300 nM PIF or
carrier substance (Ctrl) and perfused through the microfluidic devices at a constant shear
stress level of 2 dyne/cm2. Numbers of adherent leukocytes on the coated glass surface were
significantly decreased in the presence of PIF compared to control (Fig. 4.1-B), indicating
that the observed reduction of leukocyte adhesion in vivo is predominantly mediated by a
direct effect of PIF on leukocytes.
To further validate this assumption, WT mice were i.s. injected with 1 µg PIF or scrPIF
and 2 h later directly connected to E-selectin, ICAM-1 and CXCL1 coated flow chambers
via the carotid artery catheter. Indeed, i.s. application of PIF reduced number of adherent
leukocytes in ex vivo flow chambers to a similar extent as in vivo and in vitro (Fig. 4.1-C). Of
note, reduced leukocyte adhesion in vitro and ex vivo could not be attributed to differences
in number of overall WBCs or cells per field of view (FOV) (Tab. 4.2). Taken together, PIF
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reduces leukocyte adhesion in vivo in TNF-α induced acute inflammation, an effect which
may be primarily related to a direct impact of PIF on leukocytes, because the same reduction






































































Figure 4.1.: PIF impairs leukocyte adhesion in vivo, in vitro and ex vivo. (A) Number of adherent leukocytes
in TNF-α stimulated cremaster postcapillary venules of WT mice pre-treated with either vehicle control (Ctrl),
scrPIF, PIF or H-PIF, respectively (mean±SEM, n=8-10 mice per group, 1-way ANOVA, Tukey’s multiple
comparison, ns.: not significant). (B) Number of adherent leukocytes in E-selectin, ICAM-1 and CXCL1 coated
flow chambers perfused with whole blood from WT mice pre-incubated with either vehicle control (Ctrl) or PIF
(mean±SEM, n=5 mice per group, unpaired student’s t-test). (C) Number of adherent leukocytes in E-selectin,
ICAM-1 and CXCL1 coated flow chambers auto-perfused with whole blood from WT mice pre-treated i.s. with
either scrPIF or PIF (mean±SEM, n=5-6 mice per group, unpaired student’s t-test).
Table 4.1.: Hemodynamic parameters of WT mice treated with TNF-α. Ven.: venules, Ø: vessel diameter,
Syst. count: systemic white blood cell count (WBC). ns.: not significant (mean±SEM, 1-way ANOVA, Tukey’s
multiple comparison).
Treatment Mice Ven. Ø Centerline velocity Shear rate Syst. count
n n [µm] [µm/s] [s−1] [cells/µl]
Ctrl 8 23 33±1 1565±115 1171±81 4033±364
scrPIF 8 24 33±1 1621±134 1199±85 4095±508
PIF 10 33 32±1 1652±142 1296±116 3969±339
H-PIF 8 23 31±1 1674±145 1326±121 3889±223
ns. ns. ns. ns.
p=0.8872 p=0.9556 p=0.7081 p=0.9832
4.1.2. PIF prevents leukocyte slow rolling in vivo, ex vivo and in vitro
Neutrophil adhesion in TNF-α stimulated post-capillary venules of the mouse cremaster
muscle is predominantly mediated by the activated β2 integrin LFA-1 on neutrophils and
endothelium expressed ICAM-1199. β2 integrins further contribute to the deceleration of
rolling leukocytes during their recruitment87. To check whether reduced leukocyte adhesion
is caused by altered β2 integrin activation on leukocytes, leukocyte rolling velocities in
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Table 4.2.: Number of mice, flow chambers, cells per FOV, and WBCs in in vitro and ex vivo flow chamber
assays. WBC: white blood cell count, ns.: not significant (mean±SEM, unpaired student’s t-test).
Treatment Mice Flow chambers WBC Cells FOV-1
n n [cells/µl]
in vitro Ctrl 5 8 - 74±11
PIF 5 10 - 88±21
ns.
p=0.6038
ex vivo scrPIF 6 12 5608±632 34±5
PIF 5 10 5125±362 25±4
ns. ns.
p=0.5375 p=0.1722
TNF-α stimulated venules of cremaster muscles were analyzed. Injection of PIF and H-PIF
1 h prior to induction of inflammation resulted in increased rolling velocities along the
inflamed endothelium compared to controls (Fig. 4.2-A).
To demonstrate that increased slow rolling velocities are a consequence of direct interaction
of PIF with leukocytes, flow chamber assays were performed to measure leukocyte slow
rolling velocities in vitro. Incubation of murine whole blood with 300 nM PIF significantly in-
creased rolling velocities in E-selectin, ICAM-1 and CXCL1 coated flow chambers compared
to control treatment (Fig. 4.2-B). In line, i.s. injection of 1 µg PIF 2 h prior to investigation
significantly increased rolling velocities of leukocytes in E-selectin and ICAM-1 as well as
in E-selectin, ICAM-1 and CXCL1 coated autoperfused flow chambers compared to control
(Fig. 4.2,-C,-D). Additionally, rolling velocities of isolated human neutrophils were investi-
gated in E-selectin and in E-selectin and ICAM-1 coated microfluidic devices. As expected,
rolling velocities of control cells were significantly slower in E-selectin and ICAM-1 coated
flow chambers compared to E-selectin coated chambers (Fig. 4.2-E). Incubation with 100 nM
PIF in turn prevented neutrophil slow rolling on E-selectin and ICAM-1 substrate, whereas
E-selectin dependent rolling velocities were not altered. In summary, analyses of leukocyte
rolling velocities in vivo, in vitro and ex vivo revealed that leukocyte slow rolling is disturbed
in the presence of PIF, suggesting altered β2 integrin activity.
4.1.3. PIF does not change expression levels of adhesion relevant surface
molecules on neutrophils
To exclude that different levels of adhesion relevant molecules on neutrophils are the rea-
son for observed alterations in leukocyte interaction with inflamed endothelium, surface
expression of CD18 (β2 integrin subunit), CD11a (LFA-1), CD11b (Mac-1) and the GPCR
CXCR2 were analyzed on peripheral blood neutrophils with or without pre-treatment with
PIF. WT mice were i.p. injected with 1 µg PIF or carrier substance (Ctrl) 2 h prior to retro-
orbital exsanguination and subsequently analyzed by flow cytometry. Administration of
PIF did not alter expression levels of investigated surface molecules compared to control
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Figure 4.2.: PIF prevents leukocyte slow rolling in vivo, ex vivo and in vitro.( A) Leukocyte rolling velocities
in postcapillary venules of TNF-α treated mouse cremaster muscles, injected i.s. with either PIF, H-PIF, scrPIF or
carrier substance (Ctrl) 1 h prior to induction of inflammation (cumulative frequency, n= 192 (Ctrl), 215 (scrPIF),
222 (PIF), 164 (H-PIF) cells of 8-10 mice, 1-way ANOVA, Tukey’s multiple comparison, ns.: not significant).
(B) Leukocyte rolling velocties in E-selectin, ICAM-1 and CXCL1 coated flow chambers perfused with murine
whole blood, pre-incubated with PIF or vehicle (Ctrl, cumulative frequency, n= 78 (Ctrl), 90 (PIF) cells of 5 mice
per group, unpaired student’s t-test). WT mice were i.s. injected with PIF or scrPIF and directly connected to
microflow chambers 2 h after injection. Leukocyte rolling velocities were analyzed in (C) E-selectin and ICAM-1
(cumulative frequency, n= 80 (scrPIF), 80 (PIF) cells of 5-7 mice, unpaired student’s t-test) and in (D) E-selectin,
ICAM-1 and CXCL1 coated flow chambers (cumulative frequency, n= 74 (scrPIF), 43 (PIF) cells of 5-6 mice,
unpaired student’s t-test). (E) Rolling velocities of isolated human neutrophils on E-selectin and E-selectin and
ICAM-1 coated flow chambers (mean±SEM, E-selectin: n= 50 (scrPIF), 50 (PIF) of 4-5 donors, E-selectin, ICAM-1:
n= 60 (scrPIF), 60 (PIF) of 4 donors, 2-way ANOVA, Sidak’s multiple comparison).
be attributed to altered expression of β2 integrins or to different levels of CXCR2.
4.1.4. PIF does not alter β2 integrin activation
Next, the influence of PIF on β2 integrin activation was investigated by an ICAM-1 binding
assay. For this, bone marrow derived murine neutrophils were stimulated with CXCL1 to
induce GPCR mediated inside-out integrin activation and subsequent binding of integrins
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Figure 4.3.: PIF does not alter expression levels of adhesion relevant surface molecules on neutrophils.
Surface expression levels of (A) CD18, (B) CD11a, (C) CD11b and (D) CXCR2 on peripheral blood neutrophils of
WT mice injected i.p. with PIF or vehicle (Ctrl) (MFI= Mean fluorescence intensity, mean±SEM, n=3 mice per
group, unpaired student’s t-test, ns.: not significant).
to soluble ICAM-1. In this assay, binding of activated neutrophils to ICAM-1 is mainly medi-
ated by LFA-1124. Activation with CXCL1 increased the binding capacity of LFA-1 on control
neutrophils to ICAM-1 (Fig. 4.4-A). Pre-incubation with 300 nM PIF did not significantly
change this affinity, demonstrating that CXCL1 induced LFA-1 integrin activation is not
affected by the presence of PIF.
In a second set of experiments, human neutrophils were used in order to study the different
affinity states of LFA-1, the predominant β2 integrin mediating neutrophil adhesion199, in
more detail. Isolated human neutrophils were incubated with 100 nM PIF or scrPIF and
stimulated with CXCL8 in the presence of the LFA-1 binding antibodies KIM127 (recogniz-
ing the intermediate and fully activated β2 integrin conformation) or mAB24 (recognizing
exclusively the fully activated β2 integrin conformation, see Fig. 3.1). Application of CXCL8
increased binding of KIM127 and mAB24 to control neutrophils, reflecting LFA-1 activation
(Fig. 4.4-B,-C). No differences could be detected in PIF treated cells compared to control. In
addition, overall LFA-1 and Mac-1 surface expression before and after CXCL8 incubation
were monitored. In line with the previous experiments (Fig. 4.3), PIF did not change surface
levels of LFA-1 and Mac-1 on human neutrophils (Fig. 4.4-D,-E). These results indicate that
GPCR mediated inside-out signaling, leading to β2 integrin activation in neutrophils, is not
affected under static conditions by PIF.
4.1.5. KV1.3 is expressed on human and murine neutrophils
Conducted experiments revealed that impaired leukocyte adhesion in the presence of PIF
cannot be explained by an interference of PIF with β2 integrin activation. Therefore, alterna-
tive pathways important for leukocyte adhesion were studied. Mass spectometry analysis of
decidua cells revealed a multitude of potential binding partners of PIF70, but their functional
relevance has not been addressed so far. One putative candidate PIF is proposed to interfere
with, is the voltage gated potassium channel KV1.3. KV1.3 is expressed in vascular smooth




























































































































































Figure 4.4.: PIF does not alter β2 integrin activation. (A) CXCL1 induced binding capacity of bone marrow
derived murine neutrophils pre-incubated with PIF or scrPIF to ICAM-1 (MFI= Mean fluorescence intensity,
mean±SEM, n=4 mice per group, 2-way repeated measurements ANOVA, repeated Sidak’s multiple comparison).
(B) KIM127 and (C) mAB24 binding to human neutrophils pre-treated with PIF or scrPIF and stimulated with
CXCL8. (D) Total LFA-1 and (E) total Mac-1 expression of human neutrophils before and after stimulation with
CXCL8 (mean±SEM, n=3, 2-way repeated measurements ANOVA, repeated Sidak’s multiple comparison, ns.:
not significant).
sets182. In lymphocytes, it was shown to interfere with β1 integrin function200. Expression
of KV1.3 on neutrophils is controversial, since only one publication reported the presence of
the K+ channel on human neutrophils190 and functional data is lacking completely.
KV1.3 expression on neutrophils was assessed by western blot (Fig. 4.5-A), revealing expres-
sion on both, human and murine neutrophils. Jurkat cells, which are known to express
KV1.3201, were used as a positive control. Immune fluorescence stainings analyzed by
confocal microscopy and flow cytometry demonstrated surface location of KV1.3 on human
and murine neutrophils (Fig. 4.5-B and 4.5-C).
34

























































































































































Figure 4.5.: KV1.3 is expressed on human and murine neutrophils. (A) Total KV1.3 and GAPDH (loading
control) protein levels of human (hPMN) and murine neutrophils (mPMN). Jurkat cell lysates served as postive
control (representative blot; n=3). (B) Representative confocal micrographs of Jurkat cells, hPMNs and mPMNs
stained for KV1.3 (scale bar: 10 µm; n=3 independent experiments). (C) Surface expression of KV1.3 analyzed by
flow cytometry (representative overlays (upper panel) and quantification (lower panel); MFI= Mean fluorescence
intensity; mean±SEM, n=3-4, unpaired student’s t-test).
4.1.6. KV1.3 on human neutrophils is functional
Whole cell patch clamp technique was used to validate the electrophysiological function-
ality of KV1.3 on neutrophils. Isolated human neutrophils seeded on poly-D-lysine coated
cover slips were activated with a 10 mV step protocol ranging from −80 mV to +40 mV
at a holding potential of −80 mV with 30 s intervals202 to induce voltage activated potas-
sium currents. Control cells exhibited a typical voltage dependent increase of currents203,
(Fig. 4.6-A) which was reduced by pre-incubation of the cells with the KV1.3-specific inhibitor
5-(4-Phenoxybutoxy)psoralen (PAP-1, 10 nM)196 (Fig. 4.6-B). In addition, KV1.3-currents were
activated with a single voltage-step up to +40 mV before and after direct and local ap-
plication of PAP-1. Again, PAP-1 reduced potassium currents (Fig. 4.6-C), demonstrating
35
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expression of functional KV1.3 on primary human neutrophils.











































































Figure 4.6.: KV1.3 on human neutrophils is functional. Voltage-activated potassium currents induced by
application of consecutive 10 mV steps from −80 mV to +40 mV in (A) control and in (B) PAP-1 pre-treated
neutrophils (representative traces no. 1, 4, 8, 13; n=10 cells per group). (C) Potassium currents in human
neutrophils before (black) and after direct application of PAP-1 (grey) after current activation with a single
voltage-step from the holding-potential of −80 mV to +40 mV (representative traces; n=4 cells).
4.1.7. Genetic deletion and inhibition of KV1.3 impairs leukocyte adhesion in
vivo
To elucidate whether genetic deletion or pharmacological inhibition of KV1.3 affects leuko-
cyte adhesion in vivo similar to PIF treatment, KV1.3-/- mice191 were i.s. injected with TNF-α
2 h prior to IVM and numbers of adherent leukocytes to inflamed postcapillary venules in
the mouse cremaster were analyzed. Western blot and immune fluorescence staining were
carried out to prove absence of KV1.3 on protein level in knockout neutrophils (Fig. 4.7).
Genetic loss of KV1.3 resulted in decreased numbers of adherent cells to inflamed endothe-
lium compared to control (Fig. 4.8-A). Of note, this decrease was equivalent to the reduction
in PIF treated WT mice (Fig. 4.1-A). To demonstrate that PIF exerts its inhibitory effect on
leukocyte adhesion predominantly via interference with KV1.3, PIF was i.s. injected into
KV1.3-/- mice 1 h prior to induction of inflammation. Application of PIF did not further lower
leukocyte adhesion, indicating no additive effects of PIF in KV1.3-/- mice. In line, WT mice
i.s. injected with 30 µg PAP-1 1 h prior to TNF-α stimulation displayed a significant reduced
number of adherent leukocytes in postcapillary vessels of the cremaster muscle compared
to vehicle treated control mice (Fig. 4.8-B). Again, a combination of PIF and PAP-1 resulted
in the same phenotype. No differences in the overall WBCs could be detected among all
experimental groups in both settings (Tab. 4.3). Taken together, these results demonstrate
that KV1.3 is crucial for leukocyte adhesion in vivo. Lack or inhibition of KV1.3 leads to
reduced number of adherent leukocytes comparably to PIF treatment, suggesting that PIF
might influence leukocyte adhesion by interfering with KV1.3 activity.
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Figure 4.7.: Neutrophils from KV1.3-/- mice do not express KV1.3. (A) Total KV1.3 protein levels of Jurkat
cells (positive control) and of KV1.3-/- neutrophils. GAPDH served as loading control (representative blot; n=3
independent experiments). (B) Representative confocal micrographs of Jurkat cells and KV1.3-/- neutrophils



























































Figure 4.8.: Genetic deletion or pharmacological inhibition of KV1.3 impairs leukocyte recruitment in TNF-
α stimulated mouse cremaster muscle. (A) Leukocyte adhesion was analyzed in TNF-α stimulated mouse
cremaster muscles venules of WT and KV1.3-/- mice and of KV1.3-/- mice pre-treated with PIF (mean±SEM,
n=5 mice per group, 1-way ANOVA, Tukey’s multipe comparison, ns.: not significant). (B) Additionally, WT
mice received an i.s. injection of either vehicle (Ctrl), PAP-1 or PAP-1 plus PIF 1 h prior to TNF-α stimulation
and leukocyte adhesion was quantified (mean±SEM, n=4 mice per group, 1-way ANOVA, Tukey’s multipe
comparison).
4.1.8. Genetic deletion and inhibition of KV1.3 prevents leukocyte slow rolling
in vivo
Leukocyte rolling velocities were analyzed to investigate whether genetic loss or pharma-
cological inhibition of KV1.3 interferes with leukocyte slow rolling in vivo similar to PIF
treatment. WT, KV1.3-/- and KV1.3-/- mice pre-treated i.s. with 1 µg PIF, were stimulated i.s.
with TNF-α 2 h prior to IVM of the cremaster muscle and rolling velocities were analyzed.
KV1.3-/- leukocytes rolled significantly faster along inflamed postcapillary venules compared
to WT cells and additional PIF application did not further increase leukocyte slow rolling
velocities (Fig. 4.9-A). In addition, leukocyte rolling velocities in WT mice i.s. injected with
30 µg PAP-1 prior to TNF-α were significantly faster compared to control cells. A combi-
nation of PAP-1 and PIF did not further affect leukocyte slow rolling velocities, suggesting
37
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Table 4.3.: Hemodynamic parameters of WT and KV1.3-/- mice pre-treated as indicated prior to TNF-α stim-
ulation. Ven.: venules, Ø: vessel diameter, Syst. count: systemic white blood cell count (WBC). ns.: not
significant (mean±SEM, 1-way ANOVA, Tukey’s multiple comparison).
Mice Ven. Ø Centerline velocity Shear rate Syst. count
n n [µm] [µm/s] [s−1] [cells/µl]
WT 5 19 31±1 1737±151 1381±122 2064±234
KV1.3-/- 5 19 29±1 1742±150 1465±126 2516±456
KV1.3-/-+PIF 5 19 31±1 1900±106 1541±106 2956±347
ns. ns. ns. ns.
p=0.2633 p=0.6358 p=0.6350 p=0.2509
Ctrl 4 17 30±1 1753±172 1448±154 3818±189
PAP-1 4 15 30±1 2047±294 1677±230 4085±406
PAP-1+PIF 4 15 29±1 1513±157 1283±116 3393±495
ns. ns. ns. ns.
p=0.4690 p=0.3543 p=0.4324 p=0.2649
that genetic loss and pharmacological inhibition of KV1.3 impairs leukocytes to decelerate
during rolling along inflamed vessels in acute inflammations to a comparable extent as PIF
treatment.
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Figure 4.9.: Genetic deletion and inhibition of KV1.3 prevents leukocyte slow rolling. Leukocyte rolling
velocities were analyzed in TNF-α stimulated (A) WT, KV1.3-/- and KV1.3-/- mice pre-treated with PIF (cumulative
frequency, n=175 (WT), 123 (KV1.3-/-) 124 (KV1.3-/-+PIF) cells of 5 mice per group, 1-way ANOVA, Tukey’s
multiple comparison) and in (B) WT mice pre-treated with PAP-1, PAP-1 plus PIF or carrier substance (Ctrl,
cumulative frequency, n=136 (Ctrl), 105 (PAP-1), 82 (PAP-1+PIF) cells of 4 mice per group, 1-way ANOVA,
Tukey’s multiple comparison).
4.1.9. Genetic loss of KV1.3 does not alter surface expression levels of adhesion
relevant molecules
Expression levels of β2 integrins and the GPCR CXCR2 were also determined in peripheral
blood neutrophils from KV1.3-/- mice to exclude alterations in surface molecule composition
38
4.1. PIF disrupts neutrophil adhesion by reducing KV1.3-regulated SOCE

















































































































Figure 4.10.: Genetic deletion of KV1.3 does not alter the expression of adhesion relevant surface molecules
on peripheral blood neutrophils. Expression levels of (A) CD18, (B) CD11a, (C) CD11b, and (D) CXCR2 were
measured by flow cytometry (MFI: mean fluorescence intensity; mean±SEM, n=3 mice per group, unpaired
student’s t-test, ns.: not significant).
as a reason for the observed adhesion defect in knockout mice. Indeed, no differences in
CD18, CD11a, CD11b and CXCR2 surface expression could be detected in knockout cells
compared to WT control (Fig. 4.10).
4.1.10. PIF reduces voltage-induced KV1.3 currents in KV1.3-overexpressing
HEK-293 cells
To test whether PIF modifies neutrophil function by inhibition of KV1.3, whole cell patch
clamp experiments were conducted using KV1.3-overexpressing HEK-293 cells (hKV1.3-
HEK-293). Experiments were carried out in collaboration with Susanna Zierler and Wiebke
Nadolni from the Walther-Straub-Institut, LMU, Munich, Germany (see Fig. A.1 in A.1),
demonstrating that PIF inhibits KV1.3 in a dose dependent manner with an IC50 of 10.2±5 nM.
4.1.11. PIF reduces voltage-induced KV1.3 currents in human neutrophils
Whole cell patch clamp experiments were repeated with isolated human neutrophils to verify
PIF’s inhibitory properties on KV1.3 in these cells. The same consecutive step protocol was
applied to induce KV1.3-specific currents in neutrophils incubated with either 300 nM PIF,
10 nM PAP-1, or carrier substance (Ctrl). In addition, neutrophils were treated with 1 µM 1-
[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34), a specific inhibitor for KCa3.1204,
a K+ channel also expressed on neutrophils205. Control cells developed voltage-dependent
currents upon activation (Fig. 4.11-A). Pre-incubation with PIF in turn significantly inhibited
voltage induced currents, comparably to inhibition using PAP-1 (Fig. 4.11-B, -C and -E).
Application of TRAM-34 to the cells did not significantly lower currents (Fig. 4.11-D). These








































































































































Figure 4.11.: PIF reduces voltage-induced KV1.3 currents in human neutrophils. Voltage-dependent KV1.3
currents in human neutrophils, triggered by the application of 13 consecutive 10 mV voltage steps from −80 mV
to +40 mV after incubation with (A) carrier substance (Ctrl, representative traces no. 1, 4, 8, 10, 13, of n=15 cells),
(B) PIF (representative traces no. 1, 4, 8, 13 of n=8 cells), (C) PAP-1 (representative traces no. 1, 4, 8, 13, of n=10
cells), or (D) TRAM-34 (representative traces no. 1, 4, 8, 12, of n=13 cells). (E) Quantification of current densities
extracted at 100 ms (mean±SEM, 1-way ANOVA, Tukey’s multiple comparison, ns.: not significant).
4.1.12. Inhibition of KV1.3 by PIF impairs calcium signaling in human
neutrophils
In lymphocytes, KV1.3 was shown to be involved in the regulation of Ca2+ signaling by
sustaining Ca2+ influx via store-operated Ca2+ entry (SOCE)156. K+ efflux via KV1.3 maintains
an electrical gradient over the cell membrane, enabling continuous Ca2+ influx into the
cells183. To elucidate the role of KV1.3 in Ca2+ signaling in human neutrophils, Scott I.
Simon and Vasilios Morikis from the University of California, Davis, USA investigated in
a collaboration changes in [Ca2+]i in isolated human neutrophils in the presence of PIF
and PAP-1. Their experiments demonstrated that inhibition of KV1.3 in neutrophils using
PIF and PAP-1 significantly reduces [Ca2+]i both, under static and under flow conditions,
thereby revealing a substantial contribution of KV1.3 to regulation of SOCE in neutrophils.
(see Fig. A.2, Fig. A.3 and Fig. A.4 in A.2).
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4.1.13. PIF impairs post-arrest modifications in neutrophils
High [Ca2+]i in neutrophils during arrest is essential for the cells to polarize and to initialize
a migratory phenotype165,166. To study how reduced [Ca2+]i upon KV1.3 inhibition via PIF
influences post-arrest modifications under shear, neutrophil spreading was observed. Flow
chambers were coated with E-selectin, ICAM-1 and CXCL8 and isolated human neutrophils
pre-incubated with either 300 nM PIF, 10 nM PAP-1 or vehicle (Ctrl). Neutrophils were
then introduced into the chambers to monitor changes in cell shape over time at a constant
shear stress level of 1 dyne/cm2 (Fig. 4.12-A). Analysis of cell perimeter, cell circularity
(reflecting the roundness of a cell) and cell solidity (reflecting the number of extensions
and protrusions of a cell) revealed that neutrophils incubated with PIF or PAP-1 remained
smaller (Fig. 4.12-B), rounder (Fig. 4.12-C) and displayed fewer protrusions (Fig. 4.12-D) over
time. These results demonstrate that inhibition of KV1.3 with PIF or PAP-1 reduces the
ability of neutrophils to spread properly and to polarize under physiological shear stress
conditions.
4.1.14. PIF increases susceptibility to shear forces in vitro and in vivo
To evaluate whether the disability of neutrophils to polarize and to switch to a migratory
phenotype in the presence of PIF has implications on the resistance to shear forces, a
detachment-assay was carried out by Anna Yevtushenko in the course of a Bachelor’s
thesis (title: ’The role of PreImplantation Factor (PIF) in leukocyte recruitment’ at the faculty
for Chemistry and Pharmacy, LMU Munich, 2017), co-supervised by me. In this assay,
incubation with PIF or PAP-1 resulted in an higher susceptibility to increasing shear forces
(see Fig. A.5 in A.3).
To validate these findings in an in vivo setting, WT mice were injected i.s. with 1 µg PIF or
scrPIF 2 h prior to dissection of the cremaster muscle and subsequent IVM. One postcapillary
venule was recorded before and after application of 600 ng CXCL1 via the carotid catheter
and number of adherent leukocytes was assessed. Injection of CXCL1 induced a strong
increase in adherent leukocytes 1 min after injection in scrPIF controls compared to before
and number of adherent leukocytes did not change after 5 min (Fig. 4.13). An initial increase
in number of adherent cells 1 min after CXCL1 application could be observed in PIF treated
animals as well. In contrast to control treatment, number of adherent cells already decreased
5 min after in vivo stimulation, suggesting that in PIF treated animals, CXCL1 injection is
able to initially increase leukocytes adhesion, but activated and arrested cells are not able to
efficiently adhere under in vivo flow conditions. Of note, hemodynamic parameters did not
differ among the groups (Tab. 4.4).
Summarizing, PIF reduces leukocyte adhesion and prevents leukocyte slow rolling in vivo in
a mouse model of TNF-α induced acute inflammation. In vitro and ex vivo flow chambers and
functional assays revealed that this phenotype is due to a direct effect of PIF on leukocytes,
but not mediated by an interference of PIF with β2 integrin surface expression or activation.
In turn, PIF inhibits KV1.3 on neutrophils, thereby reducing β2 integrin and GPCR mediated
increase in [Ca2+]i. Reduced [Ca2+]i leads to impaired neutrophil spreading and adhesion



















































































Figure 4.12.: PIF impairs neutrophil spreading. Isolated human neutrophils were incubated with either PIF,
PAP-1 or vehicle (Ctrl) and introduced into E-selectin, ICAM-1 and CXCL8 coated flow chambers. (A) Changes
in cell shape was investigated over time and (B) cell perimeter, (C) cell circularity and (D) cell solidity were
analyzed (mean±SEM, n=49 (Ctrl), 60 (PAP-1) and 42 (PIF) cells from n=5 independent experiments, 1-way
ANOVA, Dunnett’s multiple comparison).
4.2. PIF reduces extravasation of neutrophil into inflamed tissue
4.2.1. PIF reduces the number of transmigrated neutrophils in TNF-α
stimulated cremaster muscles
To exert its functions during acute inflammatory processes, neutrophils need to exit the
vascular compartment and enter the surrounding tissue86. To see whether PIF treatment
also influences the number of perivascular leukocytes in acute inflammation, neutrophil
extravasation was assessed in TNF-α stimulated cremaster muscles. Therefore, 1 µg PIF was
injected i.s. into WT mice 1 h prior to TNF-α stimulation. 2 h later cremaster muscles were
removed, fixed, stained with Giemsa and number of transmigrated leukocytes was analyzed.
As controls, mice received either an i.s. injection of 1 µg scrPIF or carrier substance (Ctrl)
(Fig. 4.14-A). PIF treated animals exhibited significantly reduced numbers of perivascular
42































Figure 4.13.: PIF increases susceptibility to shear forces in vivo. WT mice were i.s. injected with PIF or scrPIF
2 h prior to IVM of the mouse cremaster muscle. Number of adherent leukocyte were analyzed before and
after application of CXCL1 via the carotid catheter (n=4-5 mice, repeated 2-way ANOVA, Sidak’s and Tukey’s
multiple comparison, ns.: not significant).
Table 4.4.: Hemodynamic parameters before and after CXCL1 injection in vivo. Ø: vessel diameter, WBC:
white blood cell count, ns.: not significant (mean±SEM, unpaired student’s t-test).
Time Treatment Ø Centerline velocity Shear rate WBC
[µm] [µm/s] [s−1] [cells/µl]
before scrPIF 32±1 1900±430 1449±322 5983±651
PIF 30±2 2260±340 1861±335 7250±751
ns. ns. ns. ns.
p=0.4634 p=0.5262 p=0.4122 p=0.2565
60s scrPIF - 2100±567 1622±446 -
PIF - 2240±470 1873±448 -
- ns. ns. -
- p=0.8532 p=0.7074 -
360s scrPIF - 1675±496 1290±380 3683±342
PIF - 2280±445 1903±430 4618±553
- ns. ns. ns.
- p=0.3944 p=0.3341 p=0.2204
neutrophils in stimulated cremaster muscles compared to both controls, whereas number of
perivascular eosinophils and other leukocyte subsets was not altered (Fig. 4.14-B).
4.2.2. Inhibition and genetic deletion of KV1.3 reduces the number of
transmigrated neutrophils in TNF-α stimulated cremaster muscles
Neutrophil migration and cytoskeletal rearrangement are highly dependent on changes in
[Ca2+]i 158. Since KV1.3 regulates Ca2+ influx via SOCE in neutrophils, KV1.3-/- mice and PAP-
1 treatment were used to investigate neutrophil extravasation as a function of KV1.3 activity.
Cremaster muscles from untreated WT and KV1.3-/- mice and from WT mice i.s. injected

































Figure 4.14.: PIF reduces the number of transmigrated neutrophils in TNF-α stimulated cremaster muscles.
(A) Giemsa stained cremaster muscles from WT mice pre-treated with either PIF, scrPIF or carrier substance
(Ctrl) 1 h prior to TNF-α stimulation were analyzed (representative micrographs, scale bar: 30 µm) and (B) the
number of extravasated leukocytes was analyzed (Eos: eosinophils, mean±SEM, n=3 mice per group, 1-way
ANOVA, Tukey’s multiple comparison, ns.: not significant).
of extravasated leukocytes (Fig. 4.15-A). Both, inhibition and genetic deletion of KV1.3
significantly lowered the number of transmigrated neutrophils into inflamed tissue compared
to WT (Fig. 4.15-B), not affecting the number of perivascular eosinophils and other leukocyte
subsets. These observations suggest that reduced numbers of perivascular neutrophils in PIF
treated animals are a consequence of KV1.3 inhibition. Whether this phenotype is a direct
consequence of reduced leukocyte adhesion, or whether PIF additionally affects neutrophil



































Figure 4.15.: Inhibition and genetic loss of KV1.3 reduces the number of transmigrated neutrophils in TNF-
α stimulated cremaster muscles. (A) TNF-α stimulated cremaster muscles from WT and KV1.3-/--mice and from
WT mice pre-treated with PAP-1 were stained with Giemsa (representative micrographs, scale bar: 30 µm) and
(B) the number of extravasated leukocytes was quantified (Eos: eosinophils, mean±SEM, n=3 mice per group,
1-way ANOVA, Tukey’s multiple comparison, ns.: not significant).
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4.2. PIF reduces extravasation of neutrophil into inflamed tissue
4.2.3. PIF impairs neutrophil recruitment in an animal model of acute lung
injury (ALI) after LPS stimulation.
Many severe airway diseases such as bronchitis, cystic fibrosis, chronic obstructive pulmonary
disease (COPD) or acute lung injury (ALI) are characterized by substantial neutrophil infiltra-
tion206,207. To investigate whether inhibition of KV1.3 by PIF might be a suitable therapeutic
approach to treat overgrowing neutrophil infiltration in a clinically relevant setting, an
ALI-mouse model after LPS inhalation208 was carried out in collaboration with Oliver
Söhnlein, Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany,
Jochen Grommes and Jessica Tilgner, RWTH Aachen, Aachen, Germany. In line with the
TNF-α cremaster muscle model, they could show that PIF treatment significantly reduced
neutrophil infiltration into LPS stimulated lung tissue (Fig. A.6 in A.4).
4.2.4. PIF does not change neutrophil transmigration in a transwell assay
Next, a transwell assay was carried out to delineate whether PIF treatment directly influences
the ability of neutrophils to sense chemokines, thereby altering transmigration. Bone marrow
derived murine neutrophils were incubated with 300 nM PIF, scrPIF or vehicle (Ctrl) and
allowed to transmigrate through transwells towards different concentrations of CXCL1
(0.1, 1, 10 nM) for 45 min. CXCL1 in the lower compartment caused the cells to transmigrate
through the pores in a dose-dependent manner compared to unstimulated conditions, with
no differences in PIF treated cells compared to controls (Fig. 4.16). These results indicate






























Figure 4.16.: PIF does not change neutrophil transmigration in a transwell assay. Isolated murine neutrophils
were incubated with either PIF, scrPIF or vehicle (Ctrl) and transmigration was induced by different concen-
trations of CXCL1 (mean±SEM, n=4 mice per group, repeated 1-way ANOVA, repeated Tukey’s multiple
comparison, ns.: not significant).
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4.2.5. PIF reduces vascular leakage in a model of ALI but does not alter TNF-α
induced changes in the resistance of HUVEC monolayers
Massive infiltration of neutrophils into inflamed lungs is accompanied by an increase in
permeability and by elevated protein content in the BAL, due to endothelial and epithelial
injury207. Hence, in addition to the assessment of neutrophil recruitment to inflamed lungs
in the ALI model, LPS induced vascular leakage was determined208 by Oliver Söhnlein,
Jochen Grommes and Jessica Tilgner, showing that PIF pre-treatment prior to LPS inhalation
significantly reduced vascular leakage (Fig. A.7 in A.5).
To find indications if PIF directly affects the integrity of stimulated endothelial cells, ECIS
measurements were carried out. HUVEC cells were grown to confluence, 300 nM PIF or
vehicle (Ctrl) was added together with 10 µg/ml TNF-α and impedance was measured
over time. Application of TNF-α reduced resistance of a HUVEC monolayer compared to
non-stimulated cells (w/o) and no differences could be observed in HUVEC cells treated
with PIF, indicating no effect of PIF on the integrity of endothelial cells in a static in vitro
model.
Taken together, besides impaired leukocyte adhesion, PIF treatment reduces numbers of
perivascular neutrophils in vivo in two animal models of acute inflammation. Lower numbers
of transmigrated neutrophils could be attributed to the inhibitory effect of PIF on KV1.3.
Further, PIF does not alter neutrophil sensing of the chemokine CXCL1 in an tanswell
assay. In an acute lung injury model after LPS inhalation, PIF treatment kept endothelial
permeability on basal levels, but impedance measurements of TNF-α stimulated HUVEC
cells did not reveal any changes in endothelial integrity upon PIF stimulation.






























Figure 4.17.: PIF does not alter integrity of cultured HUVEC cells upon TNF-α stimulation. In ECIS experi-
ments, resistance of HUVEC monolayers treated with PIF or vehicle (Ctrl) was measured after TNF-α stimulation.
As control HUVEC cells were left untreated (w/o, mean±SEM, n=5 independent experiments, repeated 1-way
ANOVAs, Tukey’s multiple comparison).
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4.3. PIF alters selectin dependent leukocyte rolling
4.3.1. PIF alters leukocyte rolling in vivo
Here, the influence of PIF on leukocyte rolling was investigated. For that purpose, WT
mice were i.s. injected with either 1 µg of PIF, scrPIF, H-PIF or carrier substance (Ctrl),
respectively 1 h prior to i.s. stimulation with TNF-α. 2 h later leukocyte rolling in postcapil-
lary venules of the cremaster muscle was assessed using IVM. Administration of PIF and
H-PIF resulted in reduced rolling flux fraction (number of rolling leukocytes, normalized to
vessel size, blood flow velocity and WBC198) compared to both controls (Fig. 4.18-A, (none)).
To investigate the different contributions of endothelial expressed selectins on leukocyte
rolling, selective antibodies against E- and P-selectin were injected into the mice during the
experiments via the carotid artery catheter. P-selectin dependent rolling after administration
of E-selectin blocking antibodies was significantly reduced in PIF and H-PIF pre-treated
animals compared to controls (Fig. 4.18-A, (anti-E)) whereas E-selectin dependent rolling
after administration of P-selectin blocking antibodies was not significantly different among
all groups (Fig. 4.18-A, (anti-P)). Blockade of both, E- and P-selectin almost completely
abolished leukocyte rolling in all treatment groups, demonstrating that leukocyte rolling
in post-capillary venules of TNF-α stimulated mouse cremaster muscles is predominantly
mediated by these two selectins. Of note, hemodynamic parameters did not differ among
experimental groups (Tab. 4.1 and Tab. 4.5).
In addition to TNF-α induced inflammation, leukocyte rolling was also assessed in a trauma
induced acute inflammatory scenario. Here, surgical preparation of the cremaster muscle
alone leads to a rapid release of P-selectin out of Weibel-Palade bodies and subsequent
P-selectin dependent rolling91. WT mice were i.s. injected with 1 µg PIF or scrPIF and
IVM was carried out 2 h later. Analysis revealed that the number of rolling leukocytes was
significantly decreased compared to control (Fig. 4.18-B). Application of P-selectin antibod-
ies via the carotid artery catheter completely abolished leukocyte rolling, demonstrating
that rolling is exclusively P-selectin mediated in the trauma induced acute inflammation.
P-selectin-dependent leukocyte rolling velocities were measured as well, revealing increased
rolling velocities in PIF treated animals compared to control (Fig. 4.18-C). Application of PIF
did not change the WBC (Tab. 4.6). In summary, PIF affects P-selectin dependent leukocyte
rolling in TNF-α and trauma induced inflammation, suggesting that P-selectin dependent
rolling is controlled by PIF.
4.3.2. PIF does not influence the expression level of surface molecules important
for neutrophil rolling
PSGL-1 is the major selectin ligand on neutrophils100,209, but also CD44 and L-selectin
contribute to leukocyte rolling97,108. Therefore, expression levels of these surface molecules
were determined by flow cytometry. I.p. injection of 1 µg PIF 2 h prior to retro-orbital
exsanguination did not alter the expression of PSGL-1, CD44 or L-selectin compared to ap-
plication of carrier substance (Ctrl, Fig. 4.19), displaying that alteration in surface expression





























































































Figure 4.18.: PIF alters leukocyte rolling in vivo. (A) IVM was carried out in TNF-α stimulated WT mice
pre-treated with either PIF, scrPIF, H-PIF or carrier substance (Ctrl) to analyze leukocyte rolling before (none)
and after administration of selectin blocking antibodies (9A9: E-selectin blocking antibody, RB40.34: P-selectin
blocking antibody, mean±SEM, n=8-10 mice per group, 1-way ANOVA, Tukey’s multiple comparison, ns.:
not significant). WT mice were injected with PIF or scrPIF 2 h prior to IVM to quantify (B) leukocyte rolling
(mean±SEM, n=7 mice per group, 2-way ANOVA, Sidak’s multiple comparison) and (C) leukocyte rolling
velocity in trauma induced acute inflammation (cumulative frequency, n=258 (scrPIF), 234 (PIF) of 7 mice per
group, unpaired student’s t-test).
Table 4.5.: Hemodynamic parameters of WT mice treated with TNF-α after the application of selectin block-
ing antibodies 9A9: E-selectin blocking antibody, RB40.34: P-selectin blocking antibody, Ven.: venules, Ø:
vessel diameter, Syst. count: systemic white blood cell count (WBC). ns.: not significant (mean±SEM, 1-way
ANOVA, Tukey’s multiple comparison).
Mice Ven. Ø Centerline velocity Shear rate Syst. count
n n [µm] [µm/s] [s−1] [cells/µl]
9A9 Ctrl 5 14 35±1 1529±288 1089±211 4250±369
scrPIF 5 16 32±1 1638±198 1229±137 4190±735
PIF 5 20 32±1 1605±142 1226±107 5054±846
H-PIF 5 15 32±1 1987±157 1549±115 5364±770
ns. ns. ns. ns.
p=0.1503 p=0.3899 p=0.1680 p=0.5711
RB40.34 Ctrl 3 12 33±2 1808±234 1393±218 3803±466
scrPIF 3 12 32±1 1883±304 1477±255 5763±537
PIF 3 10 31±1 1940±298 1578±266 5337±289
H-PIF 3 11 33±2 1855±234 1370±159 4950±391
ns. ns. ns. ns.
p=0.6957 p=0.9889 p=0.9222 p=0.0574
9A9 & RB40.34 Ctrl 4 9 34±1 1189±70 862±52 4885±696
scrPIF 3 8 31±1 1900±253 1490±163 8080±812
PIF 3 10 32±1 1650±243 1399±202 7143±797
H-PIF 3 9 33±1 1900±242 1425±184 6543±1489
ns. ns. ns. ns.
p=0.2328 p=0.0897 p=0.0504 p=0.1654
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Table 4.6.: Hemodynamic parameters of WT mice in a trauma induced inflammation model of the mouse
cremaster before and after the application of P-selectin blocking antibodies. RB40.34: P-selectin blocking
antibody, Ven.: venules, Ø: vessel diameter, Syst. count: systemic white blood cell count (WBC). ns.: not
significant (mean±SEM, unpaired student’s t-test).
Mice Ven. Ø Centerline velocity Shear rate Syst. count
n n [µm] [µm/s] [s−1] [cells/µl]
scrPIF 7 26 32±1 1585±128 1227±98 6620±535
PIF 7 26 32±1 1665±126 1291±93 6710±595
ns. ns. ns. ns.
p=0.7141 p=0.6555 p=0.6387 p=0.9123
RB40.34 scrPIF 4 12 31±1 1550±179 1228±148 5813±741
PIF 4 14 31±1 1940±298 1550±163 5950±479
ns. ns. ns. ns.

















































































Figure 4.19.: PIF does not influence the expression level of surface molecules important for neutrophil
rolling. PIF or carrier substance (Ctrl) was injected into WT mice 2 h prior to exsanguination and surface
expression of (A) PSGL-1, (B) CD44 and (C) L-selectin was measured by flow cytometry (MFI: mean fluorescence
intensity, mean±SEM, n=3 mice per group, unpaired student’s t-test, ns.: not significant).
leukocyte rolling.
4.3.3. PIF does not change neutrophil binding capacity to E- and P-selectin in
vitro
Next, binding capacity of murine peripheral blood neutrophils to E- and P-selectin was
assessed by flow cytometry. WT mice were i.s. injected with 1 µg PIF, scrPIF or carrier
substance (Ctrl) 2 h prior to retro-orbital exsanguination and whole blood was incubated
with either E- or P-selectin. As a negative control whole blood was incubated with selectins
in the presence of EDTA to chelate divalent ions which are necessary for selectin–PSGL-1
interaction91. Neutrophils from PIF pre-treated animals did not exhibit altered binding to
neither E-, nor P-selectin (Fig. 4.20), suggesting that selectin–selectin ligand interaction is not


























































































Figure 4.20.: PIF does not change neutrophil binding capacity to E- and P-selectin under static conditions
in vitro. Binding capacity of peripheral blood neutrophils from WT mice pre-treated with either PIF, scrPIF
or carrier substance (Ctrl) to (A) E-selectin (mean±SEM, n=6 mice per group, 2-way repeated measurements
ANOVA, Tukey’s multiple comparison) and (B) P-selectin (mean±SEM, n=4 mice per group, 2-way repeated
measurements ANOVA, Tukey’s multiple comparison, ns.: not significant) was measured by flow cytometry.
4.3.4. Genetic deletion or pharmacological inhibition of KV1.3 does not
influence leukocyte rolling in vivo
PIF inhibits KV1.3 on neutrophils, thereby reducing the ability of the cells to adhere and to
withstand shear forces. To investigate whether interference of PIF with KV1.3 activity results
also in reduced leukocyte rolling in vivo, IVM of TNF-α stimulated creamster muscle venules
of KV1.3-/- mice was performed. Surprisingly, lack of KV1.3 did not change the number of
rolling cells compared to WT controls, but i.s. injection of 1 µg PIF 1 h prior to onset of
inflammation significantly reduced leukocyte rolling in knock-out animals (Fig. 4.21-A). In
addition, WT mice were pre-treated with 30 µg PAP-1 or carrier substance (Ctrl) 1 h prior to
TNF-α stimulation. In line with the experiments using KV1.3-/- animals, pharmacological
inhibition of KV1.3 did not alter leukocyte rolling compared to control, but a combination of
PAP-1 and 1 µg PIF together significantly reduced number of rolling leukocytes (Fig. 4.21-B).
These results clearly demonstrate that PIF interferes with leukocyte rolling independent of
its inhibitory capacity on KV1.3.
4.3.5. Genetic deletion of KV1.3 does not alter the expression of rolling relevant
surface molecules on peripheral blood neutrophils
Next, surface expression of molecules important for neutrophil rolling was determined in
WT and KV1.3-/- peripheral blood neutrophils. As expected, surface expression of PSGL-1,
CD44 and L-selectin were not found to be different on knockout neutrophils compared to
WT control (Fig. 4.22).
4.3.6. PIF does not alter E- and P-selectin dependent leukocyte rolling in vitro.
As a last step, leukocyte rolling was analyzed in E- and P-selectin coated flow chambers
in vitro. Whole blood from WT mice was incubated with 300 nM PIF, scrPIF or vehicle
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Figure 4.21.: Genetic deletion or pharmacological inhibition of KV1.3 does not influence leukocyte rolling.
(A) WT, KV1.3-/-- and KV1.3-/--mice pre-treated with PIF were i.s. stimulated with TNF-α and number of rolling
leukocytes in postcapillary venules of the cremaster muscle was analyzed by IVM (mean±SEM, n=5 mice per
group, 1-way ANOVA, Tukey’s multipe comparison). (B) WT mice were injected with PAP-1, a combination of
PAP-1 and PIF, or carrier substance (Ctrl) and leukocyte rolling was assessed by IVM (mean±SEM, n=4 mice per

















































































Figure 4.22.: Genetic deletion of KV1.3 does not alter the expression of rolling relevant surface molecules
on peripheral blood neutrophils. Expression levels of (A) PSGL-1, (B) CD44 and (C) L-selectin were measured
by flow cytometry on KV1.3-/- and WT neutrophils. (MFI: mean fluorescence intensity; n=3 mice per group,
unpaired student’s t-test, ns.: not significant).
(Ctrl) and perfused through mircofluidic devices coated with either E-selectin or P-selectin,
respectively at a defined shear stress level of 2 dyne/cm2 (Tab. 4.7). Incubation of murine
whole blood with PIF did neither change the number of rolling cells, nor rolling velocities in
E-selectin and in P-selectin coated flow chambers compared to controls (Fig. 4.23).
Taken together, PIF reduces P-selectin dependent leukocyte rolling in TNF-α induced inflam-
mation in vivo. This reduction is independent of PIF mediated inhibition of KV1.3. Neither
the expression of rolling relevant surface molecules, nor selectin binding capacity is affected
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by the presence of PIF. In vitro flow chamber assays demonstrated that changes in selectin
dependent rolling in vivo are not due to a direct effect of PIF selectins or selectin ligands,










































































































Figure 4.23.: PIF does not change E- and P-selectin dependent leukocyte rolling in in vitro microflow cham-
bers. Murine whole blood was incubated with PIF, scrPIF or vehicle (Ctrl) and perfused through E-selectin
coated flow chambers to assess (A) E-selectin-dependent leukocyte rolling (mean±SEM, n=5 mice per group,
1-way ANOVA, Tukey’s multiple comparison, ns.: not significant) and (B) E-selectin-dependent leukocyte rolling
velocity (cumulative frequency, n=80 (Ctrl), 90 (scrPIF), 80 (PIF) cells of 5 mice per group, 1-way ANOVA,
Tukey’s multiple comparison). Additionally, P-selectin coated flow chambers were perfused as well and (C)
P-selectin-dependent leukocyte rolling (mean±SEM, n=4-5 mice per group, 1-way ANOVA, Tukey’s multiple
comparison) and (D) P-selectin dependent rolling velocities were analyzed (cumulative frequency, n=70 (Ctrl),
70 (scrPIF), 80 (PIF) cells of 4-5 mice per group, 1-way ANOVA, Tukey’s multiple comparison).
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Table 4.7.: Number of mice, flow chambers and cells per FOV of in vitro flow chamber assay. Mean±SEM,
unpaired student’s t-test
Mice Flow chambers WBC Cells FOV-1
n n [cells/µl]
E-selectin Ctrl 5 8 6964±351 49±10
scrPIF 5 9 6659±409 52±6
PIF 5 8 6843±432 47±4
ns. ns.
p=0.8612 p=0.8797
P-selectin Ctrl 4 7 5747±566 33±5
scrPIF 5 7 5596±556 36±6






During pregnancy, the maternal immune system fulfills a double function. Locally, in close
proximity to the fetus, it requires to be desensitized to embryonic tissue in order not to
recognize it as a ’semi-allogenic transplant’. Globally, it needs to efficiently protect the organ-
ism from viral and bacterial infections. A closer look however reveals that pregnant women
are more susceptible to infections210,211,212 and that the course of pre-existing autoimmune
diseases often appears attenuated213,214. After parturition, the immune system reverts to its
non-pregnant state and autoimmune diseases often relapse. These observations argue for
pregnancy specific factors, which are able to systemically modulate maternal immune cell
functions.
The 15 amino acid small peptide Preimplantation factor (PIF) is expressed by trophoblast
cells75 and present in maternal serum throughout pregnancy (see Tab. 1.1)69. It was shown
to modulate immune cell functions in autoimmune disease models outside the context
of pregnancy, but the molecular mechanisms, how PIF interferes with immune cells are
still elusive. This work examined potential effects of PIF on neutrophil recruitment in
acute inflammatory scenarios, reflecting its role in maternal circulation during pregnancy.
Conducted experiments revealed that PIF interferes with neutrophil recruitment at several
steps by influencing the hematopoietic as well as the endothelial compartment.
5.1. PIF reduces selectin dependent leukocyte rolling
Recruitment of neutrophils to sites of inflammation is initialized by endothelium expressed
selectins88. Interaction of E- or P-selectin with their ligands PSGL-1, CD44 and ESL-1 on
immune cells results in tethering and rolling along inflamed vessels87. Administration of
PIF in a mouse model of TNF-α induced acute inflammation reduced leukocyte rolling
(Fig. 4.18) in cremaster muscle postcapillary venules. Unchanged expression levels of PSGL-1,
CD44 and L-selectin in the presence of PIF (Fig. 4.19) and similar rolling behavior in E- or
P-selectin coated flow chambers (Fig. 4.23) indicate that altered neutrophil rolling in vivo is
predominantly caused by PIF affecting the endothelial compartment. Equal E- and P-selectin
binding in vitro further suggests that PIF unlikely alters glycosylation of selectin ligands, an
important prerequisite for selectin–selectin ligand interactions215. Reduction of leukocyte
rolling in vivo by approximately 50% was still observable after blockade of E- or P-selectin
dependent rolling, respectively, suggesting that PIF might alter selectin expression in en-
dothelial cells. Cytokines like TNF-α or IL-1β induce transcriptional upregulation of E- and
P-selectin94. PIF was shown to reduce serum levels of pro-inflammatory cytokines in LPS
induced placental inflammation76 and lowers expression of endothelium adhesion molecules
in atherosclerotic ApoeE-/- mice84. These observations suggest that PIF treatment might affect
selectin expression in TNF-α stimulated endothelial cells, either directly by interfering with
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transcription, expression or stability on the surface, or indirectly by changing the cytokine
profile. Indeed, Weiss et al. observed reduced transcription of P-selectin in spinal cord
tissue of PIF treated animals in an EAE model79. Further, this study demonstrated that PIF
treatment reduces IL-6 and IL-17 secretion of activated splenocytes, both pro-inflammatory
cytokines, influencing expression of adhesion molecules. Whereas IL-6 directly induces E-
selectin expression in HUVEC cells in vitro216, monocytes and macrophages produce TNF-α
in response to IL-17217, which in turn induces transcriptional upregulation of E-selectin94.
In contrast to E-selectin, P-selectin is pre-stored in Weibel-Palade bodies and transferred to
the luminal surface of endothelial cells within minutes upon stimulation218,219. In trauma
induced inflammation, surgical preparation of the mouse cremaster leads to the rapid release
of P-selectin and subsequent P-selectin dependent leukocyte rolling91. Also in this model,
PIF treatment reduced leukocyte rolling and at the same time increased rolling velocities
(Fig. 4.18). These results suggest that in addition to selectin transcription, mobilization or
turn-over rate of P-selectin may be affected by PIF. Besides P-selectin, the tetraspanin CD63
is stored in Weibel-Palade bodies and integrated into the luminal site of the PM of activated
endothelial cells as well220. There, CD63 stabilizes expressed P-selectin and reduces its
internalization rate, thereby contributing to P-selectin dependent leukocyte rolling and re-
cruitment221. Loss of CD63 results in reduced leukocyte rolling in mouse cremaster venules.
One explanation might therefore be that PIF also affects P-selectin stabilization on the en-
dothelial surface via or similar to CD63. Another molecule regulating neutrophil recruitment
by interfering with P-selectin activity is pentraxin 3 (PTX3)222. Produced and secreted by
macrophages223, DCs224 and neutrophils225, PTX3 binds to P-selectin and competes with
PSGL-1 binding, thereby affecting neutrophil–endothelium interaction222. However, whether
PIF regulates expression or activity of either CD63 or PTX3 to modulate P-selectin dependent
rolling, requires further investigation.
5.2. PIF disrupts leukocyte adhesion and extravasation
5.2.1. PIF does not affect chemokine induced inside-out β2 integrin activation
During recruitment, rolling along inflamed endothelium leads to deceleration of neutrophils
up to total arrest44. In a model of TNF-α induced acute inflammation, mice that were
pre-treated with PIF exhibited reduced numbers of adherent leukocyte in postcapillary
venules of stimulated cremaster muscles (Fig. 4.1), accompanied by increased slow rolling
velocities (Fig. 4.2). In contrast to the decrease in number of rolling cells, reduced leukocyte
adhesion and increased rolling velocities could be attributed to a direct effect of PIF on
the immune cells, as the same phenotype could be observed in E-selectin, ICAM-1 and
CXCL1 coated flow chambers ex vivo and in vitro. Neutrophil slow rolling and adhesion is
mainly mediated by activated LFA-1 integrin binding to its endothelial counterpart ICAM-
1199. GPCR- or TLR4-downstream signaling induces LFA-1 activation, resulting in reduced
neutrophil rolling velocities until complete arrest120,167. A crucial intracellular co-factor
during β2 integrin activation is talin-1111. Neutrophils lacking talin-1 exhibit disturbed
slow rolling and impaired adhesion in TNF-α stimulated cremaster muscle postcapillary
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venules124. Interestingly, mass spectometry analysis of human CD14+ cell lysates identified
talin-1 as a potential interaction partner of PIF74, a possible explanation for the observed
effects in vivo, ex vivo and in vitro. Surprisingly, PIF did not alter CXCL1 induced binding of
LFA-1 to soluble ICAM-1 in murine neutrophils and analysis of human neutrophils revealed
no effect of PIF on CXCL8 induced LFA-1 activation (Fig. 4.4). In addition, preliminary
pull-down experiments in collaboration with Markus Moser from the Max-Planck Institute
of Biochemistry, Martinsried, Germany, could not confirm previously published mass
spectometry data (results not shown). This indicates that GPCR-mediated inside-out LFA-1
activation is not influenced by PIF. Similar surface levels of β2 integrins and the GPCR
CXCR2 (Fig. 4.3) further suggest that different mechanisms cause the adhesion defect in PIF
treated animals.
5.2.2. PIF inhibits KV1.3 on neutrophils
Another study, aiming to reveal interaction partners of PIF using mass spectometry of human
decidual cell lysates and proteome arrays, found a broad spectrum of putative molecules
binding to PIF, among them the voltage gated potassium channel KV1.370. Depolarization
of the PM opens this voltage gated ion channel and allows K+ to efflux181. KV1.3 is ex-
pressed on vascular smooth muscle cells, cells of the nervous system and on several immune
cell subsets182, namely T lymphocytes226 , B lymphocytes185, NK cells186, marcophages187,
DCs189, and megakaryocytes/platelets188. Presence of KV1.3 on neutrophils has never been
convincingly described. Already in the early 90s, Krause and Welsh227 detected a voltage
dependent K+ current in activated human neutrophils, but they could not attributed it
to a specific channel. In a study investigating neutrophils in weak electric fields, KV1.3
was reported to be expressed in neutrophils190, but it has not been characterized in regard
to neutrophil function, although KV1.3-/- mice are available since 2003191. Using western
blotting, flow cytometry, confocal microscopy (Fig. 4.5) and electrophysiological experiments
(Fig. 4.6), the work presented here revealed the definitive existence and functionality of
KV1.3 on human and murine neutrophils. Reduced leukocyte adhesion and accompanied
increased slow rolling velocities in TNF-α stimulated cremaster muscle postcapillary venules
of KV1.3-/- mice (Fig. 4.8 and Fig. 4.9) demonstrate an important role of KV1.3 during leuko-
cyte recruitment. Pre-treatment of WT mice with the specific and well established KV1.3
inhibitor PAP-1196,228 confirmed a significant contribution of KV1.3 to leukocyte function.
Of note, rolling was not affected in these mice (Fig. 4.21), strengthening the hypothesis that
PIF affects leukocyte rolling independent of KV1.3 inhibition on leukocytes, but rather by
altering endothelial response to inflammatory cytokines.
With 40 members encoded in the genome, KV channels form the largest group of K+-selective
channels in humans229. Diversity is further increased by formation of heteromers among
KV1 family members. In macrophages for example, KV1.3 forms heterotetramers with KV1.5,
thereby changing its sensitivity and function230. Patch clamp experiments demonstrated
the voltage dependency of KV1.3203, meaning the stronger the membrane depolarization is,
the more outward current can be detected. Using this technique in KV1.3-overexpressing
HEK cells, Susanna Zierler and Wiebke Nadolni from Walther-Straub Institute LMU Munich,
Munich, Germany, illustrated in collaboration that PIF specifically inhibits KV1.3 mediated
outward currents in a dose-dependent manner with an IC50 of 10.2±5 nM (Fig. A.1). Patch
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clamp with human neutrophils instead of KV1.3-overexpressing HEK cells further demon-
strated that PIF reduces KV1.3 dependent currents also in this cell type to a similar extent as
PAP-1 (Fig. 4.11).
These findings reveal that PIF reduces K+ outward currents in neutrophils by inhibiting
KV1.3. KV1.3 may have an important role during leukocyte recruitment as shown by the use
of the pharmacological KV1.3 inhibitor PAP-1 in vivo and by KV1.3-/- mice.
5.2.3. KV1.3 on neutrophils regulates [Ca2+]i
In T lymphocytes, K+ efflux via KV1.3 regulates sustained Ca2+ entry through Ca2+ release-
activated Ca2+ (CRAC) channels by maintaining an electrochemical gradient over the PM
(Fig. 1.6)156. Measuring [Ca2+]i in human neutrophils under static and flow conditions, Scott
I Simon and Vasilios Morikis from the University of California, Davies, USA were able to
demonstrate that inhibition of KV1.3 with PIF reduces SOCE via CRAC channels (Fig. A.2),
affecting overall changes in [Ca2+]i (Fig. A.3). In neutrophils, LFA-1 outside-in signaling
under shear stress conditions leads to Ca2+ influx via CRAC channels159. Using microfluidic
devices coated with ICAM-1 and LFA-1 high affinity inducing antibodies, they could further
unravel a contribution of KV1.3 in mechanotransduced Ca2+ signaling (Fig. A.4).
In neutrophils, many functions depend on changes in [Ca2+]i 158 and impaired calcium
signaling can lead to severe dysregulation of immune responses231,232,233. Patients with
mutations in Orai1 or STIM1 for example suffer from immunodeficiency-like disorders
which are often accompanied by neutropenia and increased susceptibility to infections
or sepsis234. During recruitment, high [Ca2+]i is a prerequisite for neutrophils to firmly
adhere and to switch to a migratory phenotype180. Impaired calcium signaling results in
disturbed deceleration, arrest and polarization165,166. Under shear, tensile forces acting on
LFA-1–ICAM-1 bonds recruit kindlin-3 to intracellular β2 integrin tails (Fig. 1.5)180. Kindlin-3
in turn links Orai1 to this complex166,180, ensuring local increase of [Ca2+]i 176. High concen-
trations of Ca2+ at focal adhesion sites are required for recruitment of talin-1 and subsequent
linkage of adhesion spots to the actin cytoskeleton180. Thereby, receptor for activated protein
kinase C-1 (RACK-1) was shown to be an important co-factor, as it is able to interact with
kindlin-3, LFA-1235 and Orai1236. This has led to the hypothesis that kindlin-3/Orai1/LFA-1
focal clusters develop upon integrin outside-in mechanosignaling, resulting in Ca2+-rich
microdomains. High local Ca2+ concentrations enable linkage of focal adhesion sites to the
actin cytoskeleton and ensuing fast and efficient cytoskeletal reorganization. This hypothesis
is supported by observations that Ca2+-rich microdomains are located in uropods of human
neutrophils237, overlapping with clustered LFA-1150,238. This work now adds evidence that
K+ efflux via KV1.3 is involved in establishing multi-molecule platforms around activated
and ICAM-1 bound LFA-1, as inhibition of KV1.3 resulted in reduced [Ca2+]i and subsequent
impaired cytosekeletal rearrangement. In line with these findings, ion channels, especially
K+ channels have been shown to interact with integrins in other cell types, regulating
integrin affinity and downstream signaling239. In melanoma cells240 and T lymphocytes200,
KV1.3 physically interacts with β1 integrins and its inhibition disrupts KV1.3–β1 integrin
interaction240, indicating that physical interaction depends on channel activity. Impaired
neutrophil spreading resulted in increased susceptibility to physiological shear rates in vitro
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(Fig. A.5) and in vivo (Fig. 4.13). Application of soluble CXCL1 in vivo resulted in a rapid
increase of adherent leukocytes also in PIF pre-treated animals, confirming the hypothesis
that chemokine mediated inside-out LFA-1 activation is not affected by PIF (4.1.4). 6 minutes
after CXCL1 administration in turn, PIF mediated inhibition of KV1.3 impaired outside-in
mechanosignaling via activated LFA-1, thereby reducing the ability of neutrophils to sustain
adhesion to vessel walls.
5.2.4. PIF lowers the number of perivascular neutrophils
PIF treatment resulted in reduced numbers of extravasated neutrophils into TNF-α inflamed
cremaster muscle tissue (Fig. 4.14). This effect could be attributed to its inhibitory properties
on KV1.3, since both KV1.3-/- mice and PAP-1 treated WT mice exhibited a reduction of
perivascular neutrophils (Fig. 4.15). The question remains whether impaired transmigra-
tion upon inhibition of KV1.3 is simply a consequence of disrupted neutrophil adhesion,
or whether KV1.3 also regulates neutrophil functions important for diapedesis. Not only
cytoskeletal rearrangement during adhesion strengthening, but neutrophil migration in
general is highly dependent on Ca2+ signaling174. Besides Orai1166, additional calcium
channels like TRPC1241 or TRPC6170 have been implicated to be involved in neutrophil
migration. Also potassium efflux regulates neutrophil migration and chemotaxis, as genetic
loss or pharmacological inhibition of the Ca2+ activated potassium channel KCa3.1 leads to
reduced chemotactic behavior205. Hence, it is conceivable that KV1.3 also mediates migration,
chemotaxis and transmigration in neutrophils. Evidence comes from other cell types. In
microglia cells, reduced expression of KV1.3 goes along with reduced motility and lower
β1 integrin expression242 Further, effector memory T (TEM) cells243 and macrophages201,244
exhibit a reduced migratory phenotype in response to KV1.3 inhibitors. However, sensing of
a CXCL1 chemokine gradient in a transwell assay was not affected by PIF (Fig. 4.16). Experi-
ments investigating the precise role of PIF and KV1.3 in neutrophil migration, chemotaxis
and transmigration are currently ongoing and part of a medical doctoral thesis under my
co-supervision.
Summarizing the findings, inhibition of KV1.3 on neutrophils by PIF disrupts sustained
Ca2+ influx and thereby prevents neutrophil spreading and adhesion strengthening (Fig. 5.1),
leading to impaired recruitment into inflamed tissue.
5.3. PIF as a potential therapeutic drug to treat inflammatory
diseases
Effective host defense against invading pathogens requires fast and precisely reacting neu-
trophils44. However, many diseases like rheumatoid arthitis, psoriasis, inflammatory bowel
disease, COPD, or acute lung injury (ALI) are associated with massive neutrophil infiltra-
tion206,207,245. Overreacting immune responses and uncontrolled neutrophil recruitment can
cause tissue damage and self amplification of inflammation246. To investigate the therapeutic







































































Figure 5.1.: PIF disrupts neutrophil recruitment by reducing KV1.3-regulated SOCE. PIF inhibits the voltage-
gated potassium channel KV1.3 on neutrophils which regulates sustained Ca2+ via SOCE. During neutrophil
recruitment, lower [Ca2+]i reduces the ability of adherent neutrophils to spread and to switch to a migratory
phenotype. As a consequence, cells are more susceptible to physiological shear forces and detach back into the
blood stream.
Söhnlein from the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich,
Germany, Jochen Grommes and Jessica Tilgner from the RWTH Aachen, Aachen, Germany
tested the small peptide in a mouse model for LPS induced ALI. In ALI as well as in acute
respiratory distress syndrome (ARDS), epithelial and endothelial damage increase perme-
ability of the alveolar-capillary barrier, leading to increased protein-rich fluid in alveoli,
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accompanied by impaired gas exchange and respiratory failure247. Severity of ALI correlates
with numbers of infiltrating neutrophils248. Therefore, control of neutrophil infiltration
might be an interesting option to treat inflammatory diseases like ALI or ARDS. Blocking
KV1.3 activity with PIF reduced LPS induced neutrophil infiltration into inflamed lungs
(Fig. A.6). Importantly, PIF treatment reduced vascular leakage and protein content in the
BAL (Fig. A.6), revealing its potential to prevent neutrophil recruitment and accompanying
tissue damage in a clinically relevant setting (Fig. 5.1).
In the last decades, many drugs have been developed to suppress inflammatory diseases by
interfering with leukocyte recruitment and migration249. Nevertheless, there is a need to de-
velop additional treatments, since many approaches failed during trial phases250. This work
provides evidence that trophoblast derived PIF is able to disrupt neutrophil recruitment by
blocking KV1.3. In animal models for autoimmune diseases like multiples sclerosis (MS)79,
type I diabetes mellitus78 or graft versus host disease after bone marrow transplantation82,
PIF attenuated progression of the diseases by lowering the amount of infiltrating immune
cells into affected tissue. A safety study, testing PIF in patients with immune hepatitis is
currently ongoing251.
Over the past years, KV1.3 has become the subject of intensive research in T lymphocyte
biology183. In quiescent naive, central memory (TCM) T and TEM cells, KV1.3 is expressed to
a similar extent (∼250 channels per cell)252. Upon activation, KV1.3 gets upregulated in TEM
cells (∼1500 channels per cell), but only to a minor extent in naive T and TCM cells (∼300
channels per cell). TEM cells play a pivotal role in the pathogenesis of autoimmune dis-
eases253. They are terminally differentiated T cells which rapidly enter inflamed tissues upon
activation252, where they contribute to disease progression by releasing pro-inflammatory
cytokines181. Inhibiting TEM cells may be therefore a suitable approach to treat autoimmune
diseases and many different KV1.3 inhibitors have been designed196,181,228 and tested in
several disease models including MS252,254, TIDM255 and psoriasis256. Even outside autoim-
mune diseases, in animal models for obesity and insulin resistance, KV1.3 inhibitors have
been suggested as a potential treatment strategy257. This study introduces a new KV1.3
inhibitor, the endogenous peptide PIF, and provides evidence that PIF attenuates progression
of autoimmune diseases in animal models by interfering with KV1.3 activity. Showing that
KV1.3 is expressed on neutrophils is of further interest, since there is emerging evidence that
neutrophils contribute to a large extent to the progression of classically-seen T cell driven
diseases like psoriasis, MS or TIDM245,258. Interestingly, psoriasis, an autoimmune disease
where neutrophil infiltration plays an important role in the progression of the disease259 is
successfully treated with 5-Methoxypsoralen (5-MOP), a KV1.3 blocker182.
5.4. PIF modulates immune cells during pregnancy
KV1.3 is expressed on all leukocyte subsets which can be found in the placenta during
pregnancy. Consequently, it is very likely that PIF contributes to the establishment of the
unique immunological milieu around the fetus by influencing immune cells to a similar
extend as demonstrated in models for autoimmune diseases. Indeed, KV1.3-/- Foxp3- helper
T (Th) cells exhibit a unique, IL-10 expressing, regulatory phenotype in an EAE model




The primary aim of this work was to study the role of PIF in acute inflammatory scenarios.
The use of several in vivo, ex vivo and in vitro approaches demonstrated that PIF alters
neutrophil function, by interfering with calcium signaling, leading to impaired adhesion
strengthening after arrest. PIF reduces [Ca2+]i by blocking KV1.3 with an IC50 of 10.2±5 nM.
Many functions in neutrophils rely on changes in [Ca2+]i 158, among them phagocytosis and
ROS production175. Neutrophils from pregnant women exhibit an overall reduced phagocytic
activity261 and diminished ROS production262. Diminished ROS production in pregnancy
could be attributed to a factor present in the plasma of pregnant women, as plasma from
pregnant women reduced ROS production in neutrophils from non-pregnant women263. In
addition, serum from pregnant mice reduces T cell activation264 and neutrophils exhibit
changes in their Ca2+ oscillations upon contact with trophoblast cells in vitro265. This work
suggests that PIF, present in maternal circulation throughout pregnancy, may be involved in
reduced phagocytic activity and diminished ROS production of peripheral neutrophils from
pregnant women, thereby increasing susceptibility to infections. In addition, PIF in maternal
circulation throughout pregnancy may be an explanation why pre-existing autoimmune
diseases attenuate during this period. Concentration of PIF in serum from pregnant women
is around 50-60 nM, depending on the gestational age69. By showing that PIF inhibits KV1.3
with an IC50 of 10.2±5 nM, this study suggests that plasma PIF levels during pregnancy
are sufficient to interfere with functions of peripheral immune cells. However, further
studies are necessary to proof whether PIF indeed modulates peripheral immune responses
during pregnancy, thereby increasing susceptibility to infectious diseases and attenuating
autoimmune disorders.
5.5. Conclusion
In summary, the presented data demonstrate that the embryo-derived peptide Preimplan-
tation factor (PIF) alters immune responses in acute inflammatory scenarios. It reduces
selectin-dependent leukocyte rolling along inflamed vessels, most likely by altering transcrip-
tion, expression or stability of selectins on inflamed endothelial cells. PIF further directly
interferes with neutrophil function by blocking the voltage gated potassium channel KV1.3
on neutrophils. Inhibition of KV1.3 lowers sustained Ca2+ entry via CRAC channels, thereby
impairing cytoskeletal rearrangement during leukocyte recruitment. Hence, under physi-
ological shear stress conditions, neutrophils are not able to efficiently adhere to inflamed
endothelium and to extravasate into the surrounding tissue.
These findings for the first time uncover the role of PIF in neutrophil function at the molecular
level and help to better understand how maternal immune cells are modulated during preg-
nancy in the placenta, but also systemically by extra-embryonic derived signaling molecules.
Furthermore, it demonstrates the potency of PIF as an anti-inflammatory agent in acute and
chronic inflammatory diseases, through blocking KV1.3 function in neutrophils. Further
studies are now warranted to test whether these findings can be successfully translated into
the clinical setting. Hence, PIF might turn out to be a versatile and rather safe treatment
strategy in a whole variety of disorders with disturbed innate and adaptive immunity.
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A. Results from collaboration partners
A.1. PIF reduces voltage-induced KV1.3 currents in
KV1.3-overexpressing HEK-293 cells
To test whether PIF modifies neutrophil function by inhibition of KV1.3, whole cell patch
clamp experiments were conducted using KV1.3-overexpressing HEK-293 cells (hKV1.3-
HEK-293), incubated with 300 nM PIF or carrier substance (Ctrl). 13 consecutive 10 mV
steps from −80 mV to +40 mV were applied for 200 ms in 30 s intervals in order to activate
KV1.3. hKV1.3-HEK-293 control cells developed characteristic voltage-dependent KV1.3-
currents (Fig. A.1-A). Pre-treatment with PIF abolished current activation almost completely.
Quantification of current densities at the different voltage steps demonstrated a significant
inhibition of KV1.3 by PIF (Fig. A.1-B). The use of different concentrations of PIF revealed
that PIF inhibits KV1.3 in a dose-dependent manner with an IC50 of 10.2±5 nM (Fig. A.1-C
and -D).
A.2. Inhibition of KV1.3 by PIF impairs calcium signaling in
human neutrophils
In lymphocytes, KV1.3 was shown to be involved in the regulation of Ca2+ signaling by
sustaining Ca2+ influx via SOCE156. K+ efflux via KV1.3 maintains an electrical gradient over
the cell membrane, enabling continuous Ca2+ influx into the cells183. To elucidate the role of
KV1.3 in CRAC channel dependent Ca2+ influx in human neutrophils, isolated cells from
healthy blood donors were loaded with the fluorometric Ca2+-indicator Rhod-2 AM under
Ca2+-free conditions and incubated with Thapsigargin to deplete intracellular Ca2+ stores in
the endoplasmic reticulum (ER). Addition of Ca2+ to the medium induced a rapid increase
in [Ca2+]i in vehicle treated control cells (Ctrl, Fig. A.2). Inhibition of KV1.3 with 300 nM PIF
or 10 nM PAP-1, respectively, significantly reduced [Ca2+]i, demonstrating a central role of
KV1.3 in SOCE in neutrophils.
To see whether overall Ca2+ flux is altered by KV1.3 inhibition as well, isolated human
neutrophils were again loaded with Rhod-2 AM in Ca2+-free medium and incubated with
300 nM PIF, 10 nM PAP-1 or vehicle (Ctrl). Addition of Ca2+ to the medium resulted in an
increase of [Ca2+]i in control cells and ensuing stimulation with 10 nM CXCL8 induced a
strong elevation of [Ca2+]i (Fig. A.3-A). Inhibition of KV1.3 using PIF and PAP-1 significantly
decreased overall [Ca2+]i after application of Ca2+ and of CXCL8 (Fig. A.3-B and -C) with
PAP-1 exhibiting an even stronger inhibitory effect compared to PIF.
Sufficient Ca2+ influx in neutrophils is a prerequisite for successful transition from arrest
to a migratory phenotype under shear stress conditions158. During neutrophil adhesion
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Figure A.1.: PIF reduces voltage-induced KV1.3 currents in KV1.3-overexpressing HEK-293 cells. (A) HEK-
293 cells, transiently overexpressing hKV1.3 were incubated with PIF (gray, n=4 cells) or vehicle (Ctrl, black, n=36
cells) and activated by 13 consecutive 10 mV steps from −80 mV to +40 mV (all 13 traces of two representative
cells). (B) Current-voltage relationship of Ctrl and PIF treated hKV1.3-HEK-293 cells (mean±SEM, repeated
student’s t-tests). (C) KV1.3-currents extracted at +40 mV in the absence and after pre-incubation with two
different concentration of PIF (representative traces, n=4-6 cells per condition). (D) Dose-dependent inhibition
of KV1.3-currents by increasing PIF concentrations (IC50 of 10.2±5 nM, mean±SEM, n=4-8 cells per condition).
The results were obtained in collaboration with S. Zierler and W. Nadolni from the Walther-Straub-Institut,
LMU, Munich, Germany.
under flow, LFA-1/ICAM-1 bonds recruit Orai1 to LFA-1 containing focal adhesion spots,
mediating local increase of [Ca2+]i and subsequent remodeling of the actin cytoskeleton179,180.
To investigate the role of KV1.3 on LFA-1 mediated mechano-signaling via SOCE, isolated
human neutrophils, loaded with Rhod-2 AM and pre-treated with Thapsigargin under
Ca2+-free conditions, were perfused through microfluidic devices coated with LFA-1 high-
affinity inducing antibodies (CBR LFA1/2) and ICAM-1102 at a constant shear rate level
of 2 dyne/cm2. Ca2+ was added to the medium and changes in [Ca2+]i were monitored.
Pre-incubation with 300 nM PIF or 10 nM PAP-1 significantly reduced Ca2+ influx compared
to vehicle control (Ctrl), revealing a substantial contribution of KV1.3 to LFA-1 dependent
regulation of SOCE during post-arrest modification under flow (Fig. A.4).
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Figure A.2.: KV1.3 is involved in CRAC channel dependent Ca2+ influx in human neutrophils. Isolated
human neutrophils were loaded with Rhod-2 AM, treated with Thapsigargin and subsequently incubated with
PIF, PAP-1 or vehicle (Ctrl). (A) CRAC channel dependent changes in [Ca2+]i were investigated before and after
addition of Ca2+ to the medium (mean, n=57 (Ctrl), 60 (PAP-1), 88 (PIF) cells from 3 independent experiments)
and (B) quantified 30 s after application. (mean±SEM, 1-way ANOVA, Tukey’s multiple comparison).
The results were obtained in collaboration with S.I. Simon and V. Morikis, University of California, Davis, USA.
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Figure A.3.: KV1.3 regulates total Ca2+ flux after CXCL8 stimulation in human neutrophils. Isolated human
neutrophils were loaded with Rhod-2 AM and pre-treated with PIF, PAP-1 or vehicle (Ctrl). (A) Changes in
overall [Ca2+]i upon addition of Ca2+ and subsequent application of CXCL8 were investigated (mean) and
quantified 30 s after addition of either (B) Ca2+ (mean±SEM, n=115(Ctrl), 36 (PAP-1), 85 (PIF) cells) or (C)
CXCL8, respectively. (mean±SEM, n=115(Ctrl), 69 (PAP-1), 114 (PIF) cells from 3 independent experiments,
1-way ANOVA, Tukey’s multiple comparison).
The results were obtained in collaboration with S.I. Simon and V. Morikis, University of California, Davis, USA.
A.3. PIF increases susceptibility to shear forces in vitro
To evaluate whether the disability of neutrophils to polarize and to switch to a migra-
tory phenotype in the presence of PIF has implications on the resistance to shear forces,
a detachment-assay was carried out. Isolated human neutrophils were incubated with
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Figure A.4.: KV1.3 regulates intracellular Ca2+ concentrations under shear stress conditions. (A) Isolated
human neutrophils were loaded with Rhod-2 AM and pre-treated with Thapsigargin to deplete intracelllular
ER Ca2+ stores. KV1.3 was blocked with PIF, PAP-1 or vehicle (Ctrl) and cells were perfused through LFA-1
high-affinity inducing antibodies and ICAM-1 coated microfluidic devices (mean, n=14 (Ctrl), 38 (PAP-1), 27
(PIF) cells from 3 independent experiments) to measure [Ca2+]i over time. (B) Quantification of [Ca2+]i 60 s after
addition of Ca2+ to the medium (mean±SEM, 1-way ANOVA, Tukey’s multiple comparison).
The results were obtained in collaboration with S.I. Simon and V. Morikis, University of California, Davis, USA.
either 300 nM PIF, 10 nM PAP-1 or vehicle (Ctrl) and introduced into E-selectin, ICAM-1
and CXCL8 coated flow chambers. Cells were allowed to adhere for 3 min before shear was
applied and increased every 30 s. Remaining cells at the end of each step were quantified.
Incubation with PIF or PAP-1 resulted in an higher susceptibility of detachment to increasing
shear forces compared to control (Fig. A.5).




























Figure A.5.: PIF increases susceptibility to shear forces in vitro. Human neutrophils incubated with PIF,
PAP-1 or vehicle (Ctrl) were introduced into E-selectin, ICAM-1 and CXCL8 coated flow chambers, exposed to
increasing shear stress levels and remaining cells were quantified (n=12-15 flow chambers of 9-10 independent
experiments one-way ANOVA, Dunnett’s multiple comparison).
The results were conducted by A. Yevtushenko under my supervision.
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A.4. PIF impairs neutrophil recruitment in an animal model of acute lung injury after LPS
stimulation
A.4. PIF impairs neutrophil recruitment in an animal model of
acute lung injury after LPS stimulation
To investigate whether the inhibition of KV1.3 by PIF might be a suitable therapeutic ap-
proach to treat overgrowing neutrophil infiltration in a clinically relevant setting, a model
of acute lung injury (ALI) after LPS inhalation was performed208. Many severe airway
diseases such as bronchitis, cystic fibrosis, chronic obstructive pulmonary disease (COPD)
or ALI are characterized by substantial neutrophil infiltration206,207. WT mice received an
i.p. injection of 1 µg or 10 µg PIF or vehicle alone (Ctrl) 1 h prior to 30 min of exposure to
LPS containing aerosol. One control group (w/o) did not receive any i.p. injection and
was exposed to saline containing aerosol only. 4 h after inhalation, mice were sacrificed
and recruitment of neutrophils to the lungs was analyzed by flow cytometry. In line with
altered leukocyte adhesion in the mouse cremaster muscle (Fig. 4.1-A), i.p. application of
both, 1 µg and 10 µg PIF prior to LPS inhalation completely impaired neutrophil recruitment
to the pulmonary vasculature (Fig. A.6-A). Numbers of neutrophils in the lung interstitium
(Fig. A.6-B) and in the broncho-alveolar lavage (BAL, Fig. A.6-C) were significantly reduced
compared to control animals. Mice that were not exposed to LPS did not exhibit a noticeable
amount of neutrophils in the interstitium and in the BAL. Finally, lung tissues of the mice
were removed, fixed, stained with Mayer’s hematoxylin and eosin (HE, Fig. A.6-D) and the
sections were scored based on guidelines from the American Thoriacic Society266. Quantifi-
cation confirmed that both PIF concentrations significantly reduced the amount of invaded
neutrophils into LPS stimulated lung tissue (Fig. A.6-E).
A.5. PIF reduces vascular leakage in a model of ALI
Massive infiltration of neutrophils into inflamed lungs is accompanied by an increase in
permeability and by elevated protein content in the BAL, due to endothelial and epithelial
injury207. Hence, in addition to the assessment of neutrophil recruitment to inflamed lungs
in the ALI model, LPS induced vascular leakage was determined208. For that purpose, mice
were injected with FITC-dextran 30 min prior to euthanasia and fluorescence of the BAL was
measured and normalized to serum fluorescence levels. Albumin concentrations in the BAL
were determined using ELISA. PIF treatment prior to LPS inhalation significantly reduced
vascular leakage compared to control (Fig. A.7-A and -B) and reduced the fluorescence levels
and albumin concentration in the BAL almost to basal levels (w/o group).
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Figure A.6.: PIF impairs neutrophil recruitment in an animal model of acute lung injury. WT mice were i.p.
injected with two different concentrations of PIF or with carrier substance (Ctrl) 1 h prior to LPS inhalation.
4 h later, neutrophil recruitment to (A) the pulmonary vasculature, (B) the lung interstitium and (C) into the
broncho-alveolar space was analyzed. Animals from the w/o group did not receive an i.p. injection and
were exposed to saline aerosol only (BAL: brochno-alveolar lavage, mean±SEM, n=7-9 mice per group, 1-way
ANOVA, Tukey’s multiple comparison). (D) Representative micrographs of lung sections, treated as indicated
(scale bar: 250 µm) were (E) quantified according to266 (mean±SEM, n=3-4 mice per group, 1-way ANOVA,
Tukey’s multiple comparison).
The results were obtained in collaboration with O. Söhnlein, IPEK, LMU Munich, Munich, Germany, J. Grommes
and J. Tilgner, RWTH Aachen, Aachen, Germany.
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Figure A.7.: PIF reduces vascular leakage in a model of acute lung injury but does not alter integrity of
cultured HUVEC cells upon TNF-α stimulation. Changes in vascular permeability were assessed by the
measurement of FITC-dextran and albumin concentrations in the BAL of WT mice pre-treated i.p. with two
different concentrations of PIF or carrier substance (Ctrl) 1 h prior to LPS exposure. One group did not receive
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Immune cells within the placenta exert essential functions throughout pregnancy but require tight 47 
regulation in order to prevent recognition of the embryo as a ‘semi-allograft’. Here, we report that 48 
the embryonic derived peptide Preimplantation factor (PIF), which is secreted by trophoblast cells 49 
and continuously released into maternal circulation, impairs neutrophil recruitment. PIF blocks KV1.3 50 
on neutrophils, a voltage gated potassium channel regulating membrane potential and sustained 51 
store operated Ca2+ entry (SOCE) via K+ efflux. Inhibition of KV1.3 lowers intracellular Ca
2+ signaling, 52 
preventing post-arrest modifications by minimizing cell spreading and adhesion strengthening. 53 
Consequently, PIF treatment inhibits neutrophil retention at sites of inflamed endothelium leading to 54 
reduced neutrophil extravasation in vivo, a phenotype also observed in KV1.3 deficient mice. We 55 
conclude that PIF modulates neutrophil function and offers therapeutic capabilities beyond 56 
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1. Introduction 62 
During pregnancy, pro- and anti-inflammatory states alternate in a finely orchestrated manner1. 63 
Successful pregnancy is initiated through infiltration of immune cells into the decidua to facilitate 64 
blastocyst implantation, fetal growth and parturition1. Imbalance in the composition of intrauterine 65 
immune cell populations or of chemokine concentrations results in pregnancy complications 66 
including spontaneous abortion2, pre-eclampsia3 or preterm birth4. Trophoblast cells, which form the 67 
cellular barrier between maternal and fetal tissue, play a dual role in the modulation of immune cell 68 
function by secreting pro-inflammatory and homeostatic cytokines and growth factors1. In addition, 69 
they use the atypical chemokine receptor ACKR2 to scavenge pro-inflammatory chemokines at the 70 
feto-maternal interface5, thereby reducing the chemokine gradient towards fetal tissue. Another 71 
factor secreted by trophoblast cells is Preimplantation factor (PIF), which contributes to feto-72 
maternal crosstalk6,7. PIF is a 15 amino acid secreted small peptide that can be detected in maternal 73 
circulation at varying levels throughout pregnancy8,9. It creates a pro-receptive milieu in the decidua 74 
following conception10 and during trophoblast invasion11. The peptide was shown to enhance local 75 
progesterone activity, to increase steroid secretion and to enhance the expression of pro-tolerogenic 76 
HLA molecules in cytotrophoblasts12. Sufficient levels of PIF in the serum are required for embryo 77 
development and successful birth9,13. PIF also interacts with immune cells14 and attenuates the 78 
severity of several T cell driven autoimmune diseases in animal models15,16. However, the 79 
mechanisms how PIF regulates immune responses and its role within the maternal circulation remain 80 
elusive. Particularly, the action of PIF on innate immune cell function is largely unknown. Therefore, 81 
we investigated the immune modulatory properties of PIF in neutrophil driven, acute inflammatory 82 
scenarios outside the context of pregnancy. 83 
Acute inflammatory processes involve the infiltration of innate immune cells into affected tissue17. 84 
Neutrophils constitute the ‘first line of defense’17 and their recruitment follows a sequence of well-85 
defined steps, starting with neutrophil tethering and rolling along the inflamed endothelium18. 86 
Adhesion is followed by post-arrest modifications that strengthen the neutrophils’ attachment to the 87 
inflamed endothelium and guide the process of spreading, crawling and subsequent transmigration 88 
through the endothelium. Once neutrophils arrive at the inflammatory site, they combat invading 89 
pathogens and non-self-agents by generation of reactive oxygen species (ROS), release of granules, 90 
phagocytosis and NETosis to immobilize and destroy microbes17. Besides their beneficial role in the 91 
body’s first line of defense against invading pathogens, neutrophils contribute to chronic 92 
inflammatory disorders and autoimmune diseases17. Hence, therapeutic approaches targeting 93 




Using in vivo and in vitro mouse models, as well as electrophysiological techniques in primary human 96 
neutrophils, we show that PIF inhibits the voltage-gated potassium channel KV1.3 leading to 97 
significant impairment of neutrophil recruitment. Thus, we identify PIF as a potent endogenous anti-98 
inflammatory agent and suggest a potential role of PIF as a therapeutic molecule beyond its function 99 
during pregnancy. 100 
  101 
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2. Results 102 
PIF impairs leukocyte recruitment in vivo and in vitro. To elucidate the influence of PIF on innate 103 
immune cell functions, we studied leukocyte recruitment in an acute, predominantly neutrophil 104 
driven, inflammatory setting19. Using intravital microscopy (IVM), leukocyte interactions with the 105 
endothelium were assessed in postcapillary venules of TNF-α stimulated mouse cremaster muscles. 106 
PIF was injected into the scrotum (intrascrotal; i.s.) of C57BL/6 wild-type (WT) mice 1h prior to i.s. 107 
injection of TNF-α. As controls, either a scrambled version of the peptide (scrPIF) or the carrier 108 
substance alone (Ctrl) was applied. The number of adherent cells on the inflamed endothelium was 109 
significantly reduced in PIF-treated animals (Fig. 1a) compared to both control groups. In addition, 110 
leukocytes in PIF treated mice displayed increased rolling velocities (Fig. 1b). Prior administration of 111 
PIF further resulted in significantly reduced numbers of perivascular neutrophils compared to 112 
controls (Fig. 1c, d). Application of PIF did not affect systemic white blood cell (WBC) and neutrophil 113 
counts (Supplementary Tab. 1). In order to study whether PIF directly acts on leukocytes or mainly on 114 
endothelial cells, we performed in vitro flow chamber assays. Glass capillaries were coated with 115 
recombinant E-selectin, intracellular adhesion molecule-1 (ICAM-1) and CXCL1 to mimic inflamed 116 
endothelium and murine whole blood was perfused through the chambers. Similar to the in vivo 117 
observations, pre-incubation of murine whole blood with PIF resulted in significantly reduced 118 
numbers of adherent leukocytes per field of view (FOV) (Fig. 1e) and in increased rolling velocities 119 
(Fig. 1f) compared to controls. Overall surface expression of CD18, CD11a, CD11b, P-selectin 120 
glycoprotein ligand-1 (PSGL-1), CD44, L-selectin, and CXCR2 on peripheral blood neutrophils was not 121 
affected after i.s. injection of PIF compared to control as shown by flow cytometry (Supplementary 122 
Fig.1a-g.). Taken together, in an animal model of acute inflammation, PIF alters leukocyte 123 
recruitment by increasing rolling velocity of the cells, reducing transition to arrest on inflamed 124 
endothelium and extravasation into inflamed tissue. This is predominately mediated by a direct 125 
effect of PIF on leukocytes rather than on the endothelium, since an identical adhesion phenotype 126 
was observed under defined in vitro flow chamber conditions. 127 
Functional KV1.3 is expressed on human and murine neutrophils and is critical for leukocyte 128 
recruitment in vivo. Next, we tried to identify the molecular target of PIF. A mass spectrometry 129 
analysis of decidual cells revealed a broad spectrum of putative interaction partners, including the 130 
voltage gated potassium channel KV1.3
10. KV1.3 has been reported to regulate cell adhesion and 131 
integrin activation in lymphocytes20. Since this channel has not been functionally identified on 132 
neutrophils yet, we first analyzed expression of KV1.3. Western blot analysis, with Jurkat cell lysates 133 
as positive control, revealed expression of KV1.3 in human and murine neutrophils (Fig. 2a). 134 
Moreover, confocal microscopy (Fig. 2b) and flow cytometry (Supplementary Fig. 2) demonstrated 135 
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expression of KV1.3 on the plasma membrane. To validate functionality of the channel on 136 
neutrophils, we performed electrophysiological experiments using a whole-cell patch-clamp 137 
approach. KV1.3 channels on isolated human neutrophils were activated with a 10mV step protocol 138 
from -80mV to +40mV at a holding potential of -80 mV with 30s intervals21. Neutrophils developed 139 
typical voltage-activated potassium currents (Fig 2c), which were reduced by the addition of the 140 
KV1.3-specific inhibitor 5-(4-Phenoxybutoxy)psoralen (PAP-1)
22 (Fig. 2d). Local application of PAP-1 141 
after current activation with a single voltage-step up to +40mV further demonstrated that these 142 
potassium currents in neutrophils were sensitive to PAP-1-inhibition (Fig. 2e), indicating the 143 
expression of functional KV1.3 channels in primary human neutrophils. 144 
To test whether inhibition of KV1.3 with PAP-1 affects leukocyte recruitment in vivo similar to PIF 145 
application, PAP-1 or vehicle alone (Ctrl) was injected i.s. into WT mice followed by application of 146 
TNF-α to induce inflammation. The number of adherent leukocytes and rolling velocities were 147 
determined. Inhibition of KV1.3 via PAP-1 significantly reduced the number of adherent leukocytes 148 
(Fig. 2f) in inflamed postcapillary venules compared to control. Notably, the level of inhibition was 149 
equivalent to PIF-antagonized reduction of adhesion (Fig. 1a) and concomitant application of PAP-1 150 
and PIF did not further reduce the number of adherent cells. Likewise, blockade of KV1.3 by PAP-1 151 
elevated leukocyte rolling velocities (Fig. 2g) compared to control. Again, simultaneous application of 152 
PAP-1 and PIF did not further increase rolling velocities along inflamed endothelium. In a second set 153 
of experiments, we examined leukocyte adhesion and rolling velocities after TNF-α stimulation in 154 
mice lacking KV1.3
23. In line with the previous results, loss of KV1.3 resulted in a significant reduction 155 
of adherent cells mm-2 (Fig. 2h) and KV1.3
-/--leukocytes rolled significantly faster (Fig. 2i) compared to 156 
controls. Moreover, injection of PIF into KV1.3 deficient mice prior to TNF-α stimulation did not 157 
further suppress leukocyte adhesion or alter rolling velocities. Overall leukocyte and neutrophil blood 158 
counts did not differ among experimental groups in both experimental settings (Supplementary Tab. 159 
2). Expression levels of CD18, CD11a, CD11b, PSGL-1, CD44, L-selectin, and CXCR2 on peripheral 160 
blood neutrophils were similar between KV1.3
-/- and WT mice (Supplementary Fig. 3a-g). Finally, we 161 
quantified neutrophil extravasation in TNF-α stimulated cremaster muscles derived from PAP-1 162 
treated WT, WT and KV1.3
-/--mice (Fig. 2j). A significant reduction of perivascular neutrophils was 163 
observed with either inhibition or genetic deletion of KV1.3 (Fig. 2k) compared to control. These data 164 
demonstrate that KV1.3 is crucial for neutrophil recruitment and transmigration in vivo. 165 
PIF reduces voltage-induced KV1.3 currents in a KV1.3 overexpressing cell line and in human 166 
neutrophils. Next, we aimed to clarify whether Kv1.3 channels were indeed molecular targets of PIF. 167 
To do so, we expressed human KV1.3 in HEK-293 cells and applied consecutive 10mV voltage-steps. 168 
As expected, characteristic Kv1.3 currents developed in response to voltage-stimulation reaching 169 
7 
 
their maximum at +40mV (Fig. 3a). Application of PIF almost completely abolished current activation 170 
in response to voltage-stimulation (Fig. 3a, 300nM). Quantification showed a characteristic increase 171 
in current-voltage relationships in response to increasing membrane voltages, which was significantly 172 
inhibited in the presence of PIF (Fig. 3b). Varying concentrations of PIF applied to active Kv1.3 173 
currents revealed a dose-dependent inhibition of the channel with an IC50 of ~10.2nM using Hill 174 
equation (Fig. 3c,d). To verify its inhibitory properties on native neutrophil Kv1.3 channels, we applied 175 
the same consecutive step-protocol to induce characteristic Kv1.3 currents, which were strongly 176 
decreased by the application of PIF (Fig. 3e). Application of PIF on already active Kv1.3 currents 177 
triggered via a single +40mV step showed an even stronger inhibition of current amplitudes (Fig. 178 
3f,g), higher than the inhibition via PAP-1. Pre-incubation of human neutrophils with PIF and PAP-1 in 179 
the extracellular bath solution confirmed our results observed via direct application (Supplementary 180 
Fig. 4a-e). In contrast to PIF and PAP-1 treatment, 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole 181 
(TRAM-34), a specific inhibitor for the calcium activated potassium channel KCa3.1, which is also 182 
expressed in neutrophils24, did not show any significant inhibition of Kv1.3 currents. Our results 183 
demonstrate that PIF specifically targets Kv1.3 channels and strongly inhibits the voltage-activated 184 
potassium current in primary human neutrophils as well as in Kv1.3 overexpressing cell lines. 185 
KV1.3 is involved in calcium signaling in human neutrophils. In lymphocytes, KV1.3 regulates Ca
2+ 186 
signaling by sustaining Ca2+ influx via store-operated Ca2+ entry (SOCE)25. K+ efflux via KV1.3 affects the 187 
membrane potential, maintaining a high driving-force for continuous Ca2+ influx25. To determine the 188 
contribution of KV1.3 on SOCE in human neutrophils, we loaded neutrophils, isolated from healthy 189 
donors, with the fluorometric Ca2+-indicator Rhod-2 AM under Ca2+-free conditions and pre-treated 190 
them with Thapsigargin to deplete Ca2+ stores in the endoplasmic reticulum (ER). Subsequent 191 
addition of Ca2+ to the medium increased intracellular Ca2+ concentrations ([Ca2+]i) via SOCE in vehicle 192 
treated neutrophils (Ctrl ), while presence of PIF or PAP-1 significantly reduced Ca2+ entry (Fig. 4a,b). 193 
To study whether inhibition of KV1.3 alters the overall Ca
2+ flux in neutrophils, we measured changes 194 
in [Ca2+]i upon chemokine activation without prior ER Ca
2+ store depletion. Rhod-2 AM loaded and 195 
seeded neutrophils were exposed to Ca2+ which again induced an increase in [Ca2+]i. in control cells. 196 
Ensuing application of CXCL8 resulted in a characteristic Ca2+ spike (Fig. 4c). Neutrophils pre-treated 197 
with PIF or PAP-1 exhibited a significant drop in [Ca2+]i in response to Ca
2+ and to CXCL8 stimulation 198 
(Fig. 4d,e). PAP-1-treatment reduced [Ca2+]i to a higher extend compared to PIF treatment. Under 199 
flow conditions, sufficient Ca2+ influx is a prerequisite for the transition from arrest to a migratory 200 
phenotype in neutrophils26. Under these conditions, high-affinity Leukocyte function antigen-1 (LFA-201 
1)/ICAM-1 bonds induce adhesion strengthening that resists fluid shear stress and supports 202 
neutrophil arrest. Within membrane sites of focal adhesion, LFA-1 co-clusters with CRAC channels to 203 
signal the influx in local cytosolic Ca2+ that activates neutrophil shape change and mobility27. To 204 
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examine the role of KV1.3 and PIF on LFA-1 mechano-signaling via SOCE, neutrophils were perfused 205 
over glass substrates coated with high-affinity LFA-1 inducing antibody along with its endothelial 206 
ligand ICAM-1 using a microfluidic device28. Adherent cells were exposed to shear flow and the 207 
addition of extracellular Ca2+ and ensuing changes in [Ca2+]i were measured (Fig. 4f). Significant 208 
inhibition of Ca2+ influx was observed in the presence of PIF or PAP-1 compared to control (Fig. 4g), 209 
revealing a key role of KV1.3 in LFA-1 dependent regulation of SOCE during post-arrest modification 210 
steps. With these results, we demonstrate that KV1.3 contributes substantially to sustained SOCE in 211 
neutrophils and that an inhibition of K+ efflux via KV1.3 leads to reduced [Ca
2+]i under static and under 212 
flow conditions. 213 
PIF impairs neutrophil post-arrest modifications. To further delineate how reduced [Ca2+]i in the 214 
presence of PIF or PAP-1 exert functional defects on post-arrest modification under shear, we 215 
performed spreading assays under appropriate shear flow conditions. For this, we isolated human 216 
neutrophils from healthy donors, incubated the cells with PIF, PAP-1 or vehicle and introduced them 217 
into microfluidic channels coated with E-selectin, ICAM-1 and CXCL8, simulating inflamed venules. 218 
After a short period of interaction with the substrate, control neutrophils began to spread as 219 
indicated by flattening of the cells and the appearance of a migratory phenotype with membrane 220 
protrusions in the form of pseudopod formation (Fig. 5a). The cellular shape of neutrophils incubated 221 
with PIF or PAP-1 remained smaller and rounder over time (Fig. 5b,c), displaying fewer protrusions 222 
(Fig. 5d). To investigate whether reduced intracellular Ca2+ levels and impairment of spreading go 223 
along with defective leukocyte adhesion strengthening, we performed an in vitro-detachment assay 224 
by gradually increasing fluid shear forces. Isolated human neutrophils were incubated with PIF, PAP-1 225 
or vehicle and introduced into E-selectin, ICAM-1 and CXCL8 coated flow chambers. After 3min of 226 
settling and adhering, shear stress was applied and flow rate was incrementally increased. 227 
Neutrophils, which were pre-incubated with PIF or PAP-1 were significantly more susceptible to 228 
detachment at physiological shear stress levels (2-20 dyne cm-2) compared to control cells (Fig. 5e). 229 
These findings reveal that PIF and PAP-1 mediated inhibition of KV1.3 and the resulting decrease in 230 
[Ca2+]i affect post-arrest modification steps, leading to defective cellular spreading and reduced cell 231 
adhesion strengthening under physiological shear stress conditions. 232 
PIF impairs neutrophil recruitment in an animal model of acute lung injury after LPS stimulation. 233 
Many severe airway diseases like bronchitis, chronic obstructive pulmonary disease (COPD), cystic 234 
fibrosis and acute lung injury (ALI), are characterized by massive neutrophil infiltration into the 235 
lung29. To evaluate whether KV1.3 inhibition by PIF provides a potential therapeutic approach to 236 
interfere with neutrophil recruitment in a clinically relevant setting, we performed a model of ALI 237 
after LPS inhalation. To do so, we administered two different concentrations of PIF or carrier 238 
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substance intra-peritoneally (i.p.) to WT mice before exposing them to LPS containing aerosol. 239 
Neutrophil counts in lung tissue (pulmonary vasculature and interstitium) and bronchoalveolar 240 
lavage (BAL) were assessed by flow cytometry. In all three compartments, inhalation of LPS resulted 241 
in significantly increased numbers of neutrophils compared to mice treated with saline aerosol alone 242 
(w/o) (Fig. 6a-e). Injection of PIF prior to LPS exposure abolished neutrophil recruitment to the 243 
pulmonary vasculature, the interstitium and the bronchoalveolar space almost completely. These 244 
data clearly identify PIF as a strong immunomodulatory drug in an animal model of ALI and point out 245 
its potential role for the treatment of acute inflammatory disorders. 246 
  247 
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3. Discussion 248 
The maternal immune system plays a dual role during pregnancy. On the one hand, it remains 249 
competent and active to successfully protect the organism from bacterial and viral infections. On the 250 
other hand, it requires mechanisms for desensitization of immune responses to fetal tissue in order 251 
not to recognize it as a ‘semi-allogenic transplant’. Indeed, pregnant women are more susceptible to 252 
bacterial infections30,31 and often appear clinically protected from pre-existing autoimmune 253 
diseases32,33. After parturition, the mother’s immune system reverts to its previous state and 254 
autoimmune diseases often relapse. These facts speak for the presence of a pregnancy specific 255 
factor, sufficient to dampen immune cell functions within the maternal serum. Preimplantation 256 
factor (PIF) is a pregnancy specific small peptide, secreted by trophoblast cells14 and present in 257 
maternal serum throughout pregnancy8. In this study, we examined the role of PIF as a modulator of 258 
inflammation. We show that PIF blocks the voltage gated potassium channel KV1.3 on neutrophils, 259 
thereby reducing SOCE and [Ca2+]i. Consequently, post-arrest modification is disturbed and 260 
neutrophils are unable to spread and to withstand physiological shear forces, resulting in disrupted 261 
leukocyte adhesion and extravasation into inflamed tissue. 262 
Serum levels of PIF in maternal circulation range from ~50nM during the 1st to ~60nM during the 2nd 263 
and 3rd trimester8. Given the fact that PIF inhibits KV1.3 on peripheral blood neutrophils with an IC50 264 
of 10.2nM, we propose a role for PIF in actively desensitizing immune cells during pregnancy. In line, 265 
sera of pregnant mice were shown to reduce T cell activation and cytokine production34 and 266 
neutrophils of pregnant women exhibit an overall diminished phagocytic capacity35. ROS production 267 
is lowered in neutrophils of pregnant women as well as in neutrophils of non-pregnant women 268 
incubated with sera from pregnant women36,37. Phagocytosis as well as ROS production strongly 269 
depend on changes in intracellular Ca2+ levels26. Therefore, interference of PIF with SOCE via 270 
inhibition of KV1.3 may constitute an effective mechanism to control neutrophil activity during 271 
pregnancy with an increased susceptibility to infections. According to our findings, we suggest that 272 
the reduced phagocytic activity together with lower ROS levels shown in previous studies, are 273 
consequences of KV1.3 inhibition by PIF. The observation that neutrophils change their Ca
2+ 274 
oscillations upon contact with trophoblast cells in vitro38 further supports this hypothesis. 275 
The functional role of KV1.3 in immune cells has been investigated recently in T cells, showing that an 276 
increase in [Ca2+]i and concomitant depolarization of the cell membrane opens this voltage gated 277 
channel, allowing potassium to leave the cell39. K+ efflux in turn hyperpolarizes the cellular 278 
membrane leading to sustained Ca2+ influx via CRAC channels, thereby maintaining long lasting high 279 
[Ca2+]i. In this study, we discovered surface expression of KV1.3 on human and murine neutrophils by 280 
western blot analysis, flow cytometry and confocal immunofluorescence microscopy. Using a whole-281 
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cell patch-clamp approach, we show that depolarization of human neutrophils results in a 282 
characteristic KV1.3 outward current that was reduced by PAP-1, a specific KV1.3-inhibitor. 283 
Additionally, we demonstrate that KV1.3 directly affects Ca
2+ signaling in neutrophils. Inhibition of 284 
KV1.3 by PAP-1 lowers CRAC channel dependent Ca
2+ influx. As PIF reduces K+ outward currents 285 
similar to PAP-1, we provide evidence that PIF directly binds to and inhibits KV1.3 as recently 286 
assumed on the basis of mass spectrometry analysis10. 287 
Fluid shear forces acting on LFA-1/ICAM-1 bonds amplify CRAC channel dependent Ca2+ influx in 288 
neutrophils, enabling the cells to rearrange their cytoskeleton, a prerequisite for firm adhesion and 289 
subsequent shape polarization and migration27. Orai1 is the predominant CRAC channel in 290 
neutrophils that cooperates with LFA-1 to regulate Ca2+ entry during recruitment26. It is recruited to 291 
focal adhesive sites, co-localizes with high affinity LFA-1 and facilitates F-actin polymerization27. This 292 
has led to the hypothesis that a molecular complex consisting of LFA-1, Kindlin3 and Orai1 mechano-293 
signals a local increase of intracellular Ca2+ and the creation of Ca2+-rich microdomains, which enable 294 
fast and efficient reorganization of the cytoskeleton to guide neutrophil emigration. We expand the 295 
picture by showing that K+ efflux through KV1.3 is critical for maintaining membrane cation 296 
equilibrium during LFA-1 mediated Ca2+ influx via SOCE. KV1.3 may also be involved in the creation of 297 
locally high Ca2+ concentrations within focal adhesions in T cells, as it physically interacts with β1 298 
integrins20. Inhibition of KV1.3 by PAP-1 or PIF resulted in a higher susceptibility of neutrophils to 299 
increasing shear forces, suggesting that Kv1.3 is a central player in linking adhesion receptors to the 300 
cytoskeleton in neutrophils. In line with these findings, application of PAP-1 or PIF, or genetic 301 
deletion of KV1.3 reduced the number of adherent cells in an acute inflammation model of the mouse 302 
cremaster muscle in vivo. Consequently, extravasation of neutrophils in mice treated with PAP-1 or 303 
PIF or within KV1.3 knockout mice was severely reduced in this acute inflammation model. 304 
Modulation of neutrophil recruitment by PIF dependent inhibition of KV1.3 activity does not only 305 
provide us with new insights into neutrophil biology, but also opens new therapeutic approaches in 306 
the treatment of acute and chronic inflammatory conditions outside pregnancy. Autoimmune 307 
arthritis, COPD or psoriasis are all characterized by massive infiltration of neutrophils29,40. Here, we 308 
show that PIF application disrupts neutrophil extravasation in an animal model of LPS induced acute 309 
lung injury. Previous studies demonstrated that continuous PIF administration reduces the severity of 310 
multiple sclerosis and type I diabetes mellitus in mouse models15,16. In addition, PIF application 311 
diminished Graft-versus-Host disease after bone marrow transplantation in mice41. Furthermore, 312 
KV1.3 has been suggested a promising pharmacological target to treat T cell mediated autoimmune 313 
diseases, as it is highly upregulated on effector memory T (TEM) but not on naïve T lymphocytes
42. 314 
Inhibition of KV1.3 attenuates progression in multiple sclerosis
43, type I diabetes mellitus44 or 315 
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psoriasis45. As PIF directly acts on KV1.3, blocks the channel and negatively regulates leukocyte 316 
functions, we propose PIF as an interesting therapeutic compound in a whole variety of immune 317 
disorders. In contrast to the large number of available KV1.3 inhibitors
42, PIF is an endogenous 318 
peptide with an IC50 of 10.2nM. Maternal serum levels during pregnancy are around 50-60nM, 319 
implicating that systemic application of PIF as a therapeutic compound might exert minimal side 320 
effects. A phase I safety study using PIF in patients with autoimmune hepatitis has shown positve 321 
safety and tolerability46. The proposed function of PIF on innate immune cells is furthermore of great 322 
relevance, as there is increasing evidence that the innate immune system, especially neutrophils play 323 
an important role in the appearance and maintenance of classical T cell driven diseases, such as 324 
psoriasis, multiple sclerosis or type I diabetes mellitus 40,47. 325 
In summary, we demonstrate that PIF suppresses neutrophil functions via its direct interaction with 326 
the voltage-gated potassium channel KV1.3 leading to impaired intracellular Ca
2+ signaling and 327 
reduced neutrophil recruitment into inflamed tissue. PIF may open a broad range of new therapeutic 328 
opportunities in patients with unwanted excessive leukocyte recruitment including acute and chronic 329 
inflammatory disorders, autoimmune disorders and graft-versus-host disease. 330 
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Figure 1 PIF impairs leukocyte recruitment in vivo and in vitro 348 
WT mice were pre-treated intrascrotally (i.s.) with PIF, scrPIF or vehicle (Ctrl) 1h prior to TNF-α 349 
stimulation. a, Number of adherent leukocytes per vessel surface (n=25-30 vessels of 8-10 mice per 350 
group, one-way ANOVA, Tukey’s multiple comparison) and b, leukocyte rolling velocities (n=192 351 
(Ctrl), 225 (scrPIF) and 222 (PIF) cells of 8-10 mice per group, one-way ANOVA, Tukey’s multiple 352 
comparison) were analyzed using intravital microscopy 2h after onset of inflammation. Cremaster 353 
muscles were stained with Giemsa. c, Representative micrographs (scale bar: 30µm). d, Number of 354 
perivascular neutrophils was quantified (n=49-51 vessels from 3 mice per group, one-way ANOVA, 355 
Tukey’s multiple comparison). e,f, E-selectin, ICAM-1 and CXCL1 coated flow chambers were 356 
perfused with murine whole blood, incubated with PIF or vehicle (Ctrl) and number of adherent cells 357 
FOV-1 (n=7-9 flow chambers from 5 mice per group, unpaired student’s t-test) and leukocyte rolling 358 
velocities were assessed (n=78 (Ctrl) and 90 (PIF) cells from 5 mice per group, unpaired student’s t-359 
test). *: p≤0.05 **: p≤0.01 ***: p≤0.001, data are represented as mean±s.d. or cumulative frequency. 360 
 361 
Figure 2 Functional KV1.3 is expressed on human and murine neutrophils and plays a crucial role in 362 
leukocyte recruitment in vivo 363 
a, Total KV1.3 protein levels of Jurkat cells (positive control), human (hPMN) and murine (mPMN) 364 
neutrophils were analyzed by western blot. Detection of GAPDH served as loading control 365 
(representative blot from n=3 independent experiments). b, Surface localization of KV1.3 was 366 
determined by confocal microscopy (representative images from n=3 independent experiments, 367 
scale bar: 10µm). c,d,e Patch clamp was used to investigate functionality of KV1.3 in primary human 368 
neutrophils. c, Application of 13 consecutive 10mV steps from -80mV to +40mV induced the 369 
development of voltage-activated potassium currents in control cells. d, Presence of PAP-1 reduced 370 
voltage-activated potassium currents (representative traces no. 1, 4, 8, 13 of n=10 cells for each 371 
treatment). e, Potassium currents measured in primary human neutrophils in absence (black) and 372 
after direct application of PAP-1 (grey) after current activation with a single voltage-step from the 373 
holding-potential of -80mV to +40mV (representative traces of n=4 cells). f-i, WT and KV1.3
-/- mice 374 
were pre-treated i.s. as indicated 1h prior to TNF-α stimulation. f,h, Number of adherent leukocyte 375 
per vessel surface (n= 15-17 vessels of 4 mice per group and n=19 vessels of 5 mice per group, 376 
respectively, one-way ANOVA, Tukey’s multiple comparison) and g,i, leukocyte rolling velocities 377 
(n=136 (Ctrl), 105 (PAP-1), 82 (PAP-1+PIF), one-way ANOVA, Tukey’s multiple comparison) cells and 378 
175 (WT), 123 (KV1.3
-/-) and 124 (KV1.3
-/-+PIF) cells, respectively) were assessed. j,k, Cremaster 379 
muscles were stained with Giemsa. j, Representative micrographs (scale bar: 30µm). k, Number of 380 
perivascular neutrophils was quantified (n=19-45 vessels of 3 mice per group, one-way ANOVA, 381 
Tukey’s multiple comparison). **: p≤0.01 ***: p≤0.001, data are represented as mean±s.d. or 382 
cumulative frequency. 383 
 384 
Figure 3 PIF reduces voltage-induced KV1.3 currents in a KV1.3 overexpressing cell line and in 385 
human neutrophils 386 
a, Kv1.3 currents were measured using patch clamp in HEK-293 cells transiently overexpressing hKv1.3 387 
channels (hKv1.3-HEK-293) by the application of 13 consecutive 10mV steps from -80mV to +40mV 388 
over 200ms in the absence (Ctrl, black, n=36 cells) and presence of PIF (grey, n=4 cells). All 13 traces 389 
normalized to cell size as current density (pA/pF) of a representative cell are depicted. b, Current-390 
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voltage relationship of control measurements (Ctrl, black) and PIF (grey) treated hKv1.3-HEK-293 cells 391 
(n=4 cells, repeated unpaired student’s t-tests). c, Kv1.3 currents were extracted at +40mV in the 392 
absence and after application of two different concentrations of PIF (n=4-6 cells). d, Dose-dependent 393 
inhibition of Kv1.3 currents in hKv1.3-HEK-293 cells by increasing concentrations of PIF application 394 
was determined. Average peak current inhibition is shown in [%] plotted against increasing PIF 395 
concentrations [nM] (n=4-8 cells, IC50=10.2±5nM. Hill=0.8±0.4). e, Kv1.3 currents in primary human 396 
neutrophils were induced by the application of consecutive voltage-steps as in a, before (Ctrl, black) 397 
and after (grey) peptide application (representative traces no. 1, 4, 8, 13 from n=5 cells). f, Kv1.3 398 
currents in primary human neutrophils were induced by the application of a single voltage-step to + 399 
40mV, before (Ctrl, black) and after (PIF, grey) peptide application (representative traces of n=5 400 
cells). g, Current inhibition [%] of Kv1.3 currents in primary human neutrophils after application of the 401 
KCa3.1 blocker TRAM-34, PAP-1 and PIF (n=4-5 cells, one-way ANOVA, Tukey’s multiple comparison). 402 
*: p≤0.05; **: p≤0.01; ***: p≤0.001, data in b,d,g are represented as mean±SEM. 403 
 404 
Figure 4 KV1.3 is involved in Ca
2+ signaling in human neutrophils. 405 
Isolated human neutrophils were loaded with Rhod-2 AM and subsequently pretreated with PIF, 406 
PAP-1 or vehicle (Ctrl). Changes in [Ca2+]i were observed in Ca
2+ free buffer and after the addition of 407 
1.5mM Ca2+. a, CRAC channel dependent Ca2+ influx in human neutrophils pretreated with 408 
Thapsigargin was determined under static conditions and b, [Ca2+]i were quantified 30s after addition 409 
of Ca2+ (n=57 (Ctrl) 60 (PAP-1) and 88 (PIF) cells from 3 independent experiments, one-way ANOVA, 410 
Tukey’s multiple comparison). c, Total Ca2+ flux was investigated after the addition of Ca2+ and after 411 
stimulation with CXCL8 under static conditions. d, Total [Ca2+]i relative to baseline was quantified 30s 412 
after addition of Ca2+ (n=114 (Ctrl), 35 (PAP-1) and 80 (PIF) cells from 3 independent experiments, 413 
one-way ANOVA, Tukey’s multiple comparison) and e, 30s after stimulation with CXCL8 (n=115 (Ctrl), 414 
69 (PAP-1) and 114 (PIF) cells from 3 independent experiments, one-way ANOVA, Tukey’s multiple 415 
comparison). f, Ca2+ flux of neutrophils pretreated with Thapsigargin perfused over a substrate of 416 
ICAM-1 and CBR LFA1/2 LFA-1 antibody using microfluidic devices was measured and g, quantified 417 
60s after addition of Ca2+ under shear conditions (n=14 (Ctrl), 36 (PAP-1) and 25 (PIF) cells from 3 418 
independent experiments, one-way ANOVA, Tukey’s multiple comparison). **: p≤0.01 ***: p≤0.001, 419 
data in a,c,f are represented as mean and data in b,d,e,g are represented as mean±s.d. Dotted lines 420 
in a,c,f represent the time points of quantification. 421 
Figure 5 PIF impairs neutrophil post-arrest modifications. 422 
Human neutrophils were pretreated with PIF, PAP-1 or vehicle (Ctrl), introduced into E-selectin, 423 
ICAM-1 and CXCL8 coated flow chambers and monitored over time. a, Representative micrographs of 424 
neutrophils 30s, 210s and 360s after attachment (scale bar: 10µm). b, Cell perimeter, c, cell 425 
circularity and d, cell solidity were quantified over time (49 (Ctrl), 60 (PAP-1) and 42 (PIF) cells from 426 
n=5 independent experiments, one-way ANOVA, Dunnett’s multiple comparison). e, Human 427 
neutrophils were exposed to stepwise increasing shear rates in E-selectin, ICAM-1 and CXCL8 coated 428 
flow chambers and percentage of remaining neutrophils FOV-1 was quantified after each step (n=12-429 
15 flow chambers of 9-10 independent experiments one-way ANOVA, Dunnett’s multiple 430 




Figure 6 PIF impairs neutrophil recruitment in an animal model of acute lung injury after LPS 433 
stimulation. 434 
WT mice received an i.p. injection of two different concentrations of PIF or vehicle (Ctrl) 1h prior to 435 
LPS inhalation and number of recruited neutrophils to a, pulmonary vasculature, b, lung interstitium 436 
and c, in the bronchio-alveolar lavage (BAL) was analyzed. W/o-animals were exposed to saline 437 
aerosol only (n=7-9 mice per group, one-way ANOVA, Tukey’s multiple comparison). d, 438 
Representative histological micrographs of lungs (scale bar: 250µm) and e, histological quantification 439 
(n=3-4mice per group, one-way ANOVA, Tukey’s multiple comparison). **: p≤0.01 ***: p≤0.001, data 440 
are represented as mean±SEM. 441 






-/-) mice23 were purchased from Jackson Laboratories and backcrossed into C57BL/6 445 
WT mice. WT mice were obtained from Charles River Laboratories (Sulzfeld, Germany). All mice were 446 
maintained at the Walter Brendel Center for Experimental Medicine, LMU, Munich, at the Biomedical 447 
Center, LMU, Planegg-Martinsried, Germany and at the Animal Facility of the University Hospital 448 
Aachen. 8-25weeks old male and female mice were used for all experiments. Animal experiments 449 
were approved by the government Oberbayern and government Nordrhein-Westfalen, Germany, AZ 450 
55.2-1-54-2531-122/12, -229/15, ROB-55.2-2532.Vet_02-18-22 and 84-02.04.2013.A058. 451 
Animal models: 452 
Intravital microscopy (IVM) of the mouse cremaster muscle was performed as previously described48. 453 
Briefly, WT or KV1.3
-/- mice received an intra scrotal (i.s.) injection of either PIF, scrambled PIF (scrPIF) 454 
(both 1µg/mouse; BioSynthesis; provided by E. Barnea), 90µg of 5-(4-Phenoxybutoxy)psoralen (PAP-455 
1; Sigma-Aldrich), a combination of PIF and PAP-1, or vehicle (Ctrl; 0.25%DMSO/PBS) 1h prior to TNF-456 
α stimulation (i.s.; 500ng of recombinant murine (rm) TNF-α (R&D Systems)). 2h after induction of 457 
inflammation, the carotid artery of anesthetized mice was cannulated for later blood sampling (using 458 
a ProCyte Dx; IDEXX Laboratories) and the cremaster muscle was dissected. IVM was conducted on 459 
an OlympusBX51 WI microscope, equipped with a 40x objective (Olympus, 0.8NA, water immersion 460 
objective) and a CCD camera (KAPPA CF 8 HS). Postcapillary venules were recorded using VirtualDub 461 
software for later off-line analysis. On the basis of the generated movies, leukocyte number of 462 
adherent cells mm-2 was counted and rolling velocities, vessel diameter and vessel length were 463 
determined using FIJI software49. During the entire observation, the muscle was superfused with 464 
thermo-controlled bicarbonate buffer according to previous literature50. Centerline velocity of each 465 
venule was measured with a dual photodiode (Circusoft Instrumentation). After IVM, cremaster 466 
muscles were removed, fixed with 4% paraformaldehyde (PFA), and stained with Giemsa (Merck, 467 
Darmstadt, Germany) to calculate the number of perivascular neutrophils. Neutrophils were 468 
discriminated from other leukocyte sub populations on the basis of the shape of cell nuclei and 469 
granularity of the cytosol. The analysis of transmigrated leukocytes was carried out at the core facility 470 
Bioimaging of the Biomedical Center with a Leica DM2500 microscope, equipped with a 100x 471 
objective (Leica, 1.4NA, oil immersion) and a Leica DMC2900 CMOS camera. 472 
The LPS induced acute lung injury (ALI) model was used as described elsewhere51. WT mice were 473 
intra peritoneally (i.p.) injected with either 1µg, 10µg of PIF or vehicle (Ctrl) 1h prior to LPS 474 
stimulation. Mice were exposed to aerosolized LPS (500µg ml-1 in 0.9% saline) from Salmonella 475 
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enteritidis (Sigma-Aldrich) for 30min using a nebulizer (MicroAir, Omron Healthcare). Mice from the 476 
w/o group did not receive any i.p. injection and were exposed to saline aerosol only. 4h after 477 
inhalation, numbers of recruited neutrophils were assessed. 5µl of FITC conjugated anti-Ly6G 478 
antibodies (eBioscience) were applied i.v. via tail injection 30min prior to killing the animals to label 479 
intravascular neutrophils. After euthanasia, the trachea was cannulated and the lungs were flushed 480 
5x with 0.5ml of PBS to obtain bronchoalveolar lavage (BAL). Afterwards, the pulmonary vasculature 481 
was rinsed with 15ml of ice-cold PBS (with 0.5mM EDTA) before lungs were removed, digested with 482 
Liberase (1:20; 25mg Liberase RI ml-1 aqua; Roche) and passed through a cell strainer (70µm; Miltenyi 483 
Biotec). Number of neutrophils was analyzed using a Canto II flow cytometer (Becton Dickinson) and 484 
FlowJo software (Tree Star). Cells were labeled with PerCP-Fluor710 conjugated anti-Ly6G, PE-anti-485 
CD115, APC-eFluor780-anti-CD45 and APC-anti-F4/80 antibodies (all eBioscience). Neutrophils were 486 
defined as CD45+, CD115-, Ly6G+ cells. Intravasal neutrophils were discriminated from interstitial 487 
neutrophils according to their FITC-Ly6G+ signal. Part of the right lung was fixed in 4% PFA, 488 
embedded in paraffin and stained with Mayer’s hematoxylin and eosin (HE) and cut for histological 489 
examination. Sections were scored based on guidelines from the American Thoriacic Society52. 490 
In vitro flow chamber assays: 491 
To investigate leukocyte adhesion and leukocyte rolling velocity in vitro, flow chamber assays were 492 
carried out as previously described48. Shortly, rectangular borosilicate glass capillaries (0.04x0.4mm; 493 
VitroCom) were coated with a combination of rmE-Selectin (CD62E Fc chimera; 20µg ml-1; R&D 494 
Systems), rmICAM-1 (ICAM-1 Fc chimera; 15µg ml-1; R&D Systems) and rmCXCL1 (15µg ml-1; 495 
Peprotech) for 3h at room temperature (RT) and blocked with 5% casein (Sigma-Aldrich) over night 496 
(ON) at 4°C. Whole blood was collected from anesthetized WT mice via the carotid catheter, 497 
heparinized and incubated with either 300nM PIF or the carrier substance (Ctrl) for 10min at RT. The 498 
incubated blood was then perfused through the flow chambers at a shear rate level of 2.7 dynes cm-2 499 
using a high-precision syringe pump (Harvard Apparatus). Movies were recorded with an 500 
OlympusBX51 WI microscope, equipped with a 20x objective (Olympus, 0.95NA, water immersion 501 
objective) and a CCD camera (KAPPA CF 8 HS) and VirtualDub software. Number of adherent cells per 502 
FOV was counted and rolling velocities were analyzed with FIJI. 503 
Neutrophil isolation: 504 
Murine bone marrow derived neutrophils were isolated with a neutrophil enrichment kit (STEMCELL 505 
Technologies), whereas human neutrophils were extracted from whole blood of healthy volunteer 506 
blood donors using Polymorphprep (AXIS-SHIELD PoC AS). Blood sampling was approved by the ethic 507 
committee from the Ludwig-Maximilians-Universität München (Az. 611-15). 508 
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Western blotting: 509 
Murine and human neutrophils (106 100µl-1 lysis buffer) were lysed, homogenized with lysis buffer 510 
(containing 150mM NaCl, 1% Triton X-100 (Applichem), 0.5% Sodium deoxycholate (Sigma-Aldrich), 511 
50mM Tris-HCl pH 7.3 (Merck), 2mM EDTA (Merck) supplemented with protease (Roche), 512 
phosphatase inhibitors (Sigma-Aldrich) and 1xLaemmli sample buffer) and boiled (95°C, 5min). 513 
Proteins were resolved by SDS-PAGE and electrophoretically transferred onto PVDF membranes. 514 
Rabbit anti-KV1.3 (3µg ml
-1, Alomone labs), mouse anti-GAPDH (1.5µg ml-1; clone 6C5; Calbiochem), 515 
goat anti-rabbit-IRDye 800CW and goat anti-mouse-IRDye 680RD (both LI-COR Bioscience) were used 516 
to detect the respective proteins on an Odyssey CLx (LI-COR Bioscience). Jurkat cells were used as 517 
positive control. 518 
Confocal microscopy: 519 
Murine and human neutrophils were seeded on poly-L-lysine (0.1%; Sigma-Aldrich) coated object 520 
slides (Ibidi), fixed with 2% PFA and blocked with 2% BSA (Capricorn Scientific) for 1h. Cells were 521 
stained ON at 4°C using anti-KV1.3 antibody (5µg ml
-1, rabbit anti-KV1.3; Alomone labs. Donkey anti-522 
rabbit-Alexa488 secondary antibody (5µg ml-1, Invitrogen) was then added for 1h at RT. Finally, cells 523 
were stained with DAPI (Invitrogen) for 5min at RT before embedding them in ProLong Diamond 524 
Antifade mounting medium (Invitrogen). Samples were imaged by confocal microscopy at the core 525 
facility Bioimaging of the Biomedical Center with a Leica SP8X WLL microscope, equipped with a HC 526 
PL APO 40x/1.30NA oil immersion objective. Images were processed (including removal of outliers 527 
and background subtraction in the 488 channel) using FIJI software. 528 
Flow cytometry: 529 
Murine and human neutrophils cells were stained for 30min with rabbit anti-KV1.3 (5µg ml
-1, 530 
Alomone Labs) followed by 30min incubation with secondary antibody (5µg ml-1, donkey anti-rabbit-531 
Alexa488; Invitrogen) at 4°C. Rat anti-Ly6G (clone 1A8; BioLegend) or anti-CD15 (clone W6D3; 532 
BioLegend) together with anti-CD66b (clone G10M5; BioLegend) were used to define murine and 533 
human neutrophil population, respectively. Flow cytometry data were acquired on a Beckman 534 
Coulter Gallios flow cytometer and analyzed using Kaluza Flow Analysis Software (Beckman Coulter). 535 
The expression patterns of surface molecules which are important in the context of leukocyte 536 
recruitment were analyzed via flow cytometry. WT mice received either an i.s. injection of 1µg PIF or 537 
vehicle 2h prior to exsanguination. In a second set of experiments, non-treated WT and KV1.3
-/- mice 538 
were exsanguinated. Whole blood was stained with antibodies against CD18 (clone C71/16; 539 
Pharmingen), CD11a (clone M17/4; eBioscience), CD11b, (clone M1/70; BioLegend), PSGL-1 (CD162; 540 
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clone 2PH1; Pharmingen), CD44 (clone IM7; BioLegend), L-selectin (CD62L; clone MEL-14; 541 
BioLegend), and CXCR2 (CD182; clone 242216; R&D). Cells were fixed and erythrocytes were lysed 542 
using FACS Lysing solution (BD Bioscience). Samples were analyzed using a Beckman Coulter Gallios 543 
flow cytometer and Kaluza Flow analysis Software (Beckman Coulter). Anti-Ly6G (clone 1A8; 544 
BioLegend) was used to define murine neutrophil population. 545 
Patch clamp of KV1.3 overexpressing HEK-293 cells and isolated human neutrophils: 546 
HEK 293 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% 547 
penicillin/streptomycin at 37°C in humidified atmosphere (5% CO2). The cells were transiently co-548 
transfected with cDNA plasmid endcoding human KV1.3 (kindly provided by Prof. Dr. Grissmer) and 549 
Vivid Colors™ pcDNA™6.2/C-EmGFP-DEST Vector (Invitrogen) using Lipofectamine 3000 (Invitrogen). 550 
Cells were used the day after transfection. Human neutrophils were isolated from whole blood of 5 551 
different healthy volunteer donors using EasySep neutrophil enrichment kit (STEMCELL Technologies) 552 
and resuspended in HBSS buffer (containing 0.1% of glucose, 1mM CaCl2, 1mM MgCl2, 0.25% BSA, 553 
and 10mM HEPES (Sigma-Aldrich), pH7.4). Purity of isolated cells was determined by flow cytometry 554 
(CD66b+/CD15+ population). Cells with a purity over 98±0.5% (mean±SEM) were used for 555 
experiments. Cells were seeded on poly-D-lysine coated coverslips and subjected to patch-clamp 556 
experiments in whole-cell configuration as follows: cells were clamped at a holding potential of -557 
80mV intermitted by repeated 200ms voltage steps from -80mV to +40mV using a 10mV interval 558 
applied every 30s. Current maxima at +40mV were used for the calculation of Kv1.3 current 559 
amplitudes. Currents were normalized to cell size as current densities in pA/pF. Capacitance was 560 
measured using the automated capacitance cancellation function of the EPC-10 (HEKA, Harvard 561 
Bioscience). Patch pipettes were made of borosilicate glass (Science Products) and had resistance 2–562 
3.5MΩ. Kv1.3 currents were inhibited with 10nM PAP-1 and KCa3.1 currents were blocked by 1µM 563 
TRAM-34. Standard extracellular solution contained: 140mM NaCl, 2.8mM KCl, 2mM MgCl2, 1mM 564 
CaCl2, 10mM HEPES, 11mM glucose (pH 7.2, 300mOsm). Intracellular solution contained: 134mM KF, 565 
2mM MgCl2, 1mM CaCl2, 10mM HEPES, 10mM EGTA (pH 7.2, 300mOsm). Solutions were adjusted to 566 
300mOsm using a Vapro 5520 osmometer (Wescor Inc). Channel blocker were either added to the 567 
bath solution at least 15min prior to electrophysiological recordings or directly applied via an 568 
application pipette using constant pressure. To determine IC50 values for inhibitory effects of PIF on 569 
Kv1.3 currents, data were fitted with the following equation: 570 




with E being the effect (current inhibition) at a given concentration c of inhibitor, Emin the minimal 572 
effect (current inhibition), Emax the maximally achievable effect, IC50 the half-maximal concentration 573 
and h the Hill factor. 574 
Calcium signaling in human neutrophils: 575 
Human neutrophils were isolated from whole blood of healthy volunteers using EasySep neutrophil 576 
enrichment kit (STEMCELL Technologies) in a manner approved by the institutional review board 577 
protocol at the University of California, Davis (#235586-9). Isolated cells were suspended in HBSS 578 
with 0.1% HSA at 106 cells ml-1 and treated with Mac-1 blocking antibody (clone M1/70; BioLegend) 579 
prior to perfusion. Cells were then incubated with 1 µM Rhod-2 AM (ex/em: 552/581; Thermo Fisher 580 
Scientific) with or without Thapsigargin (Thermo Fisher Scientific) for 20min at RT in the dark. For 581 
static adhesion assays neutrophils were placed into a 48-well plate and allowed to settle for 60s prior 582 
to addition of 1.5mM calcium containing media for 3min. Additionally, cells were stimulated by 583 
addition of 10nM CXCL8 (Shenandoah) for 2min. For investigation of cellular Ca2+ signaling under flow 584 
conditions microfluidic devices were designed to have four independent flow channels to analyze 585 
multiple conditions per coverslip (dimensions: 60µm x 2mm x 8mm, hxwxl). Circular glass coverslips 586 
(35mm diameter) were treated with Piranha solution (one part concentrated sulfuric acid and 1 part 587 
30% hydrogen peroxide) for 20min followed by treatment with acetone for 2min. Coverslips were 588 
then dipped in 2% 3-aminiopropyltriethoxysilane (Fisher Scientific) in acetone for 5min. Once dry, 589 
Protein A/G (Fischer Scientific) was covalently attached to the aminosilinated surface using a 590 
bis(sulfosuccinimidyl) substrate (BS3) crosslinker ON (Pierce Thermo Scientific). Afterwards, 591 
coverslips were coated with recombinant human (rh)ICAM-1 (Fc chimera; 5 µg ml-1; R&D Systems), 592 
CBR LFA1/2 LFA-1 antibody (20 µg ml-1; BioLegend) for 1h, washed with PBS and blocked with 1% 593 
Casein for 15min (Pierce Thermo Scientific). Neutrophils pre-treated with Rhod-2 AM and 594 
Thapsigargin were perfused into the device at 0.1 dyne cm-2 and allowed to rest for 60s prior to shear 595 
ramping up to 2 dyne cm-2 in 1.5mM calcium containing media via a syringe pump (Cellix Ltd). Images 596 
were taken (1 fps) once neutrophils had settled in the 48 well plate or microfluidic device using a 597 
Nikon Eclipse TE2000-S microscope (20x phase contrast air objective; 0.45NA) equipped with a 16-bit 598 
digital CMOS camera (Andor ZYLA) with NIS Elements imaging software. All images were analyzed 599 
using FIJI Software. 600 
Neutrophil spreading and detachment: 601 
To study neutrophil spreading, rectangular borosilicate glass capillaries (0.2x2.0mm; CM Scientific) 602 
were coated with rhE-Selectin (CD62E Fc chimera; 5µg ml-1; R&D Systems), rhICAM-1 (4µg ml-1; R&D 603 
Systems) and rhCXCL-8 (10µg ml-1; Peprotech) for 3h at RT and blocked with 5% casein ON at 4°C. 604 
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Isolated human neutrophils were applied into the flow chamber with a shear rate level of 1 dyne cm-2 605 
using a high-precision syringe pump (Harvard Apparatus). To avoid interaction of the cells with the Fc 606 
part of the recombinant proteins, cells were incubated with hFc-block (human TruStain FcX; 607 
BioLegend) for 5min at RT before being introduced into the chambers. Spreading behavior of the 608 
cells was observed and recorded with a Zeiss Axioskop2 (provided with a 20x water objective, 0.5NA 609 
and a Hitachi KP-M1AP camera) and VirtualDub. Cell shape changes were quantified using FIJI 610 
software, analyzing cell perimeters, circularity (4π 
[Area]
[Perimeter]2
) and solidity (
[𝐴𝑟𝑒𝑎]
[𝐶𝑜𝑛𝑣𝑒𝑥 𝐴𝑟𝑒𝑎]
). To 611 
investigate the resistance of neutrophils against increasing shear forces, µ-slides VI0.1 (Ibidi) were 612 
coated with rhE-Selectin, rhICAM-1 and rhIL-8 as described above. Isolated human neutrophils were 613 
resuspended in HBSS, blocked with hFc-block for 5min at RT and 106 cells ml-1 were introduced into 614 
the chamber and allowed to settle for 3min, before flow was started. First, 1 dyne cm-2 was applied 615 
for 1min to remove non-attached cells and debris using HBSS and a high precision syringe pump. 616 
Number of adherent cells FOV-1 was counted and set to 100%. Flow rates were then increased every 617 
30s and the fraction of remaining cells was counted at the end of each time interval. Experiments 618 
were conducted on a ZEISS, AXIOVERT 200 microscope, provided with a ZEISS 10x objective (NA: 619 
0.25, and a SPOT RT ST Camera (Diagnostic Instruments, Inc.)) and MetaMorph software was used to 620 
generate time laps movies for later on analysis. 621 
Statistics: 622 
Data are presented as mean±S.D. (Fig.1a, d, e; Fig.2f, h, k; Fig.3g; Fig.4b, d, 4e, g; Fig.6a, b, c, and 6e), 623 
mean±SEM (Fig.3b, d; Fig.5b, c, d and e), as cumulative distribution, mean (Fig.4a, c and d), or 624 
representative images/traces as depicted in the figure legends. Group sizes were selected based on 625 
previous experiments. Data were analyzed and illustrated using GraphPad Prism 7 software 626 
(GraphPad Software Inc.). Statistical tests were performed according to the number of groups being 627 
compared. For pairwise comparison of experimental groups, an unpaired student’s t-test and for 628 
more than two groups, a 1-way or 2-way analysis of variance (ANOVA) with either Turkey’s (to 629 
compare all groups with each other) or Dunnett’s (to compare experimental groups against control) 630 
post-hoc test was carried out. P-values <0.05 were considered statistically significant and indicated as 631 
follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. 632 
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Functional KV1.3 is expressed on human and murine neutrophils and plays a crucial 























































































































































































































PIF reduces voltage-induced KV1.3 currents in a KV1.3 overexpressing cell line 
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PIF impairs neutrophil post-arrest modifications





























































































































































































































































































































































































































KV1.3 is expressed on human and murine neutrophils
Supplementary Figure 3

























































































































































KV1.3-/- neutrophils share a normal expression pattern of surface molecules 
important for neutrophil recruitment




































































































PIF reduces KV1.3 currents in isolated human neutrophils
Supplementary Figure 1 PIF does not alter expression pattern of surface molecules important for 
neutrophil recruitment. 
a-g, Surface expression of CD18, CD11a, CD11b, PSGL-1, CD44, L-selectin, and CXCR2 on peripheral 
blood neutrophil from WT mice i.p. injected with PIF or vehicle 2h prior to blood harvesting was 
determined by flow cytometry (MFI= Mean fluorescence intensity, n=3 animals per group, unpaired 
student’s t-test). Data are represented as mean±s.d. 
 
Supplementary Figure 2 KV1.3 is expressed on human and murine neutrophils. 
Surface expression of KV1.3
-/- on a, Jurkat cells (positive control) isolated b, human and c, murine 
neutrophils was analyzed by flow cytometry (MFI= Mean fluorescence intensity, n=3-5 independent 
experiments, unpaired student’s t-test). Data are presented as representative overlays and 
mean±s.d. 
 
Supplementary Figure 3 KV1.3
-/- neutrophils share a normal expression pattern of surface 
molecules important for neutrophil recruitment. 
a-g, Surface expression levels of CD18, CD11a, CD11b, PSGL-1, CD44, L-selectin, and CXCR2 on 
peripheral blood neutrophils from KV1.3
-/- and WT mice (MFI= Mean fluorescence intensity, n=3-5 
mice per group, unpaired student’s t-test). Data are presented as mean±s.d. 
 
Supplementary Figure 4 PIF reduces KV1.3 currents in isolated human neutrophils. 
Kv1.3 current densities in primary human neutrophils (calculated as pA/pF) were triggered by the 
application of 13 consecutive 10mV steps from -80mV to +40mV over 200ms. Cells were pre-treated 
with a, vehicle (Ctrl) (representative trace no. 1, 4, 8, 10, 13 of n=15 cells), b, TRAM-34 
(representative trace no. 1, 4, 8, 12 of n=13 cells), c, PAP-1 (representative trace no. 1, 4, 8, 13 of 
n=10 cells), or d, PIF (representative trace no. 1, 4, 8, 13 of n=8 cells). e, Current densities extracted 
at 100ms were quantified (n=8-15 cells, one-way ANOVA, Tukey’s multiple comparison). *: p≤0.05. 
Data in e, are represented as mean±s.d. 
 
  
Supplementary Table 1 Microvascular parameters. Vessel diameter, centerline velocity, wall shear 
rate, white blood cell counts (WBC) and neutrophil (PMN) counts of TNF-α stimulated WT mice 
























Ctrl 9 25 33±1 1696±140 1280±107 3798±385 1650±233 
scrPIF 8 25 33±1 11612±1137 1194±95 3983±501 1811±287 
PIF 10 30 31±1 1677±154 1338±124 3969±339 1632±170 











Supplementary Table 2 Microvascular parameters. Vessel diameter, centerline velocity, wall shear 
rate, white blood cell counts (WBC) and neutrophil (PMN) counts of TNF-α stimulated WT or KV1.3
-/- 
mice pretreated with either PAP-1, PIF, a combination of both substances or vehicle (Ctrl), 























Ctrl 4 17 30±1 1753±172 1448±154 3818±189 1915±194 
PAP-1 4 15 30±1 2047±294 1677±230 4085±406 1473±327 
PAP-1+PIF 4 15 29±1 1513±157 1283±116 3393±495 1670±425 










C57BL/6 5 19 31±1 1737±151 1381±122 2064±234 982±228 
KV1.3
-/-
 5 19 29±1 1742±150 1465±126 2516±456 860±339 
KV1.3
-/-
+PIF 5 19 31±1 1900±106 1541±106 2956±347 1386±161 
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